People with #multiplesclerosis with progressive course, anxiety-related disorders and absence of self-reported cognitive concerns, are more likely to decline neurocognitive testing.
Study from @Sunnybrook @UofT ▶️ journals.sagepub.com/doi/full/10.1177/13524585261491122
Multiple Sclerosis Journal
The Multiple Sclerosis Journal (formerly Multiple Sclerosis) is a monthly peer-reviewed medical journal covering the clinical neurology of multiple sclerosis. The editor-in-chief is Alan J Thompson (University College London). It was established in 1995 and is published by SAGE Publications. More on Wikipedia
-
MSJ
@MSJ_Research
-
MSJ reposted
IJMSC
@IJMSCtweets
Researchers examined dropout in a long-term MS observational cohort: 26.9% at 5 yrs, 38.6% at 10 yrs. They report that dropouts had worse early disease characteristics and recommend including them in analyses to limit survivorship bias.
#multiplesclerosis #analysis #bias
MSJ
@MSJ_Research
In a long-term observational #multiplesclerosis cohort, fewer than half completed the study, potentially causing underestimation of progression and reduced statistical power.
Study from @MScentrum020 @amsterdamumc ▶️ journals.sagepub.com/doi/full/10.1177/13524585261490350 -
MSJ reposted
Dr. Brandon Beaber
@Brandon_Beaber
Ocrevus Vs. Tysabri. This cross sectional study looked at Octave MSDA scores (a biomarker which correlates with MS relapses and new MRI lesions) in people with MS, and those getting ocrevus were more likely to have low scores (98.1% vs. 66%). pubmed.ncbi.nlm.nih.gov/43036431/
-
MSJ
@MSJ_Research
In a long-term observational #multiplesclerosis cohort, fewer than half completed the study, potentially causing underestimation of progression and reduced statistical power.
Study from @MScentrum020 @amsterdamumc ▶️ journals.sagepub.com/doi/full/10.1177/13524585261490350 -
MSJ
@MSJ_Research
The cases below show that antibody-mediated neurological disorders may sometimes be a manifestation of inherited disorders of immune tolerance.
Commentary from @DrWBRO @uclh ▶️ journals.sagepub.com/doi/full/10.1177/13524585261490254
1/🧵
MSJ
@MSJ_Research
Case report from @SunYatsen_Uni: Myelin oligodendrocyte glycoprotein antibody-associated disease #mogad in a patient with AIRE gene dominant-negative mutation.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261490277
2/🧵
MSJ
@MSJ_Research
Case report: Neuromyelitis optica spectrum disorder #nmosd associated with Kabuki syndrome caused by KMT2D mutation with immune dysregulation.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261490261
3/🧵 -
MSJ reposted
ECTRIMS
@ECTRIMS
🎓The ECTRIMS Fellowship Programme offers a valuable opportunity to enhance your expertise and advance your career in #msresearch and care.
Apply by 1 𝐃𝐞𝐜𝐞𝐦𝐛𝐞𝐫 2026: ectrims.eu/fellowships
#ectrimsfellowships #ectrimsnextgen #applynow #msresearch #healthcareprofessionals #neurology #advanceyourcareer -
MSJ
@MSJ_Research
🔊 Listen to Claudia Zbrzeski and Stephen Krieger @IcahnMountSinai on how well junior neurology residents recognize #multiplesclerosis.
📄 And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585261492141 -
MSJ reposted
ECTRIMS
@ECTRIMS
💡𝐍𝐨𝐭 𝐞𝐯𝐞𝐫𝐲 𝐧𝐞𝐰 𝐬𝐲𝐦𝐩𝐭𝐨𝐦 𝐢𝐬 𝐧𝐞𝐜𝐞𝐬𝐬𝐚𝐫𝐢𝐥𝐲 𝐌𝐒 𝐩𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧.
As we get older, distinguishing between the effects of MS, ageing and other health conditions can become increasingly challenging.
At Patient Community Day 2026, one speaker shared an important reminder: looking after your overall health matters just as much as managing your neurological condition.
And when it comes to exercise, small steps count. That’s the message from Stephanie Buxhoeveden, the Chief Scientific Officer at Accelerated Cure Project for Multiple Sclerosis, who also lives with MS.
Ten or fifteen minutes of movement throughout the day may be more manageable than one long workout. The key is finding something that works for you.
🎥 𝐖𝐚𝐭𝐜𝐡 𝐒𝐞𝐬𝐬𝐢𝐨𝐧 4 𝐨𝐟 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐲 𝐃𝐚𝐲 2026 𝐭𝐨 𝐡𝐞𝐚𝐫 𝐝𝐢𝐫𝐞𝐜𝐭𝐥𝐲 𝐟𝐫𝐨𝐦 𝐌𝐒 𝐞𝐱𝐩𝐞𝐫𝐭𝐬 𝐚𝐧𝐝 𝐩𝐞𝐨𝐩𝐥𝐞 𝐰𝐢𝐭𝐡 𝐥𝐢𝐯𝐞𝐝 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞: www.youtube.com/watch?v=H4pkR_Jx3kE&list=PLAxWaGJv9HXw&in…
@ECTRIMS #patientcommunityday #msawareness #healthyageing #ectrimsThis media couldn't be displayed. See it on the original post. -
MSJ
@MSJ_Research
Mothers with #multiplesclerosis, epilepsy, inflammatory bowel disease and diabetes share an elevated risk of mental illness in serial pregnancies, including depression, anxiety and bipolar disorder.
Study from @DalhousieU @UWaterloo ▶️ journals.sagepub.com/doi/full/10.1177/13524585261486779 -
MSJ
@MSJ_Research
Irreversible disability worsening was rare in neuromyelitis optica spectrum disease #nmosd, and was independent of relapses in only 2% of patients.
Study from @MelbourneOf @TheRMH @MSBase_Registry ▶️ journals.sagepub.com/doi/full/10.1177/13524585261489039 -
MSJ
@MSJ_Research
Autologous haematopoietic stem cell transplantation may accelerate resolution of paramagnetic rim lesions in #multiplesclerosis, suggesting an effect within the central nervous system on microglia/macrophages.
Study from @UNI_FIRENZE @AOUCareggi ▶️ journals.sagepub.com/doi/full/10.1177/13524585261489061 -
MSJ
@MSJ_Research
There is an increasing number of people experiencing housing insecurity and forcible displacement globally, but more data are needed to understand the defined risks to persons with #multiplesclerosis.
A scoping review from @HopkinsMedicine ▶️ journals.sagepub.com/doi/full/10.1177/13524585261492505 -
MSJ
@MSJ_Research
Too close to call
MSJ
@MSJ_Research
What do you think? Should exclusion of NMOSD/MOGAD be a prerequisite for initiating #multiplesclerosis disease-modifying therapy?
5/🧵 -
MSJ
@MSJ_Research
Improving outcomes for people with #multiplesclerosis in sub-Saharan Africa will depend on making the disease visible epidemiologically, clinically, and politically.
Study from @Cambridge_Uni @kfaisalhospital ▶️ journals.sagepub.com/doi/full/10.1177/13524585261489419 -
MSJ
@MSJ_Research
Early serum neurofilament light chain may stratify optic neuritis severity and guide neuroprotective trial selection.
Study from @MyUniSR ▶️ journals.sagepub.com/doi/full/10.1177/13524585261489992 -
MSJ
@MSJ_Research
Articles on patient reported outcomes in #multiplesclerosis care are sparse and lack of consistent uses and purposes.
Scoping literature review ▶️ journals.sagepub.com/doi/full/10.1177/13524585261481124 -
MSJ reposted
MSJ
@MSJ_Research
What do you think? Should exclusion of NMOSD/MOGAD be a prerequisite for initiating #multiplesclerosis disease-modifying therapy?
5/🧵 -
MSJ
@MSJ_Research
New AFCTRIMS controversy available ⚖️
Should exclusion of NMOSD/MOGAD be a prerequisite for initiating #multiplesclerosis disease-modifying therapy?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
No 👎 from @HopkinsMedicine: Instead of an approach that is clinically unnecessary and potentially harmful to most patients, only targeted testing in those with red flags should be considered.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261489054
3/🧵
MSJ
@MSJ_Research
And commentary from @karolinska: Wider access to validated testing and better evidence on the epidemiology of inflammatory demyelinating diseases in African populations remain an important goal.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261489062
4/🧵Post not available here, view on X
MSJ
@MSJ_Research
What do you think? Should exclusion of NMOSD/MOGAD be a prerequisite for initiating #multiplesclerosis disease-modifying therapy?
5/🧵 -
MSJ
@MSJ_Research
Ocrelizumab-treated people with #multiplesclerosis showed lower serum biomarker risk scores compared with natalizumab, independent of clinical and MRI, suggesting direct effect of treatment mechanisms.
🔓MSJ-ETC study from @uofcincy ▶️ journals.sagepub.com/doi/10.1177/20552173261496839 -
MSJ
@MSJ_Research
A group resilience training program for people with #multiplesclerosis was not superior for the primary endpoint (resilence) but was superior for most secondary (anxiety, well-being, psychological flexibility, quality of life).
Study from @NeuroBesta ▶️ journals.sagepub.com/doi/full/10.1177/13524585261464886 -
MSJ
@MSJ_Research
Upper cervical cord morphometry and quantitative MRI metrics capture clinically relevant pathology and are linked to #multiplesclerosis evolution, supporting their potential prognostic value.
🔓MSJ-ETC study from @UniBasel_en @RC2NB ▶️ journals.sagepub.com/doi/10.1177/20552173261479426 -
MSJ reposted
Dr. Brandon Beaber
@Brandon_Beaber
relapses in the placebo group of multiple sclerosis clinical trials are going down over time journals.sagepub.com/doi/pdf/10.1177/1352458513481009
-
MSJ
@MSJ_Research
Ultra-processed foods are increasingly recognised as drivers of adverse health outcomes, and might act as a potentially modifiable contributor to #multiplesclerosis mechanisms.
Link to study ▶️ journals.sagepub.com/doi/full/10.1177/13524585261481479 -
MSJ
@MSJ_Research
C-sections prior to 39 weeks were more common in pregnant women with #multiplesclerosis but were attributable to standard obstetric indications (high-risk myomectomy and stalled labor) rather than disease complications.
Study from @aboutKP ▶️ journals.sagepub.com/doi/full/10.1177/13524585261481729 -
MSJ
@MSJ_Research
Gaps in #multiplesclerosis care, including lower levels of care and greater time between encounters, were observed for non-Hispanic Black compared to non-Hispanic White people.
Study from @UW @HopkinsMedicine ▶️ journals.sagepub.com/doi/full/10.1177/13524585261478826 -
MSJ
@MSJ_Research
The NEuRoMS intervention provides a feasible and acceptable neuropsychological rehabilitation for people with #multiplesclerosis with mild-to-moderate cognitive difficulties.
🔓MSJ-ETC study from @roshandasari @nikosevangelou3 @nottmhospitals ▶️ journals.sagepub.com/doi/10.1177/20552173261487853 -
MSJ
@MSJ_Research
📢October issue is now available
🔽
journals.sagepub.com/toc/MSJ/current
...and the cover goes to @ErasmusMC with their study on cognitive impairment in children with #multiplesclerosis and with #mogad ▶️ journals.sagepub.com/doi/full/10.1177/13524585261465586 -
MSJ
@MSJ_Research
The 2026 @ECTRIMS @MSJ_Research F2 Award (first #multiplesclerosis paper as first authors published in 2025 on our journals) goes to Sarah Lindberg (runner up Maria Sofia Martire).
Congratulations to all participants and see you next year! -
MSJ
@MSJ_Research
Our Editor-in-Chief @J_SastreGarriga chairing the late breaking session at #mstoronto2026
-
MSJ reposted
ECTRIMS
@ECTRIMS
#mstoronto2026
A very warm welcome to the final day of the 10th Joint ACTRIMS-ECTRIMS Meeting. Start your planning!
𝐂𝐡𝐞𝐜𝐤 𝐨𝐮𝐭 𝐭𝐡𝐞 𝐨𝐧𝐥𝐢𝐧𝐞 𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐦𝐞 ➡️ mstoronto2026.virtual-meeting.org/programme?segment=sessi…
@ECTRIMS, @ACTRIMS, @MTCC_Events, @SeeTorontoNow
#mstoronto2026 #msresearch #multiplesclerosis #neurology -
MSJ
@MSJ_Research
Opening ceremony at #mstoronto2026
Are you ready for 3 days of #multiplesclerosis research, clinical practice and networking? -
MSJ reposted
ECTRIMS
@ECTRIMS
#mstoronto2026 Pre-Day is underway! Opening the third edition of Pre-Day, @ECTRIMS President Professor Bruno Stankoff highlighted the rapid progress taking place across the field and the importance of bringing experts together to address emerging scientific and clinical challenges.
Today's programme features five sessions exploring:
• Disease Mechanisms
• Diagnostic Challenges
• Prognosis and Outcomes Informed by Imaging and Fluid Biomarkers
• Clinical Course and Outcomes
• Treatment Approaches
As our understanding of neuroimmunological diseases advances, so too does the need to explore where these conditions converge, where they differ and what these discoveries mean for diagnosis and treatment.
Bringing together perspectives on MS, MOGAD, NMOSD, autoimmune encephalitis and other neuroinflammatory conditions, Pre-Day creates an important opportunity to exchange knowledge, strengthen collaboration and advance our collective understanding of neuroimmunology.
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐭𝐡𝐞 𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐦𝐞 ➡️ mstoronto2026.virtual-meeting.org/programme?segment=sessi…
@ECTRIMS, @ACTRIMS, @MTCC_Events, @SeeTorontoNow
#mstoronto2026 #multiplesclerosis #neurology #msresearch -
MSJ reposted
ECTRIMS
@ECTRIMS
#mstoronto2026 kicks off tomorrow at Metro Toronto Convention Centre!
We begin on Tuesday with Pre-Day, featuring a deep dive into MS, NMOSD/MOGAD and autoimmune encephalitis. Then, on Wednesday, the 10th Joint ACTRIMS-ECTRIMS Meeting officially begins.
Whether you’re joining us in Toronto or online, this is your opportunity to connect with the global MS community and explore the latest advances in MS research.
👉 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐟𝐨𝐫 𝐯𝐢𝐫𝐭𝐮𝐚𝐥 𝐩𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐢𝐨𝐧 𝐭𝐨𝐝𝐚𝐲: wordpress-1663091-6696071.cloudwaysapps.com/registration/
@ECTRIMS, @ACTRIMS, @MTCC_Events, @SeeTorontoNow
#mstoronto2026 #multiplesclerosis #neurology #msresearch -
MSJ reposted
ECTRIMS
@ECTRIMS
📣 Attention neurologists! #ectrims is offering a unique opportunity to advance your career with the Clinical Training Fellowship Programme.
Join leading European MS clinics and research centres to learn cutting-edge techniques in patient management and care. This one-year funded fellowship is open to physicians from all over the world, but training must be completed in Europe.
🗓️ 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐝𝐞𝐚𝐝𝐥𝐢𝐧𝐞: 1 𝐃𝐞𝐜𝐞𝐦𝐛𝐞𝐫 2026
🔗 𝐀𝐩𝐩𝐥𝐲 𝐡𝐞𝐫𝐞: ectrims.eu/fellowships/ectrims-multiple-sclerosis-clinica…
Don't miss this chance to enhance your expertise and make a significant impact in MS care.
#ectrimsfellowships #ectrimsnextgen #applynow #msresearch #healthcareprofessionals #neurology #advanceyourcareer #clinicaltraining #mscare #neurology #medicalfellowship -
MSJ reposted
ECTRIMS
@ECTRIMS
🎙️ The #ectrimspodcast is heading to #mstoronto2026!
We’ll be sharing special episodes throughout the Joint Meeting, featuring leading voices in #msresearch and care.
🎧 𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐞 𝐧𝐨𝐰 𝐬𝐨 𝐞𝐯𝐞𝐫𝐲 𝐧𝐞𝐰 𝐞𝐩𝐢𝐬𝐨𝐝𝐞 𝐢𝐬 𝐫𝐞𝐚𝐝𝐲 𝐰𝐡𝐞𝐧 𝐢𝐭 𝐝𝐫𝐨𝐩𝐬.
🟢 𝐒𝐩𝐨𝐭𝐢𝐟𝐲: open.spotify.com/show/6T9TTe9oyJhxGsCFX6viA5
🍎 𝐀𝐩𝐩𝐥𝐞: podcasts.apple.com/us/podcast/the-ectrims-podcast/id16502…
@ECTRIMS #multiplesclerosis -
MSJ reposted
ECTRIMS
@ECTRIMS
🔬 𝐂𝐚𝐧 𝐌𝐒 𝐩𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐫𝐞𝐚𝐥𝐥𝐲 𝐛𝐞 𝐝𝐞𝐭𝐞𝐜𝐭𝐞𝐝 𝐢𝐧 𝐫𝐞𝐚𝐥 𝐭𝐢𝐦𝐞?
Recognising changes in multiple sclerosis early can make a difference to clinical decision-making. But how can we know whether a change is permanent or temporary?
In our latest podcast, two leading MS experts — Professors Helmut Butzkueven and Tjalf Ziemssen — explore both sides of this important debate.
From traditional disability assessments to digital technologies and the everyday experiences of people living with MS, the conversation explores how we can better recognise meaningful changes over time.
🎧 𝐋𝐢𝐬𝐭𝐞𝐧 𝐧𝐨𝐰:
🟢 𝐒𝐩𝐨𝐭𝐢𝐟𝐲: open.spotify.com/episode/2u6rb2WdmOLCwDKfNo0WkI
🍎 𝐀𝐩𝐩𝐥𝐞 𝐏𝐨𝐝𝐜𝐚𝐬𝐭𝐬: podcasts.apple.com/za/podcast/the-ectrims-podcast/id16502…
🌐 𝐄𝐂𝐓𝐑𝐈𝐌𝐒: ectrims.eu/podcast/ms-journal-can-we-detect-ms-progressio…
@ECTRIMS #ectrims #multiplesclerosis #msresearch #msprogression -
MSJ
@MSJ_Research
A woman in her 20s was referred for demyelinating disease based on white matter lesions on MRI, but was then found to have genetic leukoencephalopathy (LBSL with biallelic DARS2 variants).
Case report from @CLENeurons ▶️ journals.sagepub.com/doi/full/10.1177/13524585261477212
1/🧵
MSJ
@MSJ_Research
...and commentary from @QSMSCENTRE @UCLIoN @UCLBrainScience: Recognising when not to diagnose #multiplesclerosis is becoming just as important as recognising when to do so.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261477216
2/🧵 -
MSJ
@MSJ_Research
New #msj & ECTRIMS podcast is available ▶️ ectrims.eu/podcast/ms-journal-can-we-detect-ms-progressio…
Anneke Van der Walt, @TjalfZiemssen and @HelmutButz discuss whether we can detect #multiplesclerosis progression in real time? -
MSJ
@MSJ_Research
The minority of people with #multiplesclerosis initiated high-intensity treatment, and later years were predictive of high-intensity treatment.
🔓MSJ-ETC study from @TirishamGyangMD @OSUWexMed @OhioStateNeuro ▶️ journals.sagepub.com/doi/full/10.1177/20552173261487868 -
MSJ reposted
IJMSC
@IJMSCtweets
"...educating primary care and emergency clinicians about the prevalence of MS in Black and Hispanic populations is essential to early pattern recognition for patient presentation."
#multiplesclerosis #diagnosis
MSJ
@MSJ_Research
The common presentation of Black and Hispanic individuals to acute care and the severe symptoms in Black individuals, require improved education about #multiplesclerosis within minoritized communities.
Study from @UCSF @AmezcuaLilyana @UniversityofSo5 ▶️ journals.sagepub.com/doi/full/10.1177/13524585261475041 -
MSJ
@MSJ_Research
After a mean follow-up of 2.4 years, authors did not observe any clinical relapse or MRI reactivation among 61 people with #multiplesclerosis switching to ofatumumab after natalizumab cessation.
🔓MSJ-ETC study from @CHRUStrasbourg @CHUBordeaux ▶️ journals.sagepub.com/doi/full/10.1177/20552173261487860 -
MSJ
@MSJ_Research
There is high prevalence, burden, and impact of symptoms in people with #multiplesclerosis, highlighting the need for multifaceted care strategies.
Survey from @peterfeys_ @uhasselt @KU_Leuven ▶️ journals.sagepub.com/doi/full/10.1177/13524585261480514 -
MSJ
@MSJ_Research
The common presentation of Black and Hispanic individuals to acute care and the severe symptoms in Black individuals, require improved education about #multiplesclerosis within minoritized communities.
Study from @UCSF @AmezcuaLilyana @UniversityofSo5 ▶️ journals.sagepub.com/doi/full/10.1177/13524585261475041 -
MSJ
@MSJ_Research
Affective reserve in older adults with #multiplesclerosis is associated with both physical and mental well-being.
A residual-based approach from @QuinnipiacU @UConnNeurology ▶️ journals.sagepub.com/doi/full/10.1177/13524585261480508 -
MSJ
@MSJ_Research
A community-validated tool for consistent and reproducible specification of disability outcomes in #multiplesclerosis.
Consensus endorsed by the International Advisory Committee on Clinical Trials in MS from @NMontobbio @UniGenova ▶️ journals.sagepub.com/doi/full/10.1177/13524585261478492 -
MSJ
@MSJ_Research
Yes! (but no diet)
MSJ
@MSJ_Research
What do you think? Does the gut microbiota play a modifiable role in #multiplesclerosis progression?
5/🧵 -
MSJ
@MSJ_Research
An interactive web-based educational platform improved healthcare providers’ ability to identify paramagnetic rim lesions for #multiplesclerosis diagnosis, with 91% achieving target proficiency.
Study from @OregonHealth ▶️ journals.sagepub.com/doi/full/10.1177/13524585261476513 -
MSJ reposted
ACTRIMS®
@ACTRIMS
What does Unifying MS mean? Dan Ontaneda explores this year’s theme and how a unified approach could shape the future of MS research and care.
📅 Oct 21–23, 2026 | Toronto + Virtual
🔗 mstoronto2026.org/registration/
Join us at #mstoronto2026!This media couldn't be displayed. See it on the original post. -
MSJ
@MSJ_Research
📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠
Register here to receive our research
🔽
journals.sagepub.com/connected/MSJ -
MSJ
@MSJ_Research
New controversy available ⚖️
Does the gut microbiota play a modifiable role in #multiplesclerosis progression?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @karolinskainst: The gut microbiome should be viewed as a plausible contributor to #multiplesclerosis progression whose therapeutic potential remains to be established.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261471368
4/🧵
MSJ
@MSJ_Research
What do you think? Does the gut microbiota play a modifiable role in #multiplesclerosis progression?
5/🧵 -
MSJ
@MSJ_Research
Self-guided online cognitive behavioral therapy interventions are promising supportive tools for managing cognitive fatigue in people with #multiplesclerosis.
🔓MSJ-ETC study from @uni_mainz ▶️ journals.sagepub.com/doi/full/10.1177/20552173261468118 -
MSJ reposted
ECTRIMS
@ECTRIMS
🏆 Congratulations to Prof. Sandra Vukusic, winner of the 2026 #rachelhorneprize for Women’s Research in MS.
🎧 Hear her discuss the research and people behind her career on the @ECTRIMS Podcast.
🎧 𝐋𝐢𝐬𝐭𝐞𝐧 𝐭𝐨 𝐭𝐡𝐞 𝐬𝐩𝐞𝐜𝐢𝐚𝐥 𝐞𝐩𝐢𝐬𝐨𝐝𝐞 𝐧𝐨𝐰:
🟢 𝐒𝐩𝐨𝐭𝐢𝐟𝐲: open.spotify.com/episode/3JSmiu2Qz3GBocRX5PVp4A?nd=1&dlsi…
🍎 𝐀𝐩𝐩𝐥𝐞 𝐏𝐨𝐝𝐜𝐚𝐬𝐭𝐬: podcasts.apple.com/es/podcast/sandra-vukusic-named-2026-r…
🌐 𝐄𝐂𝐓𝐑𝐈𝐌𝐒: ectrims.eu/podcast/sandra-vukusic-named-2026-rachel-horne…
#rachelhorneprize #multiplesclerosis #womenshealth #msresearch #womeninscience #ectrimspodcast -
MSJ
@MSJ_Research
High-dose steroids rapidly alter multiple serum biomarkers (GFAP, Serpin A9, FLRT2, contactin-2, protogenin, MOG, CXCL9, CD6, BAFF, IL-12B, CDCP1), with implications for timing, interpretation and validation.
🔓MSJ-ETC study from @UCIrvine ▶️ journals.sagepub.com/doi/full/10.1177/20552173261487037 -
MSJ
@MSJ_Research
Walking fatigability indices correspond with perception of changes in gait speed and quality during an instrumented 6-minute walking test in people with #multiplesclerosis.
🔓MSJ-ETC study from @peterfeys_ @uhasselt ▶️ journals.sagepub.com/doi/full/10.1177/20552173261471715 -
MSJ
@MSJ_Research
Among participants to a #multiplesclerosis registry most were willing to provide saliva for genetics, though overall participation represented a minority of those contacted.
🔓MSJ-ETC study from @KaarinaKowalec @umanitoba @karolinskainst @UTSWMedCenter ▶️ journals.sagepub.com/doi/full/10.1177/20552173261467203 -
MSJ
@MSJ_Research
In people with relapsing #multiplesclerosis treated with ocrelizumab, retinal atrophy is attenuated to the level of healthy controls, and clinical function relatively stable
🔓MSJ-ETC study from @HopkinsMedicine ▶️ journals.sagepub.com/doi/full/10.1177/20552173261478412 -
MSJ
@MSJ_Research
#multiplesclerosis therapies in women are associated with increased risks of HPV positivity, cervical dysplasia/cancer, cervicitis, herpes simplex virus, vulvovaginitis, and Bartholin cysts/abscess.
Study from @harvardmed @UCSF ▶️ journals.sagepub.com/doi/10.1177/13524585261475100 -
MSJ
@MSJ_Research
📢September issue is now available
🔽
journals.sagepub.com/toc/MSJ/current
...and the cover goes to @UBC @UCSF and North American Imaging in Multiple Sclerosis #naims Cooperative with their review on spinal cord imaging for #multiplesclerosis ▶️journals.sagepub.com/doi/10.1177/13524585261444600 -
MSJ
@MSJ_Research
A 35-year-old woman with relapsing #multiplesclerosis continued ofatumumab until 28 weeks of gestation and resumed maintenance therapy postpartum without re-induction. Her infant showed normal B cells and completed vaccinations.
🔓 MSJ-ETC case report ▶️ journals.sagepub.com/doi/10.1177/20552173261472641 -
MSJ
@MSJ_Research
Close call!
MSJ
@MSJ_Research
What do you think? Resources aside, would you like your family to be screened for #multiplesclerosis?
5/🧵 -
MSJ
@MSJ_Research
A 31-year-old male with #multiplesclerosis on ofatumumab who had a bat fly into his hand, needed the standard rabies vaccination series and two additional booster vaccinations, to establish humoral.
🔓MSJ-ETC case report from @UTSWMedCenter ▶️ journals.sagepub.com/doi/10.1177/20552173261474744 -
MSJ
@MSJ_Research
Juxtacortical paramagnetic rims are a characteristic feature of cortical lesions with greater clinical and radiological burden in #multiplesclerosis.
Study from @CQMU1956 @QSMSCENTRE @UCLIoN @UCLBrainScience ▶️ journals.sagepub.com/doi/10.1177/13524585261471330 -
MSJ reposted
ECTRIMS
@ECTRIMS
🎥 Why are fellowships at the heart of ECTRIMS activities?
In this short video, Prof. Gabriel Bsteh from the Medizinische Universität Wien highlights how @ECTRIMS Fellowships empower young researchers and clinicians to access opportunities they might not have at home — from advanced education to cutting-edge scientific and clinical training.
Fellowships are more than just time abroad. They create lasting bonds: most fellows remain active contributors to the ECTRIMS community long after their fellowship ends.
📅 𝐃𝐞𝐚𝐝𝐥𝐢𝐧𝐞: 1 𝐃𝐞𝐜𝐞𝐦𝐛𝐞𝐫 2026
▶️ 𝐀𝐩𝐩𝐥𝐲 𝐯𝐢𝐚 𝐦𝐲𝐄𝐂𝐓𝐑𝐈𝐌𝐒: ectrims.eu/fellowships
#msresearch #fellowships #ectrimsnextgenThis media couldn't be displayed. See it on the original post. -
MSJ
@MSJ_Research
In >10 years, 17.2% people with relapsing-onset #multiplesclerosis transitioned to secondary progression, of whom 92.8% were not relapsing by the final visit.
🔓MSJ-ETC study from @Gauruv @MassGenBrigham @harvardmed @OttawaHospital @uOttawaMed ▶️ journals.sagepub.com/doi/10.1177/20552173261473717 -
MSJ
@MSJ_Research
New controversy available ⚖️
Resources aside, would you like your family to be screened for #multiplesclerosis?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @DalhousieU @UTAS_: We must fully understand what factors (age, family history, perceived severity or treatability) would influence decision-making, and demonstrate secondary prevention of #multiplesclerosis.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261471356
4/🧵
MSJ
@MSJ_Research
What do you think? Resources aside, would you like your family to be screened for #multiplesclerosis?
5/🧵 -
MSJ
@MSJ_Research
In this #multiplesclerosis population predominantly aged 50 years or older, the recombinant zoster vaccine demonstrated robust effectiveness, preventing 64%–81% of herpes zoster cases.
Study from @harvardmed @HarvardPilgrim @PennNeurology ▶️ journals.sagepub.com/doi/10.1177/13524585261468620 -
MSJ
@MSJ_Research
🔊 Listen to @MSIntFederation on the global prevalence of multiple sclerosis surpassing 3 million in 2024.
📄 And read the full manuscript ▶️ journals.sagepub.com/doi/10.1177/13524585261479954 -
MSJ
@MSJ_Research
Increased variability in physical exertion affects subjective effort assessment in individuals with #multiplesclerosis, reflecting why exertion feels particularly costly.
Study from @JohnsHopkins ▶️ journals.sagepub.com/doi/full/10.1177/13524585261469807 -
MSJ reposted
Dr. Brandon Beaber
@Brandon_Beaber
In multiple sclerosis, starting kesimpta shortly after stopping tysabri is effective in preventing post-tysabri rebound disease activity according to this case series of 61 people with MS (mean follow up 2.4 years; no relapses or MRI activity) journals.sagepub.com/doi/10.1177/20552173261487860
-
MSJ
@MSJ_Research
Early cognitive impairment is prevalent in 47% of children with #multiplesclerosis and 43% with #mogad, with difficulties in complex attention.
Study from @ErasmusMC ▶️ journals.sagepub.com/doi/full/10.1177/13524585261465586 -
MSJ
@MSJ_Research
Let's do it!
MSJ
@MSJ_Research
What do you think? #multiplesclerosis phenotypes should be abandoned in favour of a continuous disease spectrum model?
5/🧵 -
MSJ reposted
Sharon Roman (n of 1)
@SRoman_SPQR
If I may, it’s ⬇️ for the folks who would like it explained in plain language.
tremlettsmsresearchexplained.wordpress.com/2026/09/09/eme…
MSJ
@MSJ_Research
Emergency department utilization was consistently elevated in the 5 years before #multiplesclerosis recognition, predominantly due to non-neurologic and non-specific presentations.
Study from @DMCBrainHealth @UBC ▶️ journals.sagepub.com/doi/full/10.1177/13524585261475120 -
MSJ
@MSJ_Research
Adherence to ofatumumab was similar to infusion therapies (18 months: 74% vs. 70%; 24 months: 70% vs. 65%), suggesting it is a convenient, effective, self-administered alternative to infusions in #multiplesclerosis.
🔓MSJ-ETC study from @Novartis ▶️ journals.sagepub.com/doi/full/10.1177/20552173261464369 -
MSJ
@MSJ_Research
Colorectal cancer screening is lower among older individuals with #multiplesclerosis, remains suboptimal in both people with MS and controls.
Study from @RennesUniv ▶️ journals.sagepub.com/doi/full/10.1177/13524585261465197 -
MSJ
@MSJ_Research
Emergency department utilization was consistently elevated in the 5 years before #multiplesclerosis recognition, predominantly due to non-neurologic and non-specific presentations.
Study from @DMCBrainHealth @UBC ▶️ journals.sagepub.com/doi/full/10.1177/13524585261475120 -
MSJ reposted
Afrika Winslet💜 at 🏠🌋
@AfrikaWinslet
It seems to me that we try to fit into some category but some of us are not really fitting in 😕
-
MSJ
@MSJ_Research
New controversy available ⚖️
#multiplesclerosis phenotypes should be abandoned in favour of a continuous disease spectrum model?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @MonashUni @AlfredHealth @karolinskainst: #multiplesclerosis phenotypes are not fixed identities, but should be seen as summaries of position along a continuum, with integration of serum, imaging and other biomarkers.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261471769
4/🧵
MSJ
@MSJ_Research
What do you think? #multiplesclerosis phenotypes should be abandoned in favour of a continuous disease spectrum model?
5/🧵 -
MSJ
@MSJ_Research
Vascular risk factors may contribute to increased disability, motor impairment, and region-specific sensorimotor network structural integrity in #multiplesclerosis.
Sutdy from @AlbergoniMatteo @NRU_SanRaffaele @MyUniSR @SanRaffaeleMI ▶️ journals.sagepub.com/doi/full/10.1177/13524585261464469 -
MSJ
@MSJ_Research
Certain sex-dependent bioactive lipid mediator, such as 9-HOTrE, may display neuroprotective effects in #multiplesclerosis.
🔓 MSJ-ETC study from @MScentrum020 @amsterdamumc ▶️ journals.sagepub.com/doi/full/10.1177/20552173261475501 -
MSJ
@MSJ_Research
Most risk factors, including family history, HLA-DRB1*15:01, EBNA1 antibody levels, smoking and low sun exposure, were associated with both late- and adult-onset #multiplesclerosis, suggesting a shared etiology.
Study from @karolinskainst ▶️ journals.sagepub.com/doi/full/10.1177/13524585261472320 -
MSJ
@MSJ_Research
There were no significant difference in retinal atrophy (GCIPL or pRNFL) and clinical outcomes between extended versus standard interval natalizumab therapy in #multiplesclerosis.
🔓MSJ-ETC study from @JohnsHopkins ▶️ journals.sagepub.com/doi/full/10.1177/20552173261475496 -
MSJ reposted
ECTRIMS
@ECTRIMS
🔍 Is it time to revisit how we describe the course of #multiplesclerosis?
A new IACCTMS paper in @Nature Reviews Neurology sets out a roadmap towards a more biologically informed approach to describing #ms — one that better reflects our evolving understanding of the disease.
We thank the international experts involved for their continued commitment to advancing how MS is understood, studied and treated.
🌍 IACCTMS is jointly supported by @ECTRIMS and the @mssociety.
📖 Read the paper: idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nat… -
MSJ
@MSJ_Research
Enterovirus infection in B-cell depleted patients may cause severe central nervous system involvement, and early IVIg and investigational antivirals may be considered.
Narrative review with two illustrative cases from @AKunchok @ClevelandClinic ▶️ journals.sagepub.com/doi/10.1177/20552173261471722 -
MSJ
@MSJ_Research
Real-world practice in Sweden broadly aligns with national recommendations for pregnancy in #multiplesclerosis, with widespread use of rituximab reflecting its perceived safety and durable effect
🔓MSJ-ETC study from @karolinskainst ▶️ journals.sagepub.com/doi/10.1177/20552173261472249 -
MSJ
@MSJ_Research
Post-traumatic stress disorder in people with #multiplesclerosis and its impact on activity, employment and participation.
A narrative review from @DavidEFreedman @UofTPsych @UnityHealthTO ▶️ journals.sagepub.com/doi/full/10.1177/13524585261475088 -
MSJ
@MSJ_Research
Insights from the @DK_MS_Registry following nationwide implementation of patient-reported outcomes in #multiplesclerosis across different ages and disability levels.
🔓MSJ-ETC study from @melindamagyari @Rigshospitalet @uni_copenhagen ▶️ journals.sagepub.com/doi/10.1177/20552173261468115 -
MSJ
@MSJ_Research
Two years of short-course cladribine tablets provided sustained clinical and cognitive benefits, supporting the potential for treatment-free remission in relapsing #multiplesclerosis.
Results from the MAGNIFY-MS Extension study from
@unisiena @UNSW ▶️ journals.sagepub.com/doi/full/10.1177/13524585261467624 -
MSJ
@MSJ_Research
An unrecorded interval between #multiplesclerosis onset and initial data in observational studies (left-truncation). can affect relapse estimates and, less so, disability outcomes.
Study from @TheRMH ▶️ journals.sagepub.com/doi/full/10.1177/13524585261459943 -
MSJ
@MSJ_Research
🔊 Listen to Mehari Woldemariam Merid @MelbourneOf on the mediation effect of DNA methylation on the associations of Mediterranean diet scores with #multiplesclerosis onset-risk.
📄 And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585261462517 -
MSJ reposted
Dr. Kaarina Kowalec 🧬👩🔬
@KaarinaKowalec
-
MSJ reposted
Dr. Kaarina Kowalec 🧬👩🔬
@KaarinaKowalec
New paper 🧬 We piloted saliva collection for genetics in the NARCOMS MS registry: ~62% of interested participants consented; only ~10% of invited actually took part. Hypothetical willingness to share genetic data ≠ actual behavior. 🔗journals.sagepub.com/doi/10.1177/20552173261467203 @MSJ_Research
-
MSJ
@MSJ_Research
📢August issue is now available
🔽
journals.sagepub.com/toc/MSJ/current
...and the cover goes to @karolinskainst with therr susceptibility network analysis of disease trajectories leading to #multiplesclerosis ▶️ journals.sagepub.com/doi/10.1177/13524585261421480 -
MSJ reposted
Dr. Kaarina Kowalec 🧬👩🔬
@KaarinaKowalec
New paper in @MSJ_Research from our lab:🧬1 in 20 people with MS on dimethyl fumarate develop severe lymphopenia. We found a polygenic score for lymphocyte counts predicts risk (57% risk reduction per SD increase). Genetics may help flag who needs closer monitoring.
-
MSJ
@MSJ_Research
Adding the digital health application (levidex) levidex to treatment as usual yielded meaningful improvements in depressive symptoms and social/work functioning in people with #multiplesclerosis.
LAMONT trial ▶️ journals.sagepub.com/doi/full/10.1177/20552173261475519 -
MSJ
@MSJ_Research
A three-miRNA panel (hsa-miR-122-5p, hsa-miR-15b-5p, hsa-miR-30e-5p) demonstrated high discriminative accuracy for relapses and remissions in treatment-naive #multiplesclerosis.
Study from @TelAvivUni ▶️ journals.sagepub.com/doi/10.1177/20552173261471723 -
MSJ
@MSJ_Research
Rituximab may be inferior to ocrelizumab for relapse suppression (ARR 0.05 vs 0.03), though the rarity of relapses underpowered comparisons.
Study from @UAlberta @UBC ▶️ journals.sagepub.com/doi/full/10.1177/13524585261453817 -
MSJ
@MSJ_Research
Three automated platforms for blood glial fibrillary acidic protein #gfap -Quanterix Simoa HD-X, Roche Elecsys and Fujirebio Lumipulse G600- showed strong correlations and minor biases in controls and #multiplesclerosis.
Study from @UKSH_KI_HL ▶️ journals.sagepub.com/doi/full/10.1177/20552173261460155 -
MSJ
@MSJ_Research
Perhaps we actually need more evidence...
MSJ
@MSJ_Research
What do you think? All anti-CD20 therapies are equivalent in treating #multiplesclerosis?
5/🧵 -
MSJ
@MSJ_Research
Live birth pregnancy was associated with longer time to disability in women with mild relapse-onset #multiplesclerosis, but postpartum relapse increased risks of progression.
@MSBase_Registry study from @vjokubaitis @MonashUni ▶️ journals.sagepub.com/doi/full/10.1177/13524585261464055 -
MSJ reposted
Dr. Brandon Beaber
@Brandon_Beaber
The shingles vaccine is about 64-81% effective in people with multiple sclerosis (retrospective analysis of medicare data). pubmed.ncbi.nlm.nih.gov/42590996/
-
MSJ
@MSJ_Research
New controversy available ⚖️
All anti-CD20 therapies are equivalent in treating #multiplesclerosis?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @MonashUni @AlfredHealth: Recognising both their equivalence in controlling acute inflammation and distinct long-term pharmacological paths will support clinicians to tailor therapies to persons with #multiplesclerosis.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261466524
4/🧵
MSJ
@MSJ_Research
What do you think? All anti-CD20 therapies are equivalent in treating #multiplesclerosis?
5/🧵 -
MSJ
@MSJ_Research
B-cell depletion is associated with reduced chronic lesion tissue expansion, relative to fingolimod, a promising biomarker of progressive #multiplesclerosis biology.
Study from @rpahos_school @Sydney_Uni ▶️ journals.sagepub.com/doi/full/10.1177/13524585261459228 -
MSJ
@MSJ_Research
In 25 women with #multiplesclerosis, B-cell depletion persisted into the third trimester following ofatumumab cessation for pregnancy, with low postpartum #multiplesclerosis activity.
Study from @DrWBRO @QSMSCENTRE ▶️ journals.sagepub.com/doi/full/10.1177/13524585261471448 -
MSJ
@MSJ_Research
Yes, we can do it!
MSJ
@MSJ_Research
What do you think? Preventing frailty in #multiplesclerosis is a realistic goal?
5/🧵 -
MSJ
@MSJ_Research
Neurofilament light chain #nfl and glial fibrillary acidic protein #gfap are strongly age-dependent and concordant across serum and plasma in healthy individuals (using Quanterix SR-X Simoa Neuro 4-Plex).
🔓 MSJ-ETC study from @CUMedicalSchool ▶️ journals.sagepub.com/doi/full/10.1177/20552173261466440 -
MSJ
@MSJ_Research
Borrelia miyamotoi meningoradiculitis complicating ocrelizumab treatment for #multiplesclerosis, with routine laboratory tests failing to detect the pathogen.
A report of three cases from @InstitutCerveau @HopPitieSalpe @CHUdeLyon ▶️ journals.sagepub.com/doi/full/10.1177/13524585261473068
1/🧵
MSJ
@MSJ_Research
...and commentary from @UPorto: Close collaboration between neurology and infectious diseases whenever immunocompromised patients present with atypical, relapsing neuroinflammatory syndromes.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261473072
2/🧵 -
MSJ
@MSJ_Research
New controversy available ⚖️
Preventing frailty in #multiplesclerosis is a realistic goal?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
No 👎 from @AnToSc @imperialcollege @unisiena: Targeting the biological mechanisms of #multiplesclerosis progressive brain ageing, neurodegeneration, and impaired repair processes, are the key unmet therapeutic challenges in frailty prevention.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261466107
3/🧵
MSJ
@MSJ_Research
And commentary from @univca @SUNY: Complete prevention of frailty may be unrealistic in #multiplesclerosis, but delaying onset, reducing severity, enhancing resilience, and extending healthspan appear achievable and clinically meaningful goals.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261466101
4/🧵
MSJ
@MSJ_Research
What do you think? Preventing frailty in #multiplesclerosis is a realistic goal?
5/🧵 -
MSJ
@MSJ_Research
Induced pluripotent stem cell treatment for microglia replacement in progressive #multiplesclerosis.
Review from @UTSWMedCenter▶️ journals.sagepub.com/doi/full/10.1177/13524585261459847 -
MSJ
@MSJ_Research
🔊 Listen to Marina Mastantuono @RC2NB
on choroid plexus morphological and microstructural changes across inflammatory phenotypes in #multiplesclerosis.
📄And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585261462513 -
MSJ reposted
ECTRIMS
@ECTRIMS
Should we screen people at high risk of developing MS before symptoms appear?
🎧 In the latest ECTRIMS–MS Journal Controversies episode, Helen Tremlett and Ruth Ann Marrie debate the science, ethics and practical realities of early MS screening—and whether the field is ready.
🎧 𝐋𝐢𝐬𝐭𝐞𝐧 𝐧𝐨𝐰:
𝐒𝐩𝐨𝐭𝐢𝐟𝐲: open.spotify.com/episode/2Nv6jdtZBaCvvIo86PQHIO
𝐀𝐩𝐩𝐥𝐞 𝐏𝐨𝐝𝐜𝐚𝐬𝐭𝐬: podcasts.apple.com/za/podcast/should-high-risk-population…
𝐎𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: ectrims.eu/podcast/should-high-risk-populations-be-screen…
#multiplesclerosis #ectrimspodcast #msjournal #msresearch -
MSJ
@MSJ_Research
Epiretinal membranes may identify a distinct #multiplesclerosis type, potentially characterized by pathological microglial and/or macroglial activity.
Study from @JohnsHopkins ▶️ journals.sagepub.com/doi/full/10.1177/13524585261446834
1/🧵
MSJ
@MSJ_Research
...and commentary from @chenmayo @mayoneurores: A novel line of inquiry that, with longitudinal validation, could meaningfully expand the understanding of #multiplesclerosis pathophysiology.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261464504
2/🧵 -
MSJ
@MSJ_Research
Profiling the long-term risk of severe adverse events with different treatment sequences in #multiplesclerosis.
Study from the Italian Multiple Sclerosis and Related Disorders Registry ▶️ journals.sagepub.com/doi/full/10.1177/13524585261457317 -
MSJ
@MSJ_Research
Depression, disease impact, fatigue, and executive functioning have a strong impact on social role participation in #multiplesclerosis.
Study from @nyulangone @avemariauniv ▶️ journals.sagepub.com/doi/full/10.1177/13524585261459835 -
MSJ reposted
ECTRIMS
@ECTRIMS
❄️ 𝐄𝐂𝐓𝐑𝐈𝐌𝐒 𝐖𝐢𝐧𝐭𝐞𝐫 𝐒𝐜𝐡𝐨𝐨𝐥 2027 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐩𝐞𝐫𝐢𝐨𝐝 𝐨𝐩𝐞𝐧𝐬 𝐭𝐨𝐝𝐚𝐲! Apply to join us in Brussels, Belgium, from 10–12 February 2027 for the 5th ECTRIMS Winter School, an intensive three-day programme designed for clinician-scientists, senior PhD students, and postdoctoral researchers looking to deepen their expertise in translational neuroimmunology.
𝐖𝐡𝐨 𝐬𝐡𝐨𝐮𝐥𝐝 𝐚𝐩𝐩𝐥𝐲?
Applicants should have demonstrated experience in translational neuroimmunology, supported by relevant publications.
✅ 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐫𝐞𝐪𝐮𝐢𝐫𝐞𝐦𝐞𝐧𝐭𝐬
-Motivation statement (max. 1,000 characters)
-CV (max. 2 pages)
-Supervisor recommendation letter (max. 1 page)
💡 𝐒𝐮𝐜𝐜𝐞𝐬𝐬𝐟𝐮𝐥 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐧𝐭𝐬 𝐰𝐢𝐥𝐥 𝐫𝐞𝐜𝐞𝐢𝐯𝐞:
-Three nights' accommodation (9–12 February 2027)
-Flights and travel expenses
-Meals and refreshments throughout the programme
📅 𝐃𝐞𝐚𝐝𝐥𝐢𝐧𝐞: 7 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 2026
Learn more about the ECTRIMS Winter School programme 2027 and start your application today ➡️ ectrims.eu/ongoing-educational-programmes/winter-schools/
#ectrimsnextgen #msresearch #neurology #ectrimswinterschool #neuroimmunology -
MSJ reposted
IJMSC
@IJMSCtweets
"In this multi-cohort study of PwMS, we demonstrate that tobacco smoke exposure (current smoking and nicotine exposure) disrupts two interconnected host–microbiome co-metabolic pathways: tryptophan and bile acid metabolism."
#smoking #multiplesclerosis #nicotine
MSJ
@MSJ_Research
Tobacco exposure disrupts host–microbiome tryptophan and bile acid metabolism in persons with #multiplesclerosis, highlighting a potential mechanistic pathway.
Study from @UniversityMiami @cwru @BrighamWomens @harvardmed @MayoClinic ▶️ journals.sagepub.com/doi/full/10.1177/13524585261454207 -
MSJ
@MSJ_Research
Adopting semiautomated coregistration-fusion into clinical practice can improve detection of radiologic disease activity in #multiplesclerosis.
Study from @StMichaelsFdn @UofT ▶️ journals.sagepub.com/doi/full/10.1177/13524585261453816 -
MSJ
@MSJ_Research
📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠
Register here to receive our research
🔽
journals.sagepub.com/connected/MSJ -
MSJ
@MSJ_Research
Racial identity and neighborhood marginalization may influence depression in pediatric-onset #multiplesclerosis.
Study from @ColoradoStateU @SickKidsNews @UofT ▶️ journals.sagepub.com/doi/full/10.1177/13524585261453239 -
MSJ
@MSJ_Research
Did you publish your first #multiplesclerosis article as first author in 2025 on our journals?
Apply to the 2026 F2 Award with a cash prize and one year access to the #msj (stay tuned at the @ACTRIMS @ECTRIMS 2026 Closing Ceremony) ▶️ journals.sagepub.com/pb-assets/cmscontent/MSJ/MSJF2Awards…
Deadline: TODAY -
MSJ
@MSJ_Research
Tobacco exposure disrupts host–microbiome tryptophan and bile acid metabolism in persons with #multiplesclerosis, highlighting a potential mechanistic pathway.
Study from @UniversityMiami @cwru @BrighamWomens @harvardmed @MayoClinic ▶️ journals.sagepub.com/doi/full/10.1177/13524585261454207 -
MSJ
@MSJ_Research
Did you publish your first #multiplesclerosis article as first author in 2025 on our journals?
Apply to the 2026 F2 Award with a cash prize and one year access to the #msj (stay tuned at the @ACTRIMS @ECTRIMS 2026 Closing Ceremony) ▶️ journals.sagepub.com/pb-assets/cmscontent/MSJ/MSJF2Awards…
Deadline: TOMORROW -
MSJ
@MSJ_Research
B-cell depletion is associated with reduced chronic lesion tissue expansion, relative to fingolimod, a promising biomarker of progressive #multiplesclerosis biology.
Study from @Sydney_Uni @rpahos_school ▶️ journals.sagepub.com/doi/full/10.1177/13524585261459228 -
MSJ
@MSJ_Research
Black people with #multiplesclerosis initially had an 86% higher odds of disability, than White, but attenuated to 72% after adjusting for neighborhood-level socioeconomic disadvantage, suggesting structural inequities.
Link to study ▶️ journals.sagepub.com/doi/full/10.1177/13524585261454841 -
MSJ
@MSJ_Research
Did you publish your first #multiplesclerosis article as first author in 2025 on our journals?
Apply to the 2026 F2 Award with a cash prize and one year access to the #msj (stay tuned at the @ACTRIMS @ECTRIMS 2026 Closing Ceremony) ▶️ journals.sagepub.com/pb-assets/cmscontent/MSJ/MSJF2Awards…
Deadline: Jul 24 -
MSJ
@MSJ_Research
📢July issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @ruhrunibochum with their sex-specific analysis of early disease course and treatment in #multiplesclerosis ▶️ journals.sagepub.com/doi/full/10.1177/13524585261446846 -
MSJ
@MSJ_Research
Did you publish your first #multiplesclerosis article as first author in 2025 on our journals?
Apply to the 2026 F2 Award with a cash prize and one year access to the #msj (stay tuned at the @ACTRIMS @ECTRIMS 2026 Closing Ceremony) ▶️ journals.sagepub.com/pb-assets/cmscontent/MSJ/MSJF2Awards…
Deadline: Jul 24 -
MSJ
@MSJ_Research
Ocrelizumab treatment over 2 years is associated with declining myo-inositol levels measured by MR spectroscopy in both relapsing and progressive #multiplesclerosis, possibly reflecting resolution of gliosis and reactive microglia.
Study from @UBC ▶️ journals.sagepub.com/doi/full/10.1177/13524585261456964 -
MSJ
@MSJ_Research
A registry-integrated eHealth program showed potential to support the management of fatigue and cognitive symptoms in people living with #multiplesclerosis.
🔓MSJ-ETC study from @UniEastFinland @UniTurku ▶️ journals.sagepub.com/doi/10.1177/20552173261453202 -
MSJ
@MSJ_Research
Ocular-motor conduction dynamics and variability in #multiplesclerosis–related internuclear ophthalmoparesis did not improve with dalfampridine treatment.
🔓MSJ-ETC randomized trial from @cwru ▶️ journals.sagepub.com/doi/10.1177/20552173261464348 -
MSJ
@MSJ_Research
Did you publish your first #multiplesclerosis article as first author in 2025 on our journals?
Apply to the 2026 F2 Award with a cash prize and one year access to the #msj (stay tuned at the @ACTRIMS @ECTRIMS 2026 Closing Ceremony) ▶️ journals.sagepub.com/pb-assets/cmscontent/MSJ/MSJF2Awards…
Deadline: Jul 24 -
MSJ
@MSJ_Research
With a median follow-up of 8 years, autologous haematopoietic stem cell transplantation #ahsct achieved no evidence of disease activity-3 (NEDA-3) in 16 out of 27 people with highly active #multiplesclerosis.
🔓 MSJ-ETC study ▶️ journals.sagepub.com/doi/10.1177/20552173261437600 -
MSJ
@MSJ_Research
In Kosovo, there are 776 people with #multiplesclerosis (prevalence of 48.9 per 100,000 inhabitants), with 373 new cases from 2020 to 2025.
🔓 MSJ-ETC study from @BlerimMyftiu @UniPrishtina ▶️ journals.sagepub.com/doi/10.1177/20552173261457784 -
MSJ
@MSJ_Research
Did you publish your first #multiplesclerosis article as first author in 2025 on our journals?
Apply to the 2026 F2 Award with a cash prize and one year access to the #msj (stay tuned at the @ACTRIMS @ECTRIMS 2026 Closing Ceremony) ▶️ journals.sagepub.com/pb-assets/cmscontent/MSJ/MSJF2Awards…
Deadline: Jul 24 -
MSJ
@MSJ_Research
In the Basque Country (Northern Spain) from 2009 to 2023, prevalence of #multiplesclerosis was 131.8 per 100,000 inhabitants and mean annual incidence was 4.4 per 100,000 person-years, suggesting this is high risk area.
🔓 MSJ-ETC study ▶️ journals.sagepub.com/doi/10.1177/20552173261458067 -
MSJ reposted
ECTRIMS
@ECTRIMS
🚀 New podcast series: 𝐌𝐒 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐁𝐫𝐢𝐞𝐟𝐬
Welcome to our new ECTRIMS podcast series delivering an expert guided tour of important new studies in multiple sclerosis research.
In each episode, leading MS experts will take a small number of recently published studies and go beyond the headline findings – exploring what the research shows and how it may influence clinical practice and future discovery.
In our first inaugural episode, host Prof. Alan J Thompson of UCL and guest host Prof. Olga Ciccarelli of UCL discuss two important new publications:
📄 Paramagnetic Rim Lesions and Development of Clinical MS in Radiologically Isolated Syndrome (@JAMANeuro, 2026)
📄 Machine learning-based combination of the central vein sign, cortical lesions and paramagnetic rim lesions (@braincomms, 2026)
𝐓𝐨𝐩𝐢𝐜𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞:
· Radiologically isolated syndrome (RIS)
· Paramagnetic rim lesions (PRLs)
· Central vein sign (CVS)
· Machine learning and AI-supported diagnosis
· The future of MRI biomarkers in MS
🎧 𝐋𝐢𝐬𝐭𝐞𝐧 𝐧𝐨𝐰:
𝐀𝐩𝐩𝐥𝐞: podcasts.apple.com/us/podcast/the-ectrims-podcast/id16502…
𝐒𝐩𝐨𝐭𝐢𝐟𝐲: open.spotify.com/episode/6neyxMgVXNUDH7viL0nxez
𝐖𝐞𝐛𝐬𝐢𝐭𝐞: ectrims.eu/podcast/episode-74-ms-research-briefs-mri-biom…
Timothy Reynold Lim et al. from St. Michael's Hospital, University of Toronto. Maxence Wynen et al. from UCLouvain - Université catholique de Louvain.
#multiplesclerosis #msresearch #neurology #neuroimaging #mri #artificialintelligence #ectrims #msresearchbriefs -
MSJ
@MSJ_Research
High-dose N-acetyl cysteine reduced GFAP levels, suggesting it might delay disability progression.
Exploratory results from a pilot double-blind, placebo-controlled randomized trial from @UCSF ▶️ journals.sagepub.com/doi/full/10.1177/13524585261454840 -
MSJ
@MSJ_Research
#multiplesclerosis is preceded by a prodromal phase with both specific and non-specific symptoms, including migraine, depression, urinary leakage, and restless legs syndrome.
A prospective cohort study from @KjetilBjornevik @HarvardChanSPH @ZJU_China ▶️ journals.sagepub.com/doi/full/10.1177/13524585261454827 -
MSJ
@MSJ_Research
Charcot–Marie–Tooth disease type 1X, caused by GJB1 mutations, can rarely involve the central nervous system with area postrema syndrome mimicking neuromyelitis optica spectrum disorder #nmosd.
Case report from @NCKU_official ▶️ journals.sagepub.com/doi/full/10.1177/13524585261436692
1/🧵
MSJ
@MSJ_Research
...and commentary from @NDCNOxford @UniofOxford: Red flags suggesting a genetic mimics of #nmosd include insidious/progressive course, atypical imaging features, poor treatment response and the presence of systemic or extra-CNS features.
🔽 journals.sagepub.com/doi/full/10.1177/13524585261456145
2/🧵 -
MSJ reposted
ACTRIMS®
@ACTRIMS
We want to hear from you!
MSToronto2026 is shaping up to be a key moment for the global MS community and your voice matters.
Tell us in the comments: What are you hoping to learn at MSToronto2026? -
MSJ
@MSJ_Research
Adults with #multiplesclerosis report multiple unmet clinic and support needs, including in-clinic services, appointment availability, transportation, and education on exercise and diet.
🔓 MSJ-ETC study from @tlsmincher @CUAnschutz @ChildrensColo ▶️ journals.sagepub.com/doi/10.1177/20552173261456058 -
MSJ reposted
MS Int'l Federation
@MSIntFederation
🌍New research highlights global gaps in access to MS diagnostic testing
Advances in MS diagnostic criteria mean people can be diagnosed earlier than ever before. But access to the tests needed to make that diagnosis is not equal worldwide msintfederation.org/4vNpJOI -
MSJ
@MSJ_Research
Did you publish your first #multiplesclerosis article as first author in 2025 on our journals?
Apply to the 2026 F2 Award with a cash prize and one year access to the #msj (stay tuned at the @ACTRIMS @ECTRIMS 2026 Closing Ceremony) ▶️ journals.sagepub.com/pb-assets/cmscontent/MSJ/MSJF2Awards…
Deadline: Jul 24 -
MSJ reposted
MS Int'l Federation
@MSIntFederation
Celebrating the first AFRICTRIMS Conference 🌍
The first African Committee for Research and Treatment in MS (AFRICTRIMS) conference, held from 29–31 May 2026 in Ghana, marked a historic and inspiring milestone for the MS community across Africa. 👉msintfederation.org/4am0xGH -
MSJ
@MSJ_Research
Task-oriented rehabilitation combined with virtual reality can improve motor function, inducing functional gains and brain functional plasticity in progressive #multiplesclerosis.
A randomized controlled trial from @unige_en @KingsCollegeLon ▶️ journals.sagepub.com/doi/full/10.1177/13524585261450820 -
MSJ
@MSJ_Research
In early relapsing #multiplesclerosis, there is a dissociation between physical disability and functional outcomes, with workplace difficulties being driven by non-motor symptoms.
🔓 MSJ-ETC study from @AngelPSempere @UA_Universidad @Roche ▶️ journals.sagepub.com/doi/10.1177/20552173261455229 -
MSJ reposted
ECTRIMS
@ECTRIMS
🏆 Just 1 month to go! Have you applied for the 2026 ECTRIMS MSJ "First First Author" Awards yet?
Recognising quality research from Multiple Sclerosis Journal authors who published their first MS full article as first authors in 2025, this award supports early career researchers and helps amplify their important work on the world stage at #mstoronto2026.
📩 𝐅𝐨𝐫 𝐟𝐮𝐥𝐥 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐝𝐞𝐭𝐚𝐢𝐥𝐬: journals.sagepub.com/pb-assets/cmscontent/MSJ/MSJF2Awards…
The MSJ & MSJ ETC Editorial Board will evaluate applications based on:
• Quality of the paper
• Setting of the authors
• Career stage of the applicant
• Number of downloads of manuscript presented
• Interest of manuscript (as scored by referees)
🎖️ 𝐀𝐰𝐚𝐫𝐝𝐬:
• Winner: £500 cash award + 1 year MSJ access
• Runner-up: 1 year MSJ access
• Award ceremony at the hashtag#MSToronto2026 Closing Ceremony
🗓️ 𝐃𝐞𝐚𝐝𝐥𝐢𝐧𝐞: 𝟐𝟒 𝐉𝐮𝐥𝐲 𝟐𝟎𝟐𝟔, 𝟎𝟎:𝟎𝟎 𝐂𝐄𝐓
@MSJ_Research
#multiplesclerosis #msresearch #earlycareers #ectrims #msj #neurology #ectrimsnextgen -
MSJ reposted
ECTRIMS
@ECTRIMS
🔍 What challenges remain in treating women with MS during pregnancy?
Our latest Spotlight, 𝘛𝘳𝘦𝘢𝘵𝘪𝘯𝘨 𝘞𝘰𝘮𝘦𝘯 𝘚𝘢𝘧𝘦𝘭𝘺 𝘐𝘯 𝘢𝘯𝘥 𝘈𝘳𝘰𝘶𝘯𝘥 𝘱𝘳𝘦𝘨𝘯𝘢𝘯𝘤𝘺, explores the latest evidence on disease-modifying therapy (DMT) use before, during, and after pregnancy in women with MS.
𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭 𝐡𝐞𝐫𝐞: ectrims.eu/treating-women-safely-in-and-around-pregnancy/
"We are increasingly more comfortable with the use of disease modifying therapies (DMTs) in and around pregnancy," says Professor Vilija Jokubaitisi of Monash University, Melbourne.
"Delaying treatment after diagnosis or undertreating a woman because of a pregnancy plan can have catastrophic consequences," adds Professor Sandra Vukusic of @UnivLyon1.
The @ECTRIMS Spotlight Series is curated and authored by our Scientific Content Writer, Stefania de Vito, PhD.
@vjokubaitis @VukusicSandra
#multiplesclerosis #mspregnancy #msresearch #neurology #msspotlight #neuroimmunology #ectrims -
MSJ
@MSJ_Research
There were no significant CD19 abnormalities in breastfed infants with maternal anti-CD20 use for #multiplesclerosis, supporting utilization of anti-CD20 therapies while breastfeeding.
🔓 MSJ-ETC study from @CUAnschutz ▶️ journals.sagepub.com/doi/10.1177/20552173261454808 -
MSJ
@MSJ_Research
🔊 Listen to Anke Salmen @ruhrunibochum (on behalf of the NationMS investigators and the German Competence Network Multiple Sclerosis) on sex-specific analysis of early disease course and treatment in #multiplesclerosis.
📄And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585261446846 -
MSJ
@MSJ_Research
📢June issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @ETallantyre @cardiffuni @CharlotteTeuni1 @MScentrum020 with their framework for blood biomarker discovery in #multiplesclerosis ▶️ journals.sagepub.com/doi/10.1177/13524585261432045 -
MSJ
@MSJ_Research
Western blot could be used as an alternative algorithm to detect oligoclonal bands by isoelectric focusing for the diagnosis of #multiplesclerosis, when κFLC-index<20.
🔓 MSJ-ETC study from @UBARectorado ▶️ journals.sagepub.com/doi/10.1177/20552173261430132 -
MSJ
@MSJ_Research
Did you publish your first #multiplesclerosis article as first author in 2025 on our journals?
Apply to the 2026 F2 Award with a cash prize and one year access to the #msj (stay tuned at the @ACTRIMS @ECTRIMS 2026 Closing Ceremony) ▶️ journals.sagepub.com/pb-assets/cmscontent/MSJ/MSJF2Awards…
Deadline: Jul 24 -
MSJ reposted
ECTRIMS
@ECTRIMS
🌟 Registration is now open for Patient Community Day 2026, hosted by ECTRIMS, in partnership with #mstoronto2026!
This event will bring the latest research announced at the 10th Joint @ACTRIMS-@ECTRIMS Meeting out of the scientific world and into real life. For people living with MS and related neurological conditions, this event helps them better understand what new discoveries mean for care, treatment, and daily living.
👉 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐧𝐨𝐰 𝐟𝐨𝐫 𝐟𝐫𝐞𝐞: www.ectrimspatientcommunity.eu/registration
📅 23 October 2026
🕒 15:00–18:00 EDT
🌍 Online + Toronto, Canada
𝐖𝐡𝐲 𝐉𝐨𝐢𝐧?
• MS-Focused Content: Sessions tailored to the needs and questions of people living with MS
• Live Q&A with Experts: Ask your questions directly to leading MS specialists from around the world
• Global Access: Available in 50+ languages
From Research to Real Life: Discover the latest research in MS, #nmosd, and #mogad – and what it means for daily life.
#patientcommunityday #ms #msawareness #ectrims4meThis media couldn't be displayed. See it on the original post. -
MSJ reposted
MS Int'l Federation
@MSIntFederation
📣 Registration now open! Patient Community Day is happening on 23 Oct, and we are excited to be supporting this event. Join us for this FREE online & onsite event sharing the latest research in MS, NMOSD, and MOGAD @ECTRIMS #proudsupporter
➡️ msintfederation.org/4ehyMl2This media couldn't be displayed. See it on the original post. -
MSJ
@MSJ_Research
Advances, priorities and opportunities for spinal cord imaging in #multiplesclerosis.
Review from @UBC @UCSF and North American Imaging in Multiple Sclerosis #naims Cooperative ▶️ journals.sagepub.com/doi/10.1177/13524585261444600 -
MSJ reposted
IJMSC
@IJMSCtweets
"...respiratory-related physician visits were the first to show a consistent & prolonged increase, beginning 14 years before the first demyelinating event. Subsequent increases emerged across endocrine, injury-related, ill-defined, nervous system, and mental health visits."
#poms
MSJ
@MSJ_Research
Before pediatric-onset #multiplesclerosis, there is prolonged, organ-specific healthcare use, indicating pre-onset disease heterogeneity.
Study from @UBC ▶️ journals.sagepub.com/doi/full/10.1177/13524585261445372 -
MSJ
@MSJ_Research
Microbiome-derived metabolites from vitamin B2 and B9 modulate mucosal-associated invariant T cells from #multiplesclerosis patients, revealing human-specific mechanisms not predicted by animal models.
Study from @FleniOficial @UBARectorado @UCSF ▶️ journals.sagepub.com/doi/10.1177/13524585261447695 -
MSJ reposted
Sharon Roman (n of 1)
@SRoman_SPQR
Sex & age influence disease course, disability progression & relapse rates after #ms onset. Yet potential differences before onset in paediatric MS is not well known.
New study found ⬆️ healthcare use, & differs by sex & age before paediatric-onset MS.
⤵️tremlettsmsresearchexplained.wordpress.com/2026/06/17/phe… -
MSJ reposted
Sharon Roman (n of 1)
@SRoman_SPQR
If I may, it’s ⬇️ for those who would like it explained in plain language.
tremlettsmsresearchexplained.wordpress.com/2026/06/03/pre…
MSJ
@MSJ_Research
Prescriptions of antibacterials, airway drugs and sex hormones were increased up to 15 years before #multiplesclerosis onset.
Study from @UBC ▶️ journals.sagepub.com/doi/full/10.1177/13524585261450813 -
MSJ
@MSJ_Research
🔊 Listen to Fredrik Sandesjö @karolinskainst on treatment persistence in paediatric-onset #multiplesclerosis.
📄 And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585261448789 -
MSJ
@MSJ_Research
Prescriptions of antibacterials, airway drugs and sex hormones were increased up to 15 years before #multiplesclerosis onset.
Study from @UBC ▶️ journals.sagepub.com/doi/full/10.1177/13524585261450813 -
MSJ
@MSJ_Research
New controversy available ⚖️
Non-MRI biomarkers should be accepted to guide treatment escalation in #multiplesclerosis?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @karolinskainst: The role of blood biomarkers in treatment monitoring will become clearer as evidence accumulates on assay standardization, longitudinal dynamics, and their relationship to treatment response.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261439678
4/🧵
MSJ
@MSJ_Research
What do you think? Non-MRI biomarkers should be accepted to guide treatment escalation in #multiplesclerosis?
5/🧵 -
MSJ reposted
Manitoba MS Research Centre
@MB_MSResearch
📢 🏳️🌈 Your story matters! Are you a 2SLGBTQI+ person living with #multiplesclerosis, aged 18+, and in Canada? We need YOU - Help us uncover how genes, environment, and life experiences shape health in MS. 🧬🌎 Compensation is provided. Email msepidemiology@nshealth.ca #msresearch
-
MSJ reposted
ECTRIMS
@ECTRIMS
📢 Ready to Submit a Late-Breaking Abstract?
Don't miss your opportunity to present groundbreaking research to the MS community this October.
The 10th Joint ACTRIMS-ECTRIMS Meeting unites researchers, clinicians and healthcare practitioners from around the world in Toronto, Canada, 21-23 October 2026.
🗓️ 𝐃𝐞𝐚𝐝𝐥𝐢𝐧𝐞: 16 𝐉𝐮𝐥𝐲 2026, 11:59 𝐏𝐌 𝐄𝐓
🔗 𝐒𝐮𝐛𝐦𝐢𝐭 𝐡𝐞𝐫𝐞: mstoronto2026.org/call-for-abstracts/
@ACTRIMS
#multiplesclerosis #msresearch #neurology #ectrims #actrims #mstoronto2026 #ectrimsnextgen -
MSJ
@MSJ_Research
Controlled trials are need to translate transcranial magnetic stimulation in a complementary strategy to leverage residual neuroplasticity and reduce symptom burden in individuals with #multiplesclerosis.
Review from @simonebatt92 @Unibo @unito ▶️ journals.sagepub.com/doi/full/10.1177/13524585261442777 -
MSJ reposted
Xavier Montalban
@XMontalban
Fantastic talk by @BenedettaBodin1 Bodini at #ictrims26, taking us through the different eras of knowledge on the immunological mechanisms of multiple sclerosis. A fascinating journey from early concepts to today's understanding of MS pathogenesis. #msresearch @EuropeanCharcot
-
MSJ reposted
Majed A 🍁
@sincemajed
Interesting..
Psyche, immune, and neurons … are always related.
Great -rather efficient- clinicians are the ones who pay primary attention to this special relationship.
MSJ
@MSJ_Research
Adverse childhood experiences may have a long-standing impact on the lived experience of pediatric-onset #multiplesclerosis patients into adulthood.
Study from @nationwidekids @OSUWexMed ▶️ journals.sagepub.com/doi/full/10.1177/13524585261444237 -
MSJ
@MSJ_Research
Adverse childhood experiences may have a long-standing impact on the lived experience of pediatric-onset #multiplesclerosis patients into adulthood.
Study from @nationwidekids @OSUWexMed ▶️ journals.sagepub.com/doi/full/10.1177/13524585261444237 -
MSJ
@MSJ_Research
PIRMA (progression independent of relapse and magnetic resonance imaging activity) in #multiplesclerosis is associated with aging, grey matter atrophy, and disrupted functional connectivity.
INNI Network study from @SapienzaRoma ▶️ journals.sagepub.com/doi/full/10.1177/13524585261445318 -
MSJ
@MSJ_Research
🔊 Listen to @ETallantyre @cardiffuni (and the DELIVER-MS co-investigators) on disease-modifying treatment preferences and decision-making in #multiplesclerosis.
📄And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585261449988 -
MSJ
@MSJ_Research
TSPO-PET-measurable neuroinflammation in the normal-appearing white matter is associated with future information processing speed (SDMT) decline in #multiplesclerosis.
Study from Turku University Hospital ▶️ journals.sagepub.com/doi/full/10.1177/13524585261446839 -
MSJ
@MSJ_Research
📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠
Register here to receive our research
🔽
journals.sagepub.com/connected/MSJ -
MSJ reposted
ECTRIMS
@ECTRIMS
🗓️ The 31st Annual RiMS Conference is coming to Prague next week, 11-13 June!
This year's theme: "Recovery and Compensation in MS Rehabilitation: Rethinking Mechanisms, Decisions, and Outcomes"
Join leading experts in Prague next week!
🔗 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫: www.rehabinms.org/meetings-detail-page/24/31st-annual-rim…
@eurims
#msrehabilitation #rims2026 #ectrims #neurology #prague -
MSJ
@MSJ_Research
Before pediatric-onset #multiplesclerosis, there is prolonged, organ-specific healthcare use, indicating pre-onset disease heterogeneity.
Study from @UBC ▶️ journals.sagepub.com/doi/full/10.1177/13524585261445372 -
MSJ
@MSJ_Research
Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption in #multiplesclerosis is safe, with no increased risk of infusion-related reactions.
🔓 MSJ-ETC study from @MScentrum020 @amsterdamumc ▶️ journals.sagepub.com/doi/full/10.1177/20552173261449688 -
MSJ reposted
ECTRIMS
@ECTRIMS
Can the revised 2024 McDonald Criteria reduce MS misdiagnosis?
🎧 In this ECTRIMS Podcast episode, recorded in collaboration with the MS Journals “Controversies in MS” series, Prof. Anneke van der Walt speaks with Prof. Andy Solomon from University of Vermont and Prof. Enrique Gomez Figueroa from Hospital Civil De Guadalajara about the promises and challenges of the revised criteria.
As MS diagnosis evolves, balancing earlier diagnosis with diagnostic accuracy remains one of the field’s greatest challenges.
𝐋𝐢𝐬𝐭𝐞𝐧 𝐧𝐨𝐰:
𝐒𝐩𝐨𝐭𝐢𝐟𝐲: open.spotify.com/episode/6LicVy5OlnmyiRCofR1AcS
𝐀𝐩𝐩𝐥𝐞: podcasts.apple.com/za/podcast/the-ectrims-podcast/id16502…
𝐖𝐞𝐛𝐬𝐢𝐭𝐞: ectrims.eu/podcast/episode-72-can-the-revised-2024-mcdona…
@MSJ_Research @uvmvermont @HospitalCivil
This episode is part of the MS Journal Controversies in MS series on The revised 2024 McDonald criteria can solve the misdiagnosis problem in MS. The accompanying Yes, No, and Commentary articles are available to read open access for the next month, compliments of MS Journal.
#multiplesclerosis #mcdonaldcriteria #msdiagnosis #msresearch #neurology #neuroimmunology #mri #ectrims #multiplesclerosisjournal #ectrimspodcast -
MSJ
@MSJ_Research
Diffuse myelin damage in normal-appearing white matter could be responsible for slower processing speed in radiologically isolated syndrome #ris.
🔓 MSJ-ETC study from @UBC ▶️ journals.sagepub.com/doi/full/10.1177/20552173261446217 -
MSJ
@MSJ_Research
🔊 Listen to Gina Chang @UCSF on adenotonsillectomy and risk and disease activity in pediatric-onset #multiplesclerosis.
📄And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585261444244 -
MSJ
@MSJ_Research
A 37-year-old woman with #multiplesclerosis treated with ofatumumab developed enteroviral encephalitis (with fever, confusion, seizures, altered consciousness, and residual neuropsychiatric symptoms).
Case report from @UofT @StMichaelsFdn ▶️ journals.sagepub.com/doi/full/10.1177/13524585261444606
1/🧵
MSJ
@MSJ_Research
...and commentary from @Saar_Uni: Enterovirus-associated infections looks like a matter of a class effect for anti-CD20 antibodies.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261444588
2/🧵 -
MSJ
@MSJ_Research
Did you publish your first #multiplesclerosis article as first author in 2025 on our journals?
Apply to the 2026 F2 Award with a cash prize and one year access to the #msj (stay tuned at the @ACTRIMS @ECTRIMS 2026 Closing Ceremony) ▶️ journals.sagepub.com/pb-assets/cmscontent/MSJ/MSJF2Awards…
Deadline: Jul 24 -
MSJ
@MSJ_Research
#worldmsday2026: Top trending papers in the past year in MSJ-ETC:
Incidence and prevalence of #multiplesclerosis during eras of evolving diagnostic criteria (from @HkiBrainMind
@helsinkiuni).
🔽
journals.sagepub.com/doi/full/10.1177/20552173251326173 -
MSJ
@MSJ_Research
#worldmsday2026: Top trending papers in the past year:
Clinical validation of a novel neurofilament light chain #nfl assay for disease activity in relapsing #multiplesclerosis (from @TjalfZiemssen
@tudresden_de @MSDoc_Freedman @uOttawa @UCSF).
🔽
journals.sagepub.com/doi/10.1177/13524585251389797 -
MSJ
@MSJ_Research
#worldmsday2026: Top trending papers in the past year in MSJ-ETC:
European experience of cladribine tablets in elderly people with #multiplesclerosis (from @CHULiege).
🔽
journals.sagepub.com/doi/full/10.1177/20552173251321810 -
MSJ
@MSJ_Research
#worldmsday2026: Top trending papers in the past year:
Substantial and substantive changes in the 2024 revision of the McDonald diagnostic criteria for #multiplesclerosis (from @JeffCohenMD @ClevelandClinic).
🔽
journals.sagepub.com/doi/10.1177/13524585251351860 -
MSJ
@MSJ_Research
#worldmsday2026: Top trending papers in the past year in MSJ-ETC:
#multiplesclerosis substantially impacts the quality of life of family members and partners of people with MS (from @cardiffuni).
🔽
journals.sagepub.com/doi/full/10.1177/20552173251338762 -
MSJ
@MSJ_Research
#worldmsday2026: Top trending papers in the past year:
Dietary habits and advanced imaging/laboratory markers in #multiplesclerosis (from @SerenaBorrelli4 @Pietro46069031 @UCLouvain_ADRE).
🔽
journals.sagepub.com/doi/10.1177/13524585251405695 -
MSJ
@MSJ_Research
Today is World #multiplesclerosis Day: We will be sharing some of our most trending articles from the past year - Our contribution to uncover the most controversial aspects of the disease.
More information on the #worldmsday2026 @MSIntFederation
🔽
worldmsday.org -
MSJ
@MSJ_Research
General-population ascular risk calculators do not neccesarily apply to people with #multiplesclerosis, requiring disease-specific vascular risk models.
Study from @RPalladino84 @UninaIT @imperialcollege @QSMSCENTRE @UCLBrainScience @UCLIoN ▶️ journals.sagepub.com/doi/full/10.1177/13524585261444243 -
MSJ reposted
ECTRIMS
@ECTRIMS
🏆The 2026 ECTRIMS MSJ "First First Author" Awards recognise quality research from @MSJ_Research authors who published their first MS full article as first authors in 2025.
This award supports early career researchers and helps share their important work at #mstoronto2026.
📩 𝐅𝐨𝐫 𝐟𝐮𝐥𝐥 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐝𝐞𝐭𝐚𝐢𝐥𝐬: journals.sagepub.com/pb-assets/cmscontent/MSJ/MSJF2Awards…
The MSJ & MSJ ETC Editorial Board will evaluate applications based on:
• Quality of the paper
• Setting of the authors
• Career stage of the applicant
• Number of downloads of manuscript presented
• Interest of manuscript (as scored by referees)
🎖️ 𝐀𝐰𝐚𝐫𝐝𝐬:
• Winner: £500 cash award + 1 year MSJ access
• Runner-up: 1 year MSJ access
• Award ceremony at the #mstoronto2026 Closing Ceremony
🗓️ 𝐃𝐞𝐚𝐝𝐥𝐢𝐧𝐞: 𝟐𝟒 𝐉𝐮𝐥𝐲 𝟐𝟎𝟐𝟔, 𝟎𝟎:𝟎𝟎 𝐂𝐄𝐓
#multiplesclerosis #msresearch #ectrims #msj #neurology #mstoronto2026 #ectrimsnextgen -
MSJ
@MSJ_Research
Discrepancy between subjective and objective cognitive function in #multiplesclerosis is related to mood, fatigue and pain.
🔓 MSJ-ETC study from @GMacaronMD @CRCHUM @UMontreal @ChumNeuro ▶️ journals.sagepub.com/doi/full/10.1177/20552173261449673 -
MSJ
@MSJ_Research
The #multiplesclerosis Disease Activity score (calculated from 18 proteins, sex and age) provides reliable interpretation of disease activity biomarkers.
Study from @OctaveBio @UCSanDiego ▶️ journals.sagepub.com/doi/full/10.1177/13524585261439680 -
MSJ
@MSJ_Research
Men's health research priorities in men with #multiplesclerosis include sexual dysfunction, prostate cancer and screening, benign prostatic hyperplasia, and low testosterone.
Survey from male participants in the NARCOMS
@UTSWMedCenter @ClevelandClinic ▶️ journals.sagepub.com/doi/full/10.1177/20552173261447999 -
MSJ
@MSJ_Research
📢May issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @UMontreal with their study on multi-site multi-contrast segmentation framework for spinal cord #multiplesclerosis lesion segmentation ▶️ journals.sagepub.com/doi/full/10.1177/13524585261427333 -
MSJ
@MSJ_Research
Neuromyelitis optica spectrum disorder #nmosd prevalence in Germany is increasing (from 2.9 to 4.7 per 100,000 between 2015 and 2022), with frequent diagnostic overlap with #multiplesclerosis.
🔓MSJ-ETC study from @uni_greifswald @uni_muenster ▶️ journals.sagepub.com/doi/full/10.1177/20552173261419988 -
MSJ
@MSJ_Research
Did you publish your first #multiplesclerosis article as first author in 2025 on our journals?
Apply to the 2026 F2 Award with a cash prize and one year access to the #msj (stay tuned at the @ACTRIMS @ECTRIMS 2026 Closing Ceremony) ▶️ journals.sagepub.com/pb-assets/cmscontent/MSJ/MSJF2Awards…
Deadline: Jul 24 -
MSJ reposted
Gabrielle Macaron
@GMacaronMD
Happy to share our study on the discrepancy between subjective and objective cognitive impairment in #multiplesclerosis - evaluating cognition in multiple domains decreases this discrepancy and helps corroborating patients’ complaints @MSJ_Research
journals.sagepub.com/doi/epub/10.1177/20552173261449673 -
MSJ
@MSJ_Research
6.1 κFLC index cut-off is accurate for routine screening, but testing for oligoclonal bands when the κFLC index is between 3.5 and 20 increases specificity in challenging cases for supsected #multiplesclerosis.
Study from @XtineLebrunF @CHUdeNice ▶️ journals.sagepub.com/doi/full/10.1177/13524585261442020 -
MSJ
@MSJ_Research
New controversy available ⚖️
Should autologous hematopoietic stem cell transplantation #hsct be a first-line option in highly active #multiplesclerosis?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @karolinskainst: Improved definitions of aggressive disease, standardization of transplant protocols, and comparative trials evaluating HSCT against contemporary high-efficacy therapies are needed.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261439675
4/🧵
MSJ
@MSJ_Research
What do you think? Should autologous #hsct be a first-line option in highly active #multiplesclerosis?
5/🧵 -
MSJ reposted
ECTRIMS
@ECTRIMS
🎉Congratulations to this year's recipients of the 2026 ECTRIMS Fellowship Awards! Our fellowship programmes help advance knowledge and expertise in the field of hashtag#MultipleSclerosis and related neurological conditions. Investing in future leaders is a core part of our mission and an important step toward advancing research, innovation, and patient care worldwide.
Learn more about this year's awardees ➡️ ectrims.eu/recipients-of-the-2026-ectrims-fellowships-ann…
Meet the 2026 ECTRIMS Fellowship Award recipients:
Clinical Training: Cândida Driemeyer, Andreas Liampas, & Camila Lopes Figueiredo
Postdoctoral Research: Silvia Corbisiero, Hanna Frank & Anna Stölting
Nurse and Allied Health Professionals Training: Elnaz Melhi
Application of Magnetic Resonance Imaging Studies in MS with MAGNIMS: Mar Barrantes Cepas & Lonneke Bos
(@MSIntFederation)-ECTRIMS McDonald Fellowship Programme: Reza Naeimi
NMOSD and MOGAD Research: Announcement coming soon!
#msresearch #mscommunity #fellowships #neurology #ms #ectrimsnextgen -
MSJ
@MSJ_Research
Among 4181 people with #multiplesclerosis (NARCOMS Registry), 7.4% had ever and 5.5% currently used semaglutide and tirzepatide, despite 40% having an indication for taking GLP1RAs.
Study from @DalhousieU ▶️ journals.sagepub.com/doi/full/10.1177/13524585261442033 -
MSJ
@MSJ_Research
Early use of high-efficacy disease-modifying therapies reduces the risk of progression independent of relapse and MRI activity in people with relapsing #multiplesclerosis.
Study from @FleniOficial @UBARectorado ▶️ journals.sagepub.com/doi/full/10.1177/13524585261442036 -
MSJ
@MSJ_Research
Percutaneous spinal stimulation can enhance gait kinematics and alleviate functional impairments in progressive #multiplesclerosis
🔓 MSJ-ETC study from @MayoClinic ▶️ journals.sagepub.com/doi/full/10.1177/20552173261432301 -
MSJ
@MSJ_Research
Prevalence (1.84 cases per 100,000 inhabitants) and associated clinical and demographic features of neuromyelitis optica spectrum disease #nmosd (including marked socioeconomic vulnerability) in Central-West Brazil.
🔓 MSJ-ETC study ▶️ journals.sagepub.com/doi/full/10.1177/20552173261443832 -
MSJ
@MSJ_Research
...and letter from @unirome1: Additional clinical observations of people with #multiplesclerosis and comorbid psoriatic arthritis and ankylosing spondylitis treated with cladribine in combination with the anti-IL-17A monoclonal antibody secukinumab.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261441504
MSJ
@MSJ_Research
...and commentary from @DrWBRO @QSMSCENTRE @UCLBrainScience: Cladribine is a useful option in #multiplesclerosis with other autoimmune disorders, including inflammatory bowel disease, thanks to efficacy and lack of maintenance immunosuppression.
🔽
journals.sagepub.com/doi/abs/10.1177/13524585251396293
3/🧵 -
MSJ
@MSJ_Research
A clinician-administered two-question screening tool is valid and feasible to improve depression detection in people with #multiplesclerosis.
Study from the MINDS-MS Research Team @LisaGrech4 @MonashHealth @Deakin ▶️ journals.sagepub.com/doi/full/10.1177/13524585261435415 -
MSJ reposted
ECTRIMS
@ECTRIMS
We are proud to see Professor Bruno Stankoff, President of ECTRIMS, featured in the latest issue of @TheLancet Neurology: www.thelancet.com/journals/laneur/article/PIIS1474-4422(2…
The article highlights Prof. Stankoff’s pioneering work in remyelination, molecular imaging, and translational research in multiple sclerosis, as well as his commitment to advancing collaboration, innovation, and patient representation across the global neuroinflammation community.
From discoveries in myelin repair biology to advancing the future of imaging biomarkers and regenerative therapies, his work continues to shape new possibilities for people living with MS.
Learn more about @StankoffBr and what inspired him to devote his career to multiple sclerosis: www.thelancet.com/journals/laneur/article/PIIS1474-4422(2…
#multiplesclerosis #msresearch #neuroinflammation #remyelination #neurology #ectrims -
MSJ
@MSJ_Research
Serum metabolic profile at clinical onset, with enrichment of nicotinate/nicotinamide, histidine and arginine metabolism, predicts #multiplesclerosis activity and progression after 5 years.
Study from @MariCortese_ @HarvardChanSPH ▶️ journals.sagepub.com/doi/full/10.1177/13524585261435409 -
MSJ
@MSJ_Research
On 3T MRI, filtered-phase imaging offers superior positive predictive value, while SWI provides better sensitivity and inter-rater reliability for paramagnetic rim lesion detection in #multiplesclerosis.
Study from @esilbermann @vaportland ▶️ journals.sagepub.com/doi/full/10.1177/13524585261439651 -
MSJ
@MSJ_Research
Delays in #multiplesclerosis disease-modifying therapy initiation are associated with greater geographic distance, private insurance status, and use of outside infusion centers and specialty pharmacies.
🔓 MSJ-ETC study from @UF ▶️ journals.sagepub.com/doi/full/10.1177/20552173261447996 -
MSJ
@MSJ_Research
A remotely-delivered, home-based exercise training can improve physical activity and mobility for English-speaking Hispanics/Latinos with #multiplesclerosis.
🔓MSJ-ETC study from @ULaVerne @thisisUIC ▶️ journals.sagepub.com/doi/full/10.1177/20552173261448001 -
MSJ
@MSJ_Research
Not clear standings... Perhaps we really need better tools and definitions!
MSJ
@MSJ_Research
What do you think? Do MRI-negative relapses really exist in #multiplesclerosis?
5/🧵 -
MSJ
@MSJ_Research
This multi-site multi-contrast segmentation framework provided generalizable spinal cord #multiplesclerosis lesion segmentation across MRI contrasts, protocols, and centers.
Study from @UMontreal ▶️ journals.sagepub.com/doi/full/10.1177/13524585261427333 -
MSJ
@MSJ_Research
Central vein sign and paramagnetic rim lesions represents potentially advantageous #multiplesclerosis diagnostic biomarkers, with increased specificity.
Study from @PascalSati @NeurosciencesCS @DanOntaneda @Karl0CB @ClevelandClinic ▶️ journals.sagepub.com/doi/full/10.1177/13524585261434218 -
MSJ reposted
ECTRIMS
@ECTRIMS
📖 The April 2026 (Vol. 32, No. 5) issue of the @MSJ_Research is out!
𝗞𝗲𝘆 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗶𝘀 𝗶𝘀𝘀𝘂𝗲:
· 𝗧𝗼𝗽𝗶𝗰𝗮𝗹 𝗥𝗲𝘃𝗶𝗲𝘄: AI-enabled Living Labs: Accelerating innovation in multiple sclerosis care and research
· 𝗖𝗼𝗻𝘁𝗿𝗼𝘃𝗲𝗿𝘀𝗶𝗲𝘀 𝗶𝗻 𝗠𝗦: Menopause is a physiological progression event for women with multiple sclerosis — debate and commentary
· 𝗩𝗶𝘀𝘂𝗮𝗹 𝗦𝘆𝘀𝘁𝗲𝗺: The supporting role of Visual Evoked Potentials for the diagnosis of Optic Neuritis within the 2022 ICON criteria
· 𝗣𝗿𝗲𝗴𝗻𝗮𝗻𝗰𝘆: Treatment-requiring postpartum depression in mothers with multiple sclerosis: A nationwide cohort study
· 𝗖𝗼𝗺𝗼𝗿𝗯𝗶𝗱𝗶𝘁𝗶𝗲𝘀: Cardiovascular comorbidities are associated with cross-sectional and longitudinal measures of multiple sclerosis fatigue
· 𝗦𝗵𝗼𝗿𝘁 𝗥𝗲𝗽𝗼𝗿𝘁: Outcomes and disease activity during and after pregnancy in Asian women with MOGAD
· 𝗟𝗲𝘁𝘁𝗲𝗿𝘀 𝘁𝗼 𝘁𝗵𝗲 𝗘𝗱𝗶𝘁𝗼𝗿: B-cell depletion vaginitis and pyoderma gangrenosum
𝗔𝗰𝗰𝗲𝘀𝘀 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗶𝘀𝘀𝘂𝗲 𝗵𝗲𝗿𝗲: journals.sagepub.com/toc/MSJ/current
@ECTRIMS, @ACTRIMS, @PACTRIMS_admin, @lactrims_org, @eurims, @EuropeanCharcot
#multiplesclerosis #msresearch #msj #ectrims #neurology -
MSJ
@MSJ_Research
Unemployment occurred at all disability levels in #multiplesclerosis, but could be improved if the job is individually adjusted.
🔓MSJ-ETC study from Norway ▶️ journals.sagepub.com/doi/full/10.1177/20552173261439532 -
MSJ
@MSJ_Research
New controversy available ⚖️
Do MRI-negative relapses really exist in #multiplesclerosis?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @iucagd @MayoClinic: The controversy is less about the existence of MRI-negative relapses in #multiplesclerosis, than the limits of our tools and frameworks.
🔽
journals.sagepub.com/doi/abs/10.1177/13524585261423082
4/🧵
MSJ
@MSJ_Research
What do you think? Do MRI-negative relapses really exist in #multiplesclerosis?
5/🧵 -
MSJ reposted
Wei
@wz_yeh
Does smoking affect relapse risk in #mogad?
Our new paper in @MSJ_Research 👉 journals.sagepub.com/doi/full/10.1177/13524585261429292
Current smokers had higher relapse rates, while past smokers were similar to non-smokers.
🚭 Smoking cessation may help reduce relapse risk (on top of other health benefits).
MSJ
@MSJ_Research
🔊 Listen to @wz_yeh @NDCNOxford @MonashUni on the effects of smoking and vascular risk factors on relapse risk in myelin oligodendrocyte glycoprotein antibody-associated disease #mogad.
📄And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585261429292 -
MSJ reposted
World MS Day
@WorldMSDay
LAUNCH DAY! 🚀 This free online course for #worldmsday will deepen your understanding of MS symptoms, the diagnostic process, and the impact of an MS diagnosis. 🧠Start learning today! 💡 👉 worldmsday.org/online-course/
-
MSJ reposted
ECTRIMS
@ECTRIMS
📢 Are you a female scientist doing research on multiple sclerosis (MS)? Apply now for the 2026 Rachel Horne Prize for Women’s Research in MS!
This prestigious US$40,000 award will honour a senior female scientist for outstanding contributions to women’s health-related research in MS.
📌 Why Apply? This year, The Rachel Horne Prize celebrates an established leader in the field. Should you win, you will have the opportunity to share your work globally, including recording a special episode for the ECTRIMS podcast and presenting at iWiMS organised meetings.
The winner will be announced at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting, held in Toronto, 21-23 October.
🔗 Apply here ➡️ www.rachelhorneprize.com/application
📅 Deadline: 12 June 2026
#rachelhorneprize #womeninmsmatter #msresearch #ectrims #actrims #iwims #womeninscience #mstoronto2026 -
MSJ
@MSJ_Research
Delays in #multiplesclerosis disease-modifying therapy initiation are associated with greater geographic distance, private insurance status, and use of outside infusion centers and specialty pharmacies.
🔓 MSJ-ETC study from @elsarovansmd @UF ▶️ journals.sagepub.com/doi/full/10.1177/20552173261447996 -
MSJ reposted
Dr. Brandon Beaber
@Brandon_Beaber
How many people with multiple sclerosis are taking GLP1 drugs (i.e. ozempic and wegovy)? According to the NARCOMS Registry, only about 5.5%, but nearly 40% have a condition they treat (i.e. obesity or type 2 diabetes) journals.sagepub.com/doi/10.1177/13524585261442033
-
MSJ
@MSJ_Research
Spinal cord imaging in #multiplesclerosis needs improvements in acquisition and post-processing to enhance its effectiveness and applicability in future clinical trials.
Systematic review from @ahmadtubasi99 @VUMCDiscoveries @BagnatoLab ▶️ journals.sagepub.com/doi/full/10.1177/13524585261438770 -
MSJ
@MSJ_Research
Within-person worsening in activity fragmentation using accelerometry may represent an early compensatory strategy for reduced physiologic reserve and serve as an early indicator of #multiplesclerosis progression.
Study from @HopkinsMedicine ▶️ journals.sagepub.com/doi/full/10.1177/13524585261435926 -
MSJ
@MSJ_Research
📢April II issue is now available 📷 journals.sagepub.com/toc/MSJ/current
...and the cover goes to @FondARothschild with their study on the recovery from optic neuritis in MOG antibody–associated #mogad ▶️ journals.sagepub.com/doi/abs/10.1177/13524585261428950 -
MSJ reposted
ACTRIMS®
@ACTRIMS
Early-Career Researchers: Showcase your MS research at #mstoronto2026!
✅ Clinical, Pathology, Imaging, Therapy
🎤 Present in #younginvestigator Sessions (≤35 yrs)
📅 Submit by May 7, 2026
Advance your career & connect with leaders!
🔗 mstoronto2026.org/call-for-abstracts/ -
MSJ
@MSJ_Research
📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠
Register here to receive our research
🔽
journals.sagepub.com/connected/MSJ -
MSJ reposted
ACTRIMS®
@ACTRIMS
Why submit to MSToronto2026? 🌍
Showcase your MS research on a global stage!
✅ Clinical discoveries
✅ Pathology & pathogenesis
✅ Imaging & biomarkers
✅ Therapy innovation
📅 Deadline: May 7, 2026
🔗 Submit: mstoronto2026.org/call-for-abstracts/
#msresearch #multiplesclerosis -
MSJ
@MSJ_Research
Did you publish your first #multiplesclerosis article as first author in 2025 on our journals?
Apply to the 2026 F2 Award with a cash prize and one year access to the #msj (stay tuned at the @ACTRIMS @ECTRIMS 2026 Closing Ceremony) ▶️ journals.sagepub.com/pb-assets/cmscontent/MSJ/MSJF2Awards…
Deadline: Jul 24 -
MSJ reposted
Sharon Roman (n of 1)
@SRoman_SPQR
New study asked whether a cancer diagnosis affects #ms-related care.
It’s ⤵️ for those who want it explained in plain language. tremlettsmsresearchexplained.wordpress.com/2026/04/23/imp…
MSJ
@MSJ_Research
Following cancer diagnosis, the use of #multiplesclerosis treatments declined sharply, without a strong impact on neurology visits and hospitalizations.
A multinational cohort study from @ChloePierret @Inserm @RennesUniv_EN @UBC ▶️ journals.sagepub.com/doi/full/10.1177/13524585261437966 -
MSJ reposted
Jaime Imitola MD., FAAN
@DrJim4MS
this is new validation data, the original paper was published @MSJ_Research and it is free to all. #visiblms
journals.sagepub.com/doi/full/10.1177/13524585241228739
#healthequity #ms #sdoh -
MSJ
@MSJ_Research
📢 April issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @I3ptT @TheRMH with their study on the performance of the 2024 McDonald diagnostic criteria for #multiplesclerosis ▶️ journals.sagepub.com/doi/abs/10.1177/13524585261421816 -
MSJ reposted
Nat Rev Neurology
@NatRevNeurol
Diagnostic performance of central vein sign and paramagnetic rim lesion integration for multiple sclerosis journals.sagepub.com/doi/abs/10.1177/13524585261434218?ai…
-
MSJ reposted
sciqst
@sciqst
Nice development in #multiplesclerosis rehabilitation! Exploring alternative approaches like motor imagery alongside action observation could revolutionize patient outcomes. Did the trial compare multiple intensities or combinations of these therapies? The potential to reduce fatigue while enhancing motor function is intriguing. For more detailed insights on topics like this, visit Sci-Quest, your go-to resource for comprehensive biomedical reviews: www.sciqst.com #rehabilitation #medicine
-
MSJ
@MSJ_Research
Motor imagery and action observation appear to be useful adjuncts to standard rehabilitation for enhancing walking and reducing fatigue in people with #multiplesclerosis.
A single-blind exploratory randomized controlled trial from @Hacettepe_Uni ▶️ journals.sagepub.com/doi/full/10.1177/13524585261435401 -
MSJ
@MSJ_Research
People with #multiplesclerosis have positional respiratory changes, independently of disability level or respiratory muscle strength.
Study from @orebrouni ▶️ journals.sagepub.com/doi/full/10.1177/20552173261443831 -
MSJ
@MSJ_Research
The role of a quality improvement initiative to enhance pelvic health physical therapy referrals for persons with #multiplesclerosis and related bladder symptoms.
Study from @ValerieBlock1 @UCSF ▶️ journals.sagepub.com/doi/full/10.1177/20552173261443834 -
MSJ reposted
EthelCiampiSCL
@EthelScl
If you work in LATAM, we invite you to complete this short survey to better understand our current status and how we can improve in the near future in #mri outcomes @NeuroinmunUC @SOCHEDEM1 @SonepsynChile @lactrims_org @ECTRIMS @TheMOGProject @TheSumairaFDN @MAGNIMS
-
MSJ
@MSJ_Research
Most obstetric and neonatal outcomes were comparable between women with and without #multiplesclerosis, except for preterm birth for pregnant women with MS ⩾ 35 years of age.
A nationwide matched cohort study in Korea from @MedSchool_KU ▶️ journals.sagepub.com/doi/abs/10.1177/13524585261434195 -
MSJ
@MSJ_Research
Already there, but some not quite yet...
MSJ
@MSJ_Research
What do you think? Are neurofilament light chain (NfL) levels ready for routine clinical use in #multiplesclerosis?
5/🧵 -
MSJ
@MSJ_Research
In MOG antibody–associated #mogad optic neuritis early corticosteroids predicted visual recovery, but MRI lesion extent prediced retinal atrophy.
Study from @FondARothschild ▶️ journals.sagepub.com/doi/abs/10.1177/13524585261428950 -
MSJ
@MSJ_Research
🔊 Listen to @wz_yeh @NDCNOxford @MonashUni on the effects of smoking and vascular risk factors on relapse risk in myelin oligodendrocyte glycoprotein antibody-associated disease #mogad.
📄And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585261429292 -
MSJ
@MSJ_Research
New controversy available ⚖️
Are neurofilament light chain (NfL) levels ready for routine clinical use in #multiplesclerosis?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @karolinskainst: When interpreted longitudinally, within stablished clinical and MRI measures, NfL can enhance risk stratification, treatment monitoring and detection of #multiplesclerosis.
🔽
journals.sagepub.com/doi/abs/10.1177/13524585261423006
4/🧵
MSJ
@MSJ_Research
What do you think? Are neurofilament light chain (NfL) levels ready for routine clinical use in #multiplesclerosis?
5/🧵 -
MSJ
@MSJ_Research
Cardiovascular comorbidity burden is associated with greater fatigue in #multiplesclerosis over time.
Study from @HopkinsMedicine ▶️ journals.sagepub.com/doi/full/10.1177/13524585261438014 -
MSJ
@MSJ_Research
Following cancer diagnosis, the use of #multiplesclerosis treatments declined sharply, without a strong impact on neurology visits and hospitalizations.
A multinational cohort study from @ChloePierret @Inserm @RennesUniv_EN @UBC ▶️ journals.sagepub.com/doi/full/10.1177/13524585261437966 -
MSJ
@MSJ_Research
🔊 Listen to @Mikael__Cohen @CHUdeNice on the comparisons between radiologically isolated syndrome, early #multiplesclerosis and controls using a digital neurological examination.
📄And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585261418921 -
MSJ reposted
ECTRIMS
@ECTRIMS
🔬 Published in the March 2026 issue of the Multiple Sclerosis Journal, (@MSJ_Research), the case report 𝘔𝘺𝘦𝘭𝘪𝘯𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘵𝘩𝘦 𝘙𝘦𝘵𝘪𝘯𝘢𝘭 𝘕𝘦𝘳𝘷𝘦 𝘍𝘪𝘣𝘳𝘦 𝘓𝘢𝘺𝘦𝘳 offers a rare insight into how the nervous system can repair itself in MS, and what this could mean for measuring recovery in clinical trials.
By senior author Dr. Nicholas Cunniffe and contributing authors Dr. Gioia Riboni-Verri, Riddhima Gautam and Dr. Benson Chen.
→ 📄 𝐂𝐚𝐬𝐞 𝐫𝐞𝐩𝐨𝐫𝐭: journals.sagepub.com/doi/full/10.1177/13524585251365793
→ 🎙️ 𝐏𝐨𝐝𝐜𝐚𝐬𝐭 𝐞𝐩𝐢𝐬𝐨𝐝𝐞: ectrims.eu/podcast/episode-60-positive-remyelination-tria…
#multiplesclerosis #remyelination #clinicaltrials #msresearch #ectrims -
MSJ
@MSJ_Research
Neighborhood deprivation was associated with worsening manual dexterity, walking speed and quality of life in people with #multiplesclerosis 55 years of age and older.
Study from @ClevelandClinic @CLENeurons ▶️ journals.sagepub.com/doi/abs/10.1177/13524585261423408 -
MSJ
@MSJ_Research
Did you attend the Progress in #multiplesclerosis Research Conference 2025 from @MS_Australia ?
Have a look at the abstracts
🔽
journals.sagepub.com/doi/full/10.1177/13524585261424108 -
MSJ reposted
Fiona Chan
@dr_fiona_c
Interesting study addressing a key issue we are all concerned about as neuroimmunologists. Balancing the risks of treatment vs disease relapse to optimise patient function and safety.
MSJ
@MSJ_Research
Extending low-dose rituximab after at least 1 year of clinical and radiological stability in relapsing #multiplesclerosis was not associated with an increased risk of disease activity.
Study from @KPSCALnews ▶️ journals.sagepub.com/doi/abs/10.1177/13524585261430130 -
MSJ
@MSJ_Research
The Number Needed to Treat provides a framework for contextualizing treatment efficacy against potential harms, and was progressively higher in older participants of #multiplesclerosis trials.
Study from @MScentrum020 @amsterdamumc ▶️ journals.sagepub.com/doi/full/10.1177/13524585261429245 -
MSJ
@MSJ_Research
Technology will help, may be...
MSJ
@MSJ_Research
What do you think? Detecting progressing events in #multiplesclerosis clinics in real-time is possible?
5/🧵 -
MSJ
@MSJ_Research
Extending low-dose rituximab after at least 1 year of clinical and radiological stability in relapsing #multiplesclerosis was not associated with an increased risk of disease activity.
Study from @KPSCALnews ▶️ journals.sagepub.com/doi/abs/10.1177/13524585261430130 -
MSJ
@MSJ_Research
Rescue cyclophosphamide treatment was used in 23 people with #multiplesclerosis from 2009 to 2024, and was associated with improvement in relapse-associated disability.
🔓MSJ-ETC study from @UBC ▶️ journals.sagepub.com/doi/full/10.1177/20552173261432390 -
MSJ reposted
IJMSC
@IJMSCtweets
#neuroartfriday
The #beauty of #science.
"Top 50 most connected diagnoses in the #multiplesclerosis (MS; left) and control (right) #comorbidity networks."
MSJ
@MSJ_Research
Diagnosis of #multiplesclerosis is preceded by dynamic reorganization of the comorbidity landscape, including psychiatric and metabolic, highlighting systemic disruption.
A nationwide cohort study from @karolinskainst ▶️ journals.sagepub.com/doi/full/10.1177/13524585261421480 -
MSJ reposted
Avenue Psychotherapy Services
@AvenuePsych
In a case–control study on viruses and #multiplesclerosis run in 2003, one person already had intrathecal synthesis of Epstein-Barr virus antibodies 15 years before clinical onset of #multiplesclerosis.
@MSJ_Research
journals.sagepub.com/doi/abs/10.117…
1/🧵 journals.sagepub.com/doi/abs/10.1177/13524585261427398 -
MSJ
@MSJ_Research
In a case–control study on viruses and #multiplesclerosis run in 2003, one person already had intrathecal synthesis of Epstein-Barr virus antibodies 15 years before clinical onset of #multiplesclerosis.
Study from Universidad de Granada ▶️ journals.sagepub.com/doi/abs/10.1177/13524585261427398
1/🧵
MSJ
@MSJ_Research
...and commentary from @QMUL: #multiplesclerosis is a complex disease due to an interaction between genetic risk and the environment, and #ebv exposure is its necessary trigger.
🔽
journals.sagepub.com/doi/full/10.1177/13524585261427413
2/🧵 -
MSJ
@MSJ_Research
🔊 Listen to @moeinamin_neuro @ClevelandClinic on paramagnetic rim lesions on 7T MRI after autologous hematopoietic cell transplantation in #multiplesclerosis.
📄And read the full manuscript ▶️ journals.sagepub.com/doi/abs/10.1177/13524585261429371 -
MSJ
@MSJ_Research
New controversy available ⚖️
Detecting progressing events in #multiplesclerosis clinics in real-time is possible?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @MonashUni: Early identification of progression is critical in #multiplesclerosis, but requires consistent measurement, accessible data, and timely clinical decision-making.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251409579
4/🧵
MSJ
@MSJ_Research
What do you think? Detecting progressing events in #multiplesclerosis clinics in real-time is possible?
5/🧵 -
MSJ reposted
Neurology Today
@NeurologyToday
Extending maintenance dosing with #rituximab for patients with relapsing #multiplesclerosis from every six months to every 12 months is a safe and effective strategy: neurologytoday.aan.com/doi/10.1097/01.wnt.0001191796.2642…
#neurotwitter #msresearch @KPSCALnews @MarcelloMoccia_ @nyugrossman @WashUNeurology
@OHSUNews -
MSJ
@MSJ_Research
Did you publish your first #multiplesclerosis article as first author in 2025 on our journals?
Apply to the 2026 F2 Award with a cash prize and one year access to the #msj (stay tuned at the @ACTRIMS @ECTRIMS 2026 Closing Ceremony) ▶️ journals.sagepub.com/pb-assets/cmscontent/MSJ/MSJF2Awards…
Deadline: Jul 24 -
MSJ
@MSJ_Research
📢 March issue is now available ▶️journals.sagepub.com/toc/MSJ/current
...and the cover goes to @vjokubaitis @AlfredHealth @MonashUni with their review on the risk of violence in people with #multiplesclerosis ▶️ journals.sagepub.com/doi/full/10.1177/13524585251409580 -
MSJ
@MSJ_Research
📢Listen to @ECTRIMS Podcast with @RealTalkMS_jon and Kathy Smith: The label given to my #multiplesclerosis disease course matters to me?
🔽
ectrims.eu/podcast/episode-68-the-label-given-to-my-ms-di…
ECTRIMS
@ECTRIMS
𝐃𝐨 𝐌𝐒 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐥𝐚𝐛𝐞𝐥𝐬 𝐫𝐞𝐚𝐥𝐥𝐲 𝐫𝐞𝐟𝐥𝐞𝐜𝐭 𝐭𝐡𝐞 𝐥𝐢𝐯𝐞𝐝 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐨𝐟 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬?
In this inaugural episode of a new ECTRIMS–MS Journal collaboration, a caregiver and a person living with MS debate whether disease course labels still make sense.
They explore PIRA, patient voice, and the need for a new language in MS.
🎧 𝐋𝐢𝐬𝐭𝐞𝐧 𝐧𝐨𝐰:
Spotify: open.spotify.com/episode/1Z0lxCX9is693ZxQsMMuJS
Apple: podcasts.apple.com/ch/podcast/does-the-label-given-to-my-…
Our website: ectrims.eu/podcast/episode-68-the-label-given-to-my-ms-di…
#multiplesclerosis #ectrimspodcast #msjournal #patientvoice -
MSJ reposted
Dr. Brandon Beaber
@Brandon_Beaber
A woman was diagnosed with MS in 2019. A cerebrospinal fluid sample (obtained from spinal anaesthesia in a research study) 15 years prior showed antibodies against Epstein-Barr virus (EBV). A case report from Spain pubmed.ncbi.nlm.nih.gov/41841779/
-
MSJ reposted
Dr. Brandon Beaber
@Brandon_Beaber
Using rituximab for multiple sclerosis as infrequently as every 18-24 months in those who were previously stable is associated low disease activity (MRI disease activity and/or relapses in only 2.4%. From Southern California, USA journals.sagepub.com/doi/10.1177/13524585261430130
-
MSJ reposted
ECTRIMS
@ECTRIMS
𝐃𝐨 𝐌𝐒 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐥𝐚𝐛𝐞𝐥𝐬 𝐫𝐞𝐚𝐥𝐥𝐲 𝐫𝐞𝐟𝐥𝐞𝐜𝐭 𝐭𝐡𝐞 𝐥𝐢𝐯𝐞𝐝 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐨𝐟 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬?
In this inaugural episode of a new ECTRIMS–MS Journal collaboration, a caregiver and a person living with MS debate whether disease course labels still make sense.
They explore PIRA, patient voice, and the need for a new language in MS.
🎧 𝐋𝐢𝐬𝐭𝐞𝐧 𝐧𝐨𝐰:
Spotify: open.spotify.com/episode/1Z0lxCX9is693ZxQsMMuJS
Apple: podcasts.apple.com/ch/podcast/does-the-label-given-to-my-…
Our website: ectrims.eu/podcast/episode-68-the-label-given-to-my-ms-di…
#multiplesclerosis #ectrimspodcast #msjournal #patientvoice -
MSJ
@MSJ_Research
📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠
Register here to receive our research
🔽
journals.sagepub.com/connected/MSJ -
MSJ reposted
ECTRIMS
@ECTRIMS
The March 2026 (Volume 32, Number 3) issue of the @MSJ_Research is out. 📖
𝗞𝗲𝘆 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:
• 𝗙𝘂𝘁𝘂𝗿𝗲 𝗣𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲𝘀: Violence and multiple sclerosis: towards an evidence-informed call to action in neurology
•𝗖𝗼𝗻𝘁𝗿𝗼𝘃𝗲𝗿𝘀𝗶𝗲𝘀 𝗶𝗻 𝗠𝗦: Patient voice: The label given to my MS disease course matters to me
•𝗢𝗿𝗶𝗴𝗶𝗻𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵: Neurofilament light chain as a surrogate candidate for disease activity in multiple sclerosis (LUMINOUS)
•𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻 𝗥𝗶𝘀𝗸 𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲𝗱 𝘄𝗶𝘁𝗵 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀: Predictive factors for immunosuppression-associated severe and opportunistic infections in AQP4-IgG NMOSD
•𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗠𝗼𝗱𝗶𝗳𝘆𝗶𝗻𝗴 𝗧𝗵𝗲𝗿𝗮𝗽𝘆: Long-term effectiveness and safety of satralizumab for NMOSD in a real-world clinical setting
•𝗖𝗮𝘀𝗲 𝗥𝗲𝗽𝗼𝗿𝘁: Myelination of the retinal nerve fibre layer
𝗔𝗰𝗰𝗲𝘀𝘀 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗶𝘀𝘀𝘂𝗲 𝗵𝗲𝗿𝗲 👉 journals.sagepub.com/toc/MSJ/current
𝗧𝗵𝗶𝘀 𝘄𝗲𝗲𝗸, 𝘄𝗲 𝗱𝗶𝘃𝗲 𝗱𝗲𝗲𝗽𝗲𝗿 𝗶𝗻𝘁𝗼 𝘁𝗵𝗶𝘀 𝗶𝘀𝘀𝘂𝗲'𝘀 𝗰𝗼𝗻𝘁𝗿𝗼𝘃𝗲𝗿𝘀𝘆 — 𝘛𝘩𝘦 𝘭𝘢𝘣𝘦𝘭 𝘨𝘪𝘷𝘦𝘯 𝘵𝘰 𝘮𝘺 𝘔𝘚 𝘥𝘪𝘴𝘦𝘢𝘴𝘦 𝘤𝘰𝘶𝘳𝘴𝘦 𝘮𝘢𝘵𝘵𝘦𝘳𝘴 𝘵𝘰 𝘮𝘦 — one topic, two sides. You decide. 🎧
#multiplesclerosis #msresearch #msj #ectrims #neurology -
MSJ
@MSJ_Research
Event-related potentials on EEG identified neurophysiological correlates of cognitive performance in #multiplesclerosis.
Study from @TacchiniMarta @MyUniSR ▶️ journals.sagepub.com/doi/abs/10.1177/13524585261423416 -
MSJ
@MSJ_Research
🔊 Listen to @HernanInojosa @tudresden_de on
AI-enabled Living Labs to accelerate innovation in #multiplesclerosis care and research.
📄And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585261424136 -
MSJ
@MSJ_Research
A bidirectional two-sample Mendelian randomization study supported a unidirectional causal effect of elevated antibodies against Epstein–Barr virus (anti-EBNA1 IgG) on #multiplesclerosis risk.
Study from Università degli Studi di Pavia▶️ journals.sagepub.com/doi/abs/10.1177/13524585261423063 -
MSJ
@MSJ_Research
Diagnosis of #multiplesclerosis is preceded by dynamic reorganization of the comorbidity landscape, including psychiatric and metabolic, highlighting systemic disruption.
A nationwide cohort study from @karolinskainst ▶️ journals.sagepub.com/doi/full/10.1177/13524585261421480 -
MSJ
@MSJ_Research
Following initiation of ravulizumab, rituximab-exposed and rituximab-naïve patients with AQP4+ #nmosd achieved sustained disease control and manageable safety profile.
A post hoc analysis of the CHAMPION-NMOSD trial from @CUSystem @MayoClinic ▶️ journals.sagepub.com/doi/abs/10.1177/13524585261425076 -
MSJ
@MSJ_Research
Deep learning can automate the classification of paramagnetic rim and remyelinated lesions in #multiplesclerosis, guiding personalized treatment decisions.
Study from @CristinaGranzi2 @RC2NB ▶️ journals.sagepub.com/doi/abs/10.1177/13524585261421491 -
MSJ reposted
ECTRIMS
@ECTRIMS
⛵𝗪𝗲𝗯𝗶𝗻𝗮𝗿: 𝗠𝗦 𝗜𝗿𝗲𝗹𝗮𝗻𝗱 & 𝗢𝗰𝗲𝗮𝗻𝘀 𝗼𝗳 𝗛𝗼𝗽𝗲 𝟮𝟬𝟮𝟲 𝗦𝗮𝗶𝗹𝗶𝗻𝗴 𝗣𝗿𝗼𝗴𝗿𝗮𝗺𝗺𝗲
Join @MSIRELAND and @OceansofHope for the launch of a new nationwide sailing initiative for people living with MS.
📅 𝗧𝗵𝘂𝗿𝘀𝗱𝗮𝘆, 𝟭𝟮 𝗠𝗮𝗿𝗰𝗵 𝟮𝟬𝟮𝟲
🕒 𝟯:𝟬𝟬 𝗣𝗠 (𝗚𝗠𝗧)
𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿: www.ms-society.ie/news/ms-ireland-oceans-hope-2026-sailin…
Part of our #msawarenessmonth initiative highlighting our 𝟰𝟬+ 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝗗𝗮𝘆 𝗦𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀.
#msawarenessmonth #multiplesclerosis #mscommunity #oceansofhope #msireland #ectrims4me -
MSJ
@MSJ_Research
Pharmacogenomics of response to interferon-beta and glatiramer acetate in #multiplesclerosis is mediated by ion channel pathways and IL-17 regulation, respectively.
Study from @SanRaffaeleMI @MyUniSR ▶️ journals.sagepub.com/doi/abs/10.1177/13524585261417130 -
MSJ reposted
sciqst
@sciqst
The advancements in the McDonald criteria are indeed promising for early diagnosis and management of #multiplesclerosis. The focus on sensitivity and milder cases could notably improve patient care outcomes. With the integration of these criteria, what do you see as the next steps in clinical practice to ensure efficient utilization? For deeper analysis and more on the latest scientific discussions, you might explore Sci-Quest, a one-stop platform that reviews biomedical literature: www.sciqst.com. #medicine
-
MSJ
@MSJ_Research
The 2024 McDonald criteria for #multiplesclerosis increased sensitivity, shortened time to diagnosis, and identified patients with milder disease course, compared with previous iteration.
Study from @I3ptT @TheRMH ▶️ journals.sagepub.com/doi/abs/10.1177/13524585261421816 -
MSJ reposted
Rachel Horne
@RachelHorne19
Submissions for the Rachel Horne Prize for Women's Research in MS are OPEN! 📢
This year we will honour a senior female scientist for
her exceptional contribution to women-focused MS research.
Deadline: June 12
🏆 Prize: $40,000
🔗www.rachelhorneprize.com/application
@ECTRIMS, @IntNatlWiMS -
MSJ
@MSJ_Research
The Select 6 for central vein sign achieved 69.1% sensitivity and 98.1% specificity for #multiplesclerosis (AUC 0.836), in both <50 and <70 years, and improved when combined with paramagnetic rim lesion and cortical lesion.
Study from @KyushuUniv_EN ▶️ journals.sagepub.com/doi/abs/10.1177/13524585261420650 -
MSJ
@MSJ_Research
75% of Asian women with previously monophasic #mogad transitioned to a relapsing course after delivery, suggesting pregnancy can be considered with appropriate clinical monitoring.
Study from the National Institute of Cancer Research & Hospital▶️ journals.sagepub.com/doi/abs/10.1177/13524585261424657 -
MSJ
@MSJ_Research
OCT availability and routine use by neurologists is limited in Switzerland. Awareness, education and guidelines on its clinical use in the care of people with #multiplesclerosis.
🔓MSJ-ETC study from @Unispital_USZ @RC2NB ▶️ journals.sagepub.com/doi/full/10.1177/20552173261419951 -
MSJ
@MSJ_Research
The real-world relapse-free rate at 2.5 years was 91.8% in satralizumab-treated patients with AQP4+ neuromyelitis optica spectrum disorder #nmosd, without new safety concerns.
The SAkuraBeyond Study from @TohokuUniPR ▶️ journals.sagepub.com/doi/abs/10.1177/13524585261418536 -
MSJ reposted
Avenue Psychotherapy Services
@AvenuePsych
Real-world study shows high effectiveness of ofatumumab in older relapsing #multiplesclerosiswith longer disease duration than pivotal trials, and a positive effect on progression independent of relapsing activity. @MSJ_Research
journals.sagepub.com/doi/full/10.11… journals.sagepub.com/doi/full/10.1177/20552173251414528 -
MSJ reposted
Avenue Psychotherapy Services
@AvenuePsych
Metabolomic aging is accellerated in people with #multiplesclerosis and is associated with social disadvantage. @MSJ_Research
Study from @PavanBhargavaMD @KateFitzg @HopkinsMedicine @JohnsHopkinsSPH ▶️ journals.sagepub.com/doi/10.1177/13524585261417120 -
MSJ
@MSJ_Research
Real-world study shows high effectiveness of ofatumumab in older relapsing #multiplesclerosiswith longer disease duration than pivotal trials, and a positive effect on progression independent of relapsing activity.
🔓MSJ-ETC study from Australia ▶️ journals.sagepub.com/doi/full/10.1177/20552173251414528 -
MSJ
@MSJ_Research
Metabolomic aging is accellerated in people with #multiplesclerosis and is associated with social disadvantage.
Study from @PavanBhargavaMD @KateFitzg @HopkinsMedicine @JohnsHopkinsSPH ▶️ journals.sagepub.com/doi/10.1177/13524585261417120 -
MSJ reposted
@Neuroimaging_Research_Unit_SanRaffaele
@NRU_SanRaffaele
Clinical and MRI substrates of Symbol Digit Modalities Test impairment in multiple sclerosis patients with an adult- and late-onset
Our research just published in @MSJ_Research
Great work conducted within @MAGNIMS
#ms #mri #cognition #magnims
journals.sagepub.com/doi/10.1177/13524585261417265 -
MSJ
@MSJ_Research
Did you publish your first #multiplesclerosis article as first author in 2025 on our journals?
Apply to the 2026 F2 Award with a cash prize and one year access to the #msj (stay tuned at the @ACTRIMS @ECTRIMS 2026 Closing Ceremony) ▶️ journals.sagepub.com/pb-assets/cmscontent/MSJ/MSJF2Awards…
Deadline: Jul 24 -
MSJ
@MSJ_Research
It looks like we have a new viable strategy to develop #multiplesclerosis treatments
MSJ
@MSJ_Research
What do you think? Targeting EBV is a viable therapeutic strategy in #multiplesclerosis?
5/🧵 -
MSJ
@MSJ_Research
📢 February issue is now available ▶️journals.sagepub.com/toc/MSJ/current
...and the cover goes to @CollonguesN @CHRUStrasbourg @Inserm with their study on anti-IL6R therapy in #nmosd and #mogad▶️ journals.sagepub.com/doi/full/10.1177/13524585251396421 -
MSJ
@MSJ_Research
New controversy available ⚖️
Targeting EBV is a viable therapeutic strategy in #multiplesclerosis?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @karolinskainst: Accumulating evidence supports EBV-related prevention, but viral resilience, risks of amplifying autoreactivity, and limited clinical experience argue against premature claims of therapeutic viability
🔽
journals.sagepub.com/doi/full/10.1177/13524585251409951
4/🧵
MSJ
@MSJ_Research
What do you think? Targeting EBV is a viable therapeutic strategy in #multiplesclerosis?
5/🧵 -
MSJ
@MSJ_Research
Cognitive disengagement syndrome (including daydreaming, fogginess and hypoactivity) is common in #multiplesclerosis and relates to depression, insomnia, fatigue and paresthesia.
🔓MSJ-ETC study from @StanfordPsych @wrightinstitute @UCincyMedicine▶️ journals.sagepub.com/doi/full/10.1177/20552173261417443 -
MSJ reposted
Sharon Roman (n of 1)
@SRoman_SPQR
Diversity is closely linked to health in people with #ms, yet research studies in MS lack diversity.
🆕 study sets priorities to address the lack of understanding of the diversity characteristics of people with MS. It’s explained ⬇️
tremlettsmsresearchexplained.wordpress.com/2026/02/18/set…
MSJ
@MSJ_Research
Setting priorities for how future research in #multiplesclerosis in Canada considers equity, diversity and inclusion.
A modified e-Delphi study from @DalhousieU @QueensKingston ▶️ journals.sagepub.com/doi/full/10.1177/20552173251398975 -
MSJ reposted
ECTRIMS
@ECTRIMS
A project launched at the 2024 ECTRIMS Winter School is now published in @MSJ_Research. First-authored by Roxanne Pretzsch of @UniBasel_en, it shows NfL is a promising biomarker of treatment response in #ms across 15 RCTs.
🔗 journals.sagepub.com/doi/abs/10.1177/13524585251407973
#multiplesclerosis #msresearch #neurofilament #winterschool -
MSJ
@MSJ_Research
Significant challenges characterize #multiplesclerosis care in Africa: Therapies and services are inaccessible and unaffordable, and traditional healers had a role in 14.8% of countries.
A continent-wide survey led by @AliShal52729523 @Ainshams_Univ ▶️ journals.sagepub.com/doi/full/10.1177/13524585261417591 -
MSJ
@MSJ_Research
Diagnostic pathways and barriers in #multiplesclerosis in Zambia: Misinterpretation of symptoms, lack of specialists, and systemic health system limitations.
🔓MSJ-ETC study from @mashina_chomba @UnzaOfficial @DeannaSaylor1 @UNC ▶️ journals.sagepub.com/doi/full/10.1177/20552173261417446 -
MSJ reposted
Ahmad Toubasi
@ahmadtubasi99
Our new publication on a JAKi triggering a demyelinating event!
MSJ
@MSJ_Research
Baricitinib, a Janus kinase inhibitors used for autoimmune diseases such as rheumatoid arthritis and lupus, can trigger a central nervous system inflammatory-demyelinating disease.
Case report from @RozitaKhalili @BagnatoLab @uthsc @VUMCDiscoveries ▶️ journals.sagepub.com/doi/full/10.1177/20552173251409943 -
MSJ
@MSJ_Research
📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠
Register here to receive our research
🔽
journals.sagepub.com/connected/MSJ -
MSJ reposted
Avenue Psychotherapy Services
@AvenuePsych
Baricitinib, a Janus kinase inhibitors used for autoimmune diseases such as rheumatoid arthritis and lupus, can trigger a central nervous system inflammatory-demyelinating disease.
Case report from @RozitaKhalili @BagnatoLab @MSJ_Research #therapy journals.sagepub.com/doi/full/10.1177/20552173251409943 -
MSJ reposted
ECTRIMS
@ECTRIMS
BTK inhibitors continue to be one of the most closely watched therapeutic areas in #ms — and for good reason. In this podcast episode, #fenebrutinib trial leads explain why BTK inhibition uniquely targets the cells most implicated in chronic MS progression.
🎧 Listen for a deep dive into the science and the clinical implications.
• Spotify: open.spotify.com/episode/0X1ssSM9XjY5yV7JikyWpf
• Apple: podcasts.apple.com/us/podcast/fenebrutinib-in-ppms-insigh…
#fentrepid #multiplesclerosis #primaryprogressivems #ppms #clinicaltrials #actrimsforum2026 #ectrimspodcast -
MSJ
@MSJ_Research
🔊 Listen to @uofcincy @ahmedzobeidat @MedicalCollege on the risk factors for hypogammaglobulinemia in people with #multiplesclerosis receiving ocrelizumab or ofatumumab.
📄And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585251412125 -
MSJ
@MSJ_Research
Baricitinib, a Janus kinase inhibitors used for autoimmune diseases such as rheumatoid arthritis and lupus, can trigger a central nervous system inflammatory-demyelinating disease.
Case report from @RozitaKhalili @BagnatoLab @uthsc @VUMCDiscoveries ▶️ journals.sagepub.com/doi/full/10.1177/20552173251409943 -
MSJ reposted
Avenue Psychotherapy Services
@AvenuePsych
Severe and opportunistic infections can be a complication of immunosuppression in AQP4+ #neuromyelitisoptica #nmosd, especially in older patients, with longer disease durationa and comorbidities.
Study from @jacksax13 @NDCNOxford @UniofOxford @MSJ_Research journals.sagepub.com/doi/abs/10.1177/13524585251409581 -
MSJ
@MSJ_Research
Severe and opportunistic infections can be a complication of immunosuppression in AQP4+ #neuromyelitisoptica #nmosd, especially in older patients, with longer disease durationa and comorbidities.
Study from @jacksax13 @NDCNOxford @UniofOxford @unipv ▶️ journals.sagepub.com/doi/full/10.1177/13524585251409581 -
MSJ reposted
Dr. Brandon Beaber
@Brandon_Beaber
Risk factors for serious infections with ocrevus and kesimpta: low white blood cells (p < 0.0001), long term use (p = 0.0409), progressive MS (p = 0.0001), lower baseline immunoglobulin G (IgG), and older age. journals.sagepub.com/doi/10.1177/13524585251412125
-
MSJ reposted
Avenue Psychotherapy Services
@AvenuePsych
Patient-reported outcomes, combined with other clinical variables, can predict disability evolution in people with #multiplesclerosis.
An interpretable machine learning approach from @aism_nazionale @unige_en ▶️ journals.sagepub.com/doi/full/10.11… @MSJ_Research journals.sagepub.com/doi/full/10.1177/13524585251411093 -
MSJ
@MSJ_Research
🔊 Listen to @bollo_luca @cemcat_em @UABBarcelona @AVidalJordana @neurosantpau
@ALugaresi on OCT to predict disease progression and brain and spinal atrophy in primary progressive #multiplesclerosis.
📄And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585251407976 -
MSJ reposted
ECTRIMS
@ECTRIMS
📢 New in @MSJ_Research: A scoping review led by Maria Pia Sormani (@UniGenova) synthesises the emerging literature on social determinants of health in people with MS in Italy, highlighting a strong focus on sex and gender and key gaps in other areas.
🔗journals.sagepub.com/toc/msja/current
#multiplesclerosis #msresearch #sdh #neurology -
MSJ
@MSJ_Research
Patient-reported outcomes, combined with other clinical variables, can predict disability evolution in people with #multiplesclerosis.
An interpretable machine learning approach from @aism_nazionale @unige_en ▶️ journals.sagepub.com/doi/full/10.1177/13524585251411093 -
MSJ reposted
ECTRIMS
@ECTRIMS
Save the date for #mstoronto2026! The 10th Joint ACTRIMS-ECTRIMS Meeting will foster global knowledge exchange and advance the field of #ms and related disorders.
10 Joint Meetings. One Global MS Community.
📅 When: 21-23 October 2026
📍Metro Toronto Convention Center in Toronto, Canada
Registration opens on 24 March, so mark your calendar now and subscribe to our newsletter to stay informed: 91f6c832.sibforms.com/serve/MUIFACgGoWUC770TfbaAkoKZr8us_…
Learn more about MSToronto2026: mstoronto2026.org
@ACTRIMS
#ms #multiplesclerosis #msresearch -
MSJ
@MSJ_Research
And commentary from @ResearchUGent: Clinicians should maintain a high index of suspicion for B-cell depletion vaginitis in women with #multiplesclerosis with unexplained vulvovaginal symptoms during long-term anti-CD20 therapy.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251409559
MSJ
@MSJ_Research
Gynecological health within comprehensive treatment monitoring for #multiplesclerosis.
Topical review from @BoveRiley @UCSF ▶️journals.sagepub.com/doi/full/10.1177/13524585251346371 -
MSJ
@MSJ_Research
MRI markers, including thalamic volume, lesion volume and spinal lesions, and high-efficacy treatment were associated with outcomes in pediatric #multiplesclerosis.
12-year study from @monicamargoni @rocca_mara @NRU_SanRaffaele @SanRaffaeleMI @MyUniSR▶️ journals.sagepub.com/doi/full/10.1177/13524585251408639 -
MSJ
@MSJ_Research
Apolipoprotein E4 exacerbates neurodegeneration and neuroinflammation in #multiplesclerosis, as reflected by retinal OCT, cognitive testing, biomarkers and MRI lesions.
🔓MSJ-ETC study from @TJUHospital @BUMedicine ▶️ journals.sagepub.com/doi/full/10.1177/20552173251387833 -
MSJ
@MSJ_Research
Relapses in neuromyelitis optica #nmosd were associated with debilitating symptoms and caregiver support, highlighting the need for highly effective interventions to prevent patient and caregiver burden.
🔓MSJ-ETC study from @LivUni @TheWaltonCentre ▶️ journals.sagepub.com/doi/full/10.1177/20552173251406973 -
MSJ
@MSJ_Research
In #multiplesclerosis, treatment effects on blood neurofilament light chain #nfl are moderately associated with therapeutic effects on relapses and MRI lesions.
A meta-regression of randomized controlled trials from @RC2NB @UniBasel_en @unige_en ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251407973 -
MSJ reposted
ECTRIMS
@ECTRIMS
Best of #ectrims2025: RIMS Highlight
A study led by Prof. Renato Anghinah (@FMUSPoficial) shows vertical gaze performance in MS correlates with patient-reported visual difficulties (NEIVFQ-25), helping validate visual challenges in MS.
📥 my.ectrims.eu/bestofslidedecks
@eurims @MSJ_Research -
MSJ
@MSJ_Research
Setting priorities for how future research in #multiplesclerosis in Canada considers equity, diversity and inclusion.
A modified e-Delphi study from @DalhousieU @QueensKingston ▶️ journals.sagepub.com/doi/full/10.1177/20552173251398975 -
MSJ
@MSJ_Research
Yes, optic nerve assessment is worth its complexity!
MSJ
@MSJ_Research
What do you think? Optic nerve assessments in #multiplesclerosis diagnosis are worth the added implementation complexity?
5/🧵 -
MSJ
@MSJ_Research
In youth with #multiplesclerosis (<18 years), built-environment features (intersections and green space) were associated with physical activity.
Study from @UofT @SickKidsNews ▶️ journals.sagepub.com/doi/full/10.1177/13524585251407505 -
MSJ
@MSJ_Research
Regional variations in leptomeningeal enhancement in #multiplesclerosis may point to differences in the blood-meningeal barrier, with related alterations in the adjacent cortex.
🔓MSJ-ETC study from @NIH_NINDS ▶️ journals.sagepub.com/doi/full/10.1177/20552173251408625 -
MSJ reposted
IJMSC
@IJMSCtweets
"...emerging findings...indicate that #violence is relevant to MS care."
Munroe et al: "Visible indicators of disability may contribute to perceptions of #vulnerability, esp. among [Pw #multiplesclerosis] who are racially & ethnically marginalized." doi.org/10.7224/1537-2073.2023-076
MSJ
@MSJ_Research
People with #multiplesclerosis may experience sustained risk of violence due to the intersection of chronic illness, disability, gendered dynamics and structural inequality.
An evidence-based call to action from @vjokubaitis @AlfredHealth @MonashUni
▶️ journals.sagepub.com/doi/full/10.1177/13524585251409580 -
MSJ
@MSJ_Research
Comorbidities are prevalent among newly diagnosed people with #multiplesclerosis, and should be considered carefully within treatment decisions.
A population-based register study from @MerviRyytty @UniOulu ▶️ journals.sagepub.com/doi/full/10.1177/20552173251411076 -
MSJ
@MSJ_Research
New controversy available ⚖️
Optic nerve assessments in #multiplesclerosis diagnosis are worth the added implementation complexity?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @UofT @SickKidsNews: The message for all is the need of educational efforts to increase access globally for smooth implementation of technologies to identify optic nerve involvement in #multiplesclerosis,
🔽
journals.sagepub.com/doi/full/10.1177/13524585251410415
4/🧵
MSJ
@MSJ_Research
What do you think? Optic nerve assessments in #multiplesclerosis diagnosis are worth the added implementation complexity?
5/🧵 -
MSJ reposted
@Neuroimaging_Research_Unit_SanRaffaele
@NRU_SanRaffaele
What are the clinical and #mri correlates of 12-years outcomes in pediatric-onset #ms?
Clinical features matter — but MRI adds valuable prognostic information. See our paper in @MSJ_Research
@monicamargoni @agmmeani @rocca_mara @paolopreziosa
journals.sagepub.com/doi/10.1177/13524585251408639 -
MSJ reposted
ECTRIMS
@ECTRIMS
Best of #ectrims2025: Biomarkers Highlight
A 10-year study in people with MS, led by Prof. @Mennoke (@AmsterdamUMC), shows functional network collapse is linked to disease progression. Baseline lesion and thalamic volume predict 10-year FNC risk.
📌 my.ectrims.eu/bestofslidedecks
@MSJ_Research -
MSJ
@MSJ_Research
...and letter from @Beaumont_Dublin: The cascade sign can be seen in diffuse large B-cell lymphoma, and not necessarily in neuro-Behçet’s disease.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251407866
MSJ
@MSJ_Research
🔊 Listen to @ALugaresi @Unibo on the cascade sign in AQ4+ neuromyelitis optica #nmosd (MRI showing confluent diencephalo-mesencephalic lesions).
📄 And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585251356820
1/🧵 -
MSJ reposted
DrMansillaNeurologo
@DrJPMansilla
📄 Nuevo paper en MS Journal (2026) sobre la transición de Gilenya a fingolimod genérico. Los resultados son preocupantes: mayor actividad radiológica y clínica tras el cambio, más un aumento del 8.8% en linfocitos (ALC). ¿Falla de potencia del genérico? Abro hilo 🧵👇
MSJ
@MSJ_Research
Measures of disease stability appear less optimal when transitioning from Gilenya® to generic fingolimod, based on lymphocyte count, relapses and MRI activity.
Study from @KansasCityU @UCSF_MS_Center @UTSWMedCenter ▶️ journals.sagepub.com/doi/full/10.1177/13524585251401404 -
MSJ
@MSJ_Research
People with #multiplesclerosis may experience sustained risk of violence due to the intersection of chronic illness, disability, gendered dynamics and structural inequality.
An evidence-based call to action from @vjokubaitis @AlfredHealth @MonashUni
▶️ journals.sagepub.com/doi/full/10.1177/13524585251409580 -
MSJ
@MSJ_Research
Over a follow-up of 62.2 months, progression independent of relapse activity #pira occurred in 1.7% patients with myelin oligodendrocyte glycoprotein antibody–associated disease #mogad, highlighting its rarity.
Study from @yonsei_u ▶️ journals.sagepub.com/doi/full/10.1177/13524585251408654 -
MSJ
@MSJ_Research
Personality structure, particularly neuroticism, active coping and openness may influence decisions to use high-effective treatments among people with #multiplesclerosis.
🔓MSJ-ETC study from @MedUni_Wien ▶️ journals.sagepub.com/doi/full/10.1177/20552173251408627 -
MSJ
@MSJ_Research
Measures of disease stability appear less optimal when transitioning from Gilenya® to generic fingolimod, based on lymphocyte count, relapses and MRI activity.
Study from @KansasCityU @UCSF_MS_Center @UTSWMedCenter ▶️ journals.sagepub.com/doi/full/10.1177/13524585251401404 -
MSJ
@MSJ_Research
A 42-year-old man with relapsing #multiplesclerosis and no prior cardiac history developed a severe but reversible left ventricular systolic dysfunction after 24–36 hours after ocrelizumab administration.
Case report from @UNIMORE_univ ▶️ journals.sagepub.com/doi/full/10.1177/13524585251407501
1/🧵
MSJ
@MSJ_Research
...and commentary from @ResearchNeurOUS: This case expands our understanding of anti-CD20 safety and reinforces the need for vigilance as these therapies continue to be used in an increasingly broad #multiplesclerosis population.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251407513
2/🧵 -
MSJ
@MSJ_Research
Diurnal peak activity using wrist-worn accelerometry is a sensitive marker of observable movement reserve that correlates with disability in #multiplesclerosis.
Study from @PratimNiyogi @UMMCnews @EllenMowryMD @HopkinsNeuro @vadimZip @JohnsHopkinsSPH ▶️ journals.sagepub.com/doi/full/10.1177/13524585251398689 -
MSJ
@MSJ_Research
🔊Listen to @DalhousieU @MSCanOfficial @MS_Australia on a global prevention agenda for #multiplesclerosis.
📄And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585251398381 -
MSJ
@MSJ_Research
Network-level functional and structural measures may reveal mechanisms and predictors of language dysfunction in #multiplesclerosis.
Study from @ar_neuro @ColumbiaMed @nyuniversity ▶️ journals.sagepub.com/doi/full/10.1177/13524585251398451 -
MSJ reposted
ECTRIMS
@ECTRIMS
⏰ Only four days left to apply for the ECTRIMS Summer School 2026.
The Summer School on Statistical Techniques & Tools in MS Research will be held in Naples, Italy, from 8 to 10 June 2026.
Apply now 👉 my.ectrims.eu/school/summer
Deadline: 19 January, 23:59 CET
#msresearch -
MSJ
@MSJ_Research
📢 January issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to▶️ @MorozumiTetsu @rocca_mara @NRU_SanRaffaele with their study on microstructural integrity of motor-related white matter tracts in #multiplesclerosis▶️ journals.sagepub.com/doi/full/10.1177/13524585251398386 -
MSJ
@MSJ_Research
A 34-year-old man was diagnosed with Gerstmann–Sträussler–Scheinker (GSS) after clinical presentation suggestive of primary progressive #multiplesclerosis and presence of CSF-restricted oligoconal bands.
Case report from @ChibaUniversity ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251401053
1/🧵
MSJ
@MSJ_Research
...and commentary from @QSMSCENTRE @UCLBrainScience: Paraclinical data should strengthen rather than replace clinical reasoning, especially in an era of expanding differentials.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251401038
2/🧵 -
MSJ
@MSJ_Research
kFLC index is a reliable tool for #multiplesclerosis diagnosis in Asian populations, but higher (⩾12.6) and sex-specific thresholds may improve accuracy due to high prevalence of mimics.
Study from the National Cancer Center Korea ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251399102 -
MSJ
@MSJ_Research
Periventricular gradients in axonal and myelin microstructure are present in people with #multiplesclerosis, and are related to black holes and to enlargement of lateral ventricle and choroid plexus.
MRI study from @bic_mni @TheNeuro_MNI @mcgillu ▶️ journals.sagepub.com/doi/full/10.1177/13524585251396439 -
MSJ
@MSJ_Research
People with #multiplesclerosis have less seasonal allergies than controls, possibly due to different genetic risk score.
Epidemiologic and genetic study from @umiamimedicine @cwru @KPSanFrancisco ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251398382 -
MSJ
@MSJ_Research
Opicinumab, a human monoclonal antibody against LINGO-1, did not show significant improvements in disability (ODRS) in relapsing #multiplesclerosis (vs placebo).
A randomized, controlled, phase 2 trial from @Calabre04804429 @hopkinsneurons @biogen ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251396433 -
MSJ
@MSJ_Research
Higher intake of saturated and trans-fatty acids and alcohol was associated with biomarkers of chronic inflammation and neurovascular dysfunction in #multiplesclerosis.
Study from @SerenaBorrelli4 @Pietro46069031 @UCLouvain_ADRE ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251405695 -
MSJ
@MSJ_Research
🔊Listen to @DavideAdom @UninaIT on dysarthria assessment in people with #multiplesclerosis, and related physical and cognitive disability.
📄And read the full paper ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251400108 -
MSJ
@MSJ_Research
📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠
Register here to receive our research
🔽
journals.sagepub.com/connected/MSJ -
MSJ
@MSJ_Research
New issue of Multiple Sclerosis Journal – Experimental, Translational and Clinical is now available online ▶️ journals.sagepub.com/toc/msoa/11/3 and is full open access 🔓
-
MSJ
@MSJ_Research
Microstructural integrity of motor-related white matter tracts predicts training response in #multiplesclerosis, with implications for response to rehabilitation.
Study from @MorozumiTetsu @rocca_mara @NRU_SanRaffaele ▶️ journals.sagepub.com/doi/full/10.1177/13524585251398386 -
MSJ
@MSJ_Research
Labels do matter - Very important for any future considerations on definitions of #multiplesclerosis progression.
MSJ
@MSJ_Research
What do you think? The label given to my #multiplesclerosis disease course matters to me?
5/🧵 -
MSJ
@MSJ_Research
Younger age and the use of less effective therapies are strong risk factors for #multiplesclerosis relapse across different treatment eras, with significant individuals’ heterogeneity.
🔓MSJ-ETC study from @es_madill @harvardmed @BrighamWomens ▶️ journals.sagepub.com/doi/full/10.1177/20552173251408619 -
MSJ
@MSJ_Research
🔊 Listen to @MSBase_Registry @UniMelb on the management of reactivation of #multiplesclerosis during treatment with natalizumab.
📄And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585251398682 -
MSJ
@MSJ_Research
New controversy available ⚖️
Patient voice: The label given to my #multiplesclerosis disease course matters to me?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @MonashUni: Course descriptors matter, but must evolve towards a more precise, personalised and biologically grounded approach, so that people with #multiplesclerosis better understand where they are now and what may lie ahead.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251396286
4/🧵
MSJ
@MSJ_Research
What do you think? The label given to my #multiplesclerosis disease course matters to me?
5/🧵 -
MSJ
@MSJ_Research
Anti-IL6R therapy appears effective in reducing disease activity in both #nmosd and #mogad, particularly in patients previously unresponsive to rituximab.
Study from for the NOMADMUS Study Group @CollonguesN @CHRUStrasbourg @Inserm ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251396421 -
MSJ reposted
Paolo Preziosa
@paolopreziosa
Identifying predictors of motor training response in #ms could enable truly personalized rehabilitation
Selecting the most effective intervention for each patient may maximize recovery and functional outcomes
See our paper published in @MSJ_Research
journals.sagepub.com/doi/10.1177/13524585251398386
@Neuroimaging_Research_Unit_SanRaffaele
@NRU_SanRaffaele
Contribution of structural and functional MRI in predicting response to motor training in multiple sclerosis
Our research just published in @MSJ_Research
#ms #mri #rehabilitation
@MorozumiTetsu @paolopreziosa @agmmeani @PaolaValsasina @rocca_mara
journals.sagepub.com/doi/10.1177/13524585251398386 -
MSJ reposted
sciqst
@sciqst
The study on T1-based stratification of paramagnetic rim lesions in #multiplesclerosis sounds intriguing! Understanding the clinical implications could significantly impact treatment strategies. I'd be curious to know how this stratification affects patient outcomes or treatment plans. #medicine
For those who want to dive deeper into biomedical discussions, check out www.sciqst.com, a great resource for comprehensive reviews on topics like this! -
MSJ
@MSJ_Research
📢December issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @CQMU1956 with their study on T1-based stratification of paramagnetic rim lesions in #multiplesclerosis and clinical implications ▶️ journals.sagepub.com/doi/10.1177/13524585251389809 -
MSJ
@MSJ_Research
Possibly not the solution to misdiagnosis, at least to many...
MSJ
@MSJ_Research
What do you think? The revised 2024 McDonald criteria can solve the misdiagnosis problem in #multiplesclerosis?
5/🧵 -
MSJ reposted
ECTRIMS
@ECTRIMS
📢 Applications are now open for the ECTRIMS Summer School 2026!
The programme will be held in Naples, Italy, from 8 to 10 June 2026.
📝 Apply now 👉 my.ectrims.eu/school/summer
⏰ Deadline: 19 January, 23:59 CET
#summerschool #msresearch -
MSJ
@MSJ_Research
During a mean follow-up of 17.6 years, Mediterranean diet was associated with a lower risk of #multiplesclerosis.
Study from @unimib @karolinskainst ▶️ journals.sagepub.com/doi/full/10.1177/13524585251396408 -
MSJ
@MSJ_Research
New controversy available ⚖️
The revised 2024 McDonald criteria can solve the misdiagnosis problem in #multiplesclerosis?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @MonashUni: The 2024 McDonald criteria represent a decisive step towards biologically anchored, earlier diagnosis – but they will succeed only if coupled with careful clinical reasoning, education and humility.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251396271
4/🧵
MSJ
@MSJ_Research
What do you think? The revised 2024 McDonald criteria can solve the misdiagnosis problem in #multiplesclerosis?
5/🧵 -
MSJ reposted
Dr. Brandon Beaber
@Brandon_Beaber
The Mediterranean diet is linked to a slightly lower risk of multiple sclerosis (data from 41,428 participants in the Swedish National March). "Each one-point increase in the Mediterranean Diet Score was associated with a 14% lower MS risk" Cohort.)journals.sagepub.com/doi/10.1177/13524585251396408
-
MSJ reposted
Peas & Potatoes Or Pills & Procedures?
@peasorpills
New in @MSJ_Research: "In this large prospective cohort study, a higher Mediterranean Diet Score was associated with a substantially lower risk of MS." #multiplesclerosis #neurology
journals.sagepub.com/doi/10.1177/13524585251396408 -
MSJ reposted
ECTRIMS
@ECTRIMS
Cognitive symptoms in MS are common—but not always captured well by current tools. In our latest podcast, Vicky Leavitt from @Columbia and Tom Fuchs from @AmsNeuroscience talk about the state of cognition research, if measurement still lags behind clinical need, and how new tools may change the field forever.
🎧 Listen now:
Apple: podcasts.apple.com/us/podcast/how-well-are-we-measuring-c…
#ectrimspodcast #multiplesclerosis #cognition #msresearch #neurology #mscommunity @MStranslate -
MSJ
@MSJ_Research
How do neurologists perceive the organization and functioning of #multiplesclerosis care units? Enhancing care coordination could improve care delivery and mitigate the risk of burnout for clinicians.
🔓MSJ-ETC study from @Roche ▶️ journals.sagepub.com/doi/full/10.1177/20552173251406791 -
MSJ reposted
Sudarshini Ramanathan
@darshi_r
Great to work with Andy Solomon on this invited commentary@MSJ_Research @syd_health @anzacinstitute @kids_research @ECTRIMS @mssociety @tim_coetzee @XMontalban #2024 MS Diagnostic criteria journals.sagepub.com/doi/10.1177/13524585251396284
-
MSJ
@MSJ_Research
In cuprizone-exposed rats, impaired memory function, reduced exploratory behaviour, and increased anxiety-like behaviours were improved by Nigella sativa oil.
🔓MSJ-ETC study from @UnilorinNGR ▶️ journals.sagepub.com/doi/full/10.1177/20552173251405050 -
MSJ
@MSJ_Research
This real-world study confirmed effectiveness and safety of satralizumab inAQ4+ #neuromyelitisoptica #nmosd, including in inadequate disease control and/or intolerance.
🔓MSJ-ETC study from @AbboudHesham @cwru @genentech ▶️ journals.sagepub.com/doi/full/10.1177/20552173251386895 -
MSJ
@MSJ_Research
Progression independent of relasping activity (PIRA) predominantly drives disability accrual in relapsing #multiplesclerosis, yet definitional variation substantially influenced event rates requiring better standardization.
Study from @MedUni_Wien ▶️ journals.sagepub.com/doi/full/10.1177/13524585251396283 -
MSJ
@MSJ_Research
More efforts needed for remyelination therapies in #multiplesclerosis
MSJ
@MSJ_Research
What do you think? Remyelination therapies are achievable in clinical practice?
5/🧵 -
MSJ
@MSJ_Research
Word-finding concerns are common in people with relapsing #multiplesclerosis, and can be related to semantic network disorganization and inflexibility.
🔓MSJ-ETC study from @montclairstateu ▶️ journals.sagepub.com/doi/full/10.1177/20552173251348306 -
MSJ
@MSJ_Research
In people with #multiplesclerosis with visual complaints, only 6.2% received OCT and 33% VEP, compared with brain MRI (58%) and lumbar puncture (42%).
🔓MSJ-ETC study from @ChariteBerlin ▶️ journals.sagepub.com/doi/full/10.1177/20552173251397772 -
MSJ
@MSJ_Research
New controversy available ⚖️
Remyelination therapies are achievable in clinical practice?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @karolinskainst: The gap between biological feasibility and clinical reality of remyelination therapies in #multiplesclerosis remains, but can be potentially overcome as done for disease modifying treatments.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251396267
4/🧵
MSJ
@MSJ_Research
What do you think? Remyelination therapies are achievable in clinical practice?
5/🧵 -
MSJ reposted
The Sumaira Foundation
@TheSumairaFDN
📍Dubai 🇦🇪 Middle East and North Africa Committee for Treatment & Research in Multiple Sclerosis #menactrims 10th Annual Congress
-
MSJ
@MSJ_Research
📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠
Register here to receive our research
🔽
journals.sagepub.com/connected/MSJ -
MSJ
@MSJ_Research
A 20-year-old male with Crohn’s disease was diagnosed with #multiplesclerosis, which were both successfully managed with cladribine monotherapy.
Case report from @SVieujean ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251390859
1/🧵
MSJ
@MSJ_Research
A 28-year-old female with #multiplesclerosis was diagnosed with ulcerative colitis, which were both successfully managed with cladribine monotherapy first, and, then, ozanimod.
Case report from @petracca_maria @SapienzaRoma ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251396258
2/🧵
MSJ
@MSJ_Research
...and commentary from @DrWBRO @QSMSCENTRE @UCLBrainScience: Cladribine is a useful option in #multiplesclerosis with other autoimmune disorders, including inflammatory bowel disease, thanks to efficacy and lack of maintenance immunosuppression.
🔽
journals.sagepub.com/doi/abs/10.1177/13524585251396293
3/🧵 -
MSJ
@MSJ_Research
Are you attending the 2025 @MS_Australia Progress in #multiplesclerosis Research Conference?
📅 Date: Dec 3-5, 2025
📍 Venue: Sofitel Brisbane Central, 249 Turbot Street, Brisbane, Queensland, Australia
🔗 Learn more & register: www.ivvy.com.au/event/MSA2025/welcome.html -
MSJ reposted
Omar Al-Louzi
@Omar_Al_Louzi
Retinal ganglion cell reserve matters in ON with inter-eye diff being associated with worse visual outcomes.
Preserving retinal ganglion cells following MS-related ON is key in management, and could serve as a biomarker of visual function in clinical trials of neuroprotection
MSJ
@MSJ_Research
Retinal ganglion cell-inner plexiform layer inter-eye difference (GCIPL IED) is associated with clinical visual dysfunction following optic neuritis in #multiplesclerosis and related disorders.
🔓MSJ-ETC study from @Omar_Al_Louzi @CedarsSinai ▶️ journals.sagepub.com/doi/full/10.1177/20552173251397302 -
MSJ reposted
Sharon Roman (n of 1)
@SRoman_SPQR
If I may, @MSJ_Research, it’s explained ⬇️ for the folks who would like it in plain language.
tremlettsmsresearchexplained.wordpress.com/2025/11/26/saf…
MSJ
@MSJ_Research
While the reporting of phase III clinical trials for treatments of #multiplesclerosis has improved with time, there remain gaps and opportunities for further improvement in laboratory-defined toxicity and defining adverse events.
Study from @UBC @UofT ▶️ journals.sagepub.com/doi/full/10.1177/20552173251390649 -
MSJ
@MSJ_Research
Retinal ganglion cell-inner plexiform layer inter-eye difference (GCIPL IED) is associated with clinical visual dysfunction following optic neuritis in #multiplesclerosis and related disorders.
🔓MSJ-ETC study from @Omar_Al_Louzi @CedarsSinai ▶️ journals.sagepub.com/doi/full/10.1177/20552173251397302 -
MSJ reposted
ECTRIMS
@ECTRIMS
New MS #spotlight: @StankoffBr (@Sorbonne_Univ @ParisBrainInst @APHP) highlights the breakthroughs behind the 2024 McDonald Criteria—moving toward a more universal and timely MS diagnosis framework.
🔗 ectrims.eu/insights/a-rupture-with-the-past-ectrims-presi… -
MSJ
@MSJ_Research
📢 November issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @SamanthaBanksMD @MayoClinicNeuro @MayoClinic with their study on deep brain stimulation as a potential treatment for severe tremor in #multiplesclerosis ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251387935 -
MSJ reposted
ECTRIMS
@ECTRIMS
📢 New in @MSJ_Research: A study led by Jennifer Graves (@UCSanDiego) found no correlation between epigenetic clocks and telomere length, suggesting they capture distinct aspects of biological aging in MS.
🔗 journals.sagepub.com/doi/10.1177/13524585251386217
#ms #aging #biomarkers -
MSJ
@MSJ_Research
🔊 Listen to @TjalfZiemssen @tudresden_de @MSDoc_Freedman @uOttawa @UCSF on the clinical validation of a novel in vitro diagnostic neurofilament light chain assay in #multiplesclerosis.
📰 And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585251389797 -
MSJ reposted
ECTRIMS
@ECTRIMS
🚨 Time is running out!
Only 2 weeks left to apply for the 2025 ECTRIMS Fellowship Programmes — a unique opportunity to advance your career in #multiplesclerosis research & care with support from leading experts.
📅 Deadline: 1 Dec 2025
👉 ectrims.eu/fellowships
#msresearch #neurology #fellowship #medicalresearch -
MSJ reposted
ECTRIMS
@ECTRIMS
“We need to understand how to use AI properly — to support patients, reduce bias, and make the most of our time together”— Miguel Ángel Cortés @cemcat_em
🎧 Hear more in MS Nursing: Listening, Leadership & the Role of AI in Patient Care
➡️ Spotify: open.spotify.com/episode/00SkIHGV3EziT2NrEqNn0c
#msnurse #aiinhealthcare #mscommunity -
MSJ
@MSJ_Research
Paramagnetic rim lesions classified using corresponding T1-weighted black holes (PRL+BH+) had more microstructural damage and stronger associations with motor and cognitive disability in #multiplesclerosis.
Study from @CQMU1956 ▶️ journals.sagepub.com/doi/10.1177/13524585251389809 -
MSJ
@MSJ_Research
Epigenetic age did not correlate with telomere length in pediatric-onset #multiplesclerosis, suggesting these biomarkers capture complementary and non-overlapping elements of aging-related biology.
Study from @radychildrens @UCSanDiego ▶️ journals.sagepub.com/doi/full/10.1177/13524585251386217 -
MSJ
@MSJ_Research
There were 82 cases of anaphylaxis with glatiramer acetate in #multiplesclerosis, prompting a labeling change notification to update the WARNINGS AND PRECAUTIONS section.
Study using the @FDA Adverse Events Reporting System ▶️ journals.sagepub.com/doi/full/10.1177/13524585251382397 -
MSJ reposted
Sharon Roman (n of 1)
@SRoman_SPQR
If I may, @MSJ_Research, it’s explained ⬇️ for the folks who want it in plain language.
tremlettsmsresearchexplained.wordpress.com/2025/10/27/psy…
MSJ
@MSJ_Research
Psychiatric morbidity before #multiplesclerosis recognition was associated with increased future disability, particularly in males, younger individuals and relapsing-onset.
Study from @UM_RadyFHS @helen_tremlett @UBC ▶️ journals.sagepub.com/doi/full/10.1177/13524585251382801 -
MSJ
@MSJ_Research
Psychiatric morbidity before #multiplesclerosis recognition was associated with increased future disability, particularly in males, younger individuals and relapsing-onset.
Study from @UM_RadyFHS @helen_tremlett @UBC ▶️ journals.sagepub.com/doi/full/10.1177/13524585251382801 -
MSJ
@MSJ_Research
Older age, males, Hispanics, Blacks, smokers, public insurance, greater legs impairment, progressive disease, and depression led to worsening hand function in #multiplesclerosis.
Study from @univmiami @umiamimedicine @DanOntaneda @cwru @ClevelandClinic ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251384060 -
MSJ
@MSJ_Research
While the reporting of phase III clinical trials for treatments of #multiplesclerosis has improved with time, there remain gaps and opportunities for further improvement in laboratory-defined toxicity and defining adverse events.
Study from @UBC @UofT ▶️ journals.sagepub.com/doi/full/10.1177/20552173251390649 -
MSJ reposted
BibliotecaHUVH
@BibliotecaHUVH
Long-term safety and efficacy of ozanimod in relapsing #multiple #sclerosis: Final analysis of the DAYBREAK open-label extension trial journals.sagepub.com/doi/10.1177/13524585251382796 #hvhebron #neuro [Text complet] @MSJ_Research
-
MSJ reposted
BibliotecaHUVH
@BibliotecaHUVH
Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in #multiple #sclerosis patients experiencing progression independent of relapse activity journals.sagepub.com/doi/10.1177/13524585251375780 #hvhebron #neuro [Text complet] @MSJ_Research
-
MSJ
@MSJ_Research
NfL concentration of 12.9 pg/mL, using the CE-marked Atellica® IM NfL assay, was the optimal cutoff for prognosticating new T2 lesions over 2 years in relapsing #multiplesclerosis.
Study from @TjalfZiemssen @tudresden_de @MSDoc_Freedman @uOttawa @UCSF ▶️ journals.sagepub.com/doi/full/10.1177/13524585251389797 -
MSJ
@MSJ_Research
Continuous ocrelizumab treatment resulted in lower IgG and IgM, associated with increasing risk of moderate and severe infections. highlight the importance of personalized monitoring during long-term ocrelizumab therapy.
Study from @healingsoulbook ▶️ journals.sagepub.com/doi/full/10.1177/20552173251391975 -
MSJ reposted
sciqst
@sciqst
The correlation between early life stress and exacerbated symptom burden in individuals with #multiplesclerosis is intriguing. It raises questions about the physiological and psychological pathways linking stress to MS symptoms. Can early interventions targeting stress responses alter disease progression or symptom severity?
This intersection of neurology and psycho-social factors is crucial for comprehensive patient care. For a deep dive into such complexities, I recommend checking out www.sciqst.com, a platform for generating detailed biomedical reviews and exploring multifaceted medical questions. #medicine -
MSJ
@MSJ_Research
Deep brain stimulation is a potential treatment for severe tremor in #multiplesclerosis, by not provoking relapses, optimizing tremor control and maintaining MRI access.
Study from @SamanthaBanksMD @MayoClinicNeuro
@MayoClinic ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251387935 -
MSJ
@MSJ_Research
In persons with #multiplesclerosis, a history of early life stress is associated with significantly worse symptom burden and quality of life.
Study from @VCUNeuro @VCUHealth @VCU ▶️ journals.sagepub.com/doi/full/10.1177/20552173251387824 -
MSJ reposted
Samantha Banks
@SamanthaBanksMD
MS tremor can be very difficult to treat. Here we report the outcomes from our center’s experience with DBS in 18 patients.
pubmed.ncbi.nlm.nih.gov/41143324/
@MSJ_Research
Key take aways: -
MSJ
@MSJ_Research
Did you register to the 2025 @MS_Australia Progress in #multiplesclerosis Research Conference?
📅 Date: Dec 3-5, 2025
📍 Venue: Sofitel Brisbane Central, 249 Turbot Street, Brisbane, Queensland, Australia
🔗 Learn more & register: www.ivvy.com.au/event/MSA2025/welcome.html -
MSJ
@MSJ_Research
🔊 Listen to @nyphospital @ColumbiaMed @TuftsUniversity on the language and memory test as a novel and brief multidomain digital cognitive measure for #multiplesclerosis.
📰 And read the full manuscript ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251366096 -
MSJ
@MSJ_Research
Optical coherence tomography showed increased relapse-associated neuroaxonal damage in older individuals with #multipleslcerosis, suggesting less neuronal resilience and higher risks of insidious progression.
Study from @UCSF @unimedizinhalle ▶️ journals.sagepub.com/doi/full/10.1177/13524585251374507 -
MSJ
@MSJ_Research
📢October II issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @giackbo @unige_en @RaffaellaGrecoM @SanRaffaeleMI @TheEBMT with their review on autologous haematopoietic stem cell transplantation #hsct for #multiplesclerosis▶️ journals.sagepub.com/doi/abs/10.1177/13524585251349129 -
MSJ reposted
Mar GF
@MGF30120499
@sanidadgob @esclerosiseme @FundacionGAEM
MSJ
@MSJ_Research
Among >300 proteins investigated by NUcleic Acid-Linked Immuno-Sandwich Assay in #multiplesclerosis, GFAP was the main correlate of progression independent of relapse activity.
Study from @SofiaSandgren1 @SahlgrenskaAcad @JensKuhle @RC2NB @UniBasel ▶️ journals.sagepub.com/doi/full/10.1177/13524585251375780 -
MSJ
@MSJ_Research
📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠
Register here to receive our research
🔽
journals.sagepub.com/connected/MSJ -
MSJ
@MSJ_Research
Among >300 proteins investigated by NUcleic Acid-Linked Immuno-Sandwich Assay in #multiplesclerosis, GFAP was the main correlate of progression independent of relapse activity.
Study from @SofiaSandgren1 @SahlgrenskaAcad @JensKuhle @RC2NB @UniBasel ▶️ journals.sagepub.com/doi/full/10.1177/13524585251375780 -
MSJ reposted
Jaime Imitola MD., FAAN
@DrJim4MS
@MSJ_Research we are part of that study! @uconnhealth please be inclusive!
-
MSJ reposted
Jaime Imitola MD., FAAN
@DrJim4MS
Please see our recent publication with @BIDMChealth and other about transgender MS patients disease trajectories. @uconnhealth
MSJ
@MSJ_Research
In a multicenter cohort of transgender and gender diverse people with #multiplesclerosis, disease trajectories were mild and there were no concerns regarding exogenous testosterone.
Study from @BIDMChealth @BoveRiley @UCSF ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251383330 -
MSJ
@MSJ_Research
Affective reserve in #multiplesclerosis: Definitions, measures, and potential benefits for people living with the disease, clinicians, and investigators.
Personal viewpoint from @Sunnybrook @UofT ▶️ journals.sagepub.com/doi/full/10.1177/13524585251383381 -
MSJ
@MSJ_Research
In a multicenter cohort of transgender and gender diverse people with #multiplesclerosis, disease trajectories were mild and there were no concerns regarding exogenous testosterone.
Study from @BIDMChealth @BoveRiley @UCSF ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251383330 -
MSJ
@MSJ_Research
Human papillomavirus–related conditions in women with multiple sclerosis receiving disease-modifying therapies
A pharmacovigilance disproportionality analysis using @WHO data from @UnivParisSaclay ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251377411 -
MSJ
@MSJ_Research
Pre-morbid structural reserve mitigates disability accumulation in #multiplesclerosis, supporting neuroanatomical resilience affects prognosis.
Study from @SapienzaRoma ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251372440 -
MSJ reposted
Neus Mongay-Ochoa
@Neus_Mongay
👇🏼Check out our latest work on the role of spinal cord reserve in disability progression in a cohort of MS patients with more than 10 years of follow-up @J_SastreGarriga @PAjdinaj @alexrovirarayos @cemcat_em @NeuroRX_Hebron
MSJ
@MSJ_Research
Larger spinal cord reserve at disease onset was associated with a slower rate of disability accumulation in #multiplesclerosis.
10-year clinical follow-up study from @PAjdinaj @Neus_Mongay @J_SastreGarriga @cemcat @vallhebron ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251378995 -
MSJ
@MSJ_Research
When transitioning from anti-CD20 therapies to fumarates, 83.7% people with #multiplesclerosis were free from relapse and new MRI lesions.
A multicenter, retrospective observational experience from @CUSystem ▶️ journals.sagepub.com/doi/full/10.1177/20552173251371808 -
MSJ
@MSJ_Research
Larger spinal cord reserve at disease onset was associated with a slower rate of disability accumulation in #multiplesclerosis.
10-year clinical follow-up study from @PAjdinaj @Neus_Mongay @J_SastreGarriga @cemcat @vallhebron ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251378995 -
MSJ reposted
sciqst
@sciqst
This case presents a fascinating insight into the dynamics of tumefactive demyelinating lesions, particularly in the context of ofatumumab treatment. The presence of closed-ring enhancement suggests active inflammation, while intralesional microhemorrhages add complexity to the pathology. It raises questions about the mechanisms by which ofatumumab influences lesion progression and resolution. How do we differentiate between a true lesion improvement versus transient treatment effects? For more in-depth exploration of such biomedical conundrums, visit www.sciqst.com—your go-to for generating detailed biomedical reviews and answers. #medicine #msresearch
-
MSJ
@MSJ_Research
Ten months after initiating ofatumumab, MRI showed a large tumefactive demyelinating lesion with closed-ring contrast-enhancement and intralesional microhemorrhages (progressively improving with treatment).
Case report from @KyushuUniv_EN ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251370086
1/🧵
MSJ
@MSJ_Research
...and commentary from @DrWBRO @QSMSCENTRE @UCLBrainScience: This case is a timely reminder that B-cell depletion is not universally effective and newer biomarkers might support treatment decisions.
🔽
journals.sagepub.com/doi/abs/10.1177/13524585251370087
2/🧵 -
MSJ reposted
Eric Topol
@EricTopol
Several years before onset of symptoms of multiple sclerosis, there is evidence of central nervous system myelin injury
www.nature.com/articles/s41591-025-04014-w -
MSJ
@MSJ_Research
Systematic symptom screening between study visits may improve relapse detection in #multiplesclerosis trials.
Study from @EllenMowryMD @HopkinsMedicine ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251373002 -
MSJ
@MSJ_Research
The language and memory test is a novel and brief multidomain digital cognitive measure for #multiplesclerosis.
Development and validation from @nyphospital @ColumbiaMed @TuftsUniversity ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251366096 -
MSJ reposted
ECTRIMS
@ECTRIMS
🔎 Best of #ectrims2025 Slide Deck Pathogenesis Highlight: Alberto Ascherio @HarvardChanSPH led a study of 10M+ US military personnel, showing that higher vitamin D strongly reduced MS risk in White individuals; effect was less pronounced in Black individuals.
📥 Download: my.ectrims.eu/bestofslidedecks
@MSJ_Research -
MSJ reposted
sciqst
@sciqst
This is a fascinating observation that could provide insights into the disease progression and repair mechanisms in #multiplesclerosis. It's intriguing that older lesions become less rim-positive. Could this imply a natural healing process or is it a marker of chronic damage stabilization? Understanding the underlying mechanisms might open new therapeutic pathways. Always exciting to see contributions from @Sydney_Uni! For anyone diving deeper into this topic, I'd highly recommend exploring www.sciqst.com - an excellent resource for generating biomedical reviews and enriching your study. #medicine #neuroscience
-
MSJ
@MSJ_Research
The Persian version of the fatigue scale for motor and cognitive functions is a valid and reliable instrument for assessing fatigue in Iranian people with #multiplesclerosis, with strong psychometric properties.
Study from @IsfUniversity ▶️ journals.sagepub.com/doi/full/10.1177/20552173251375781 -
MSJ
@MSJ_Research
In a 5-year retrospective study of 60 people with relapsing #multiplesclerosis, the proportion of rim-positive lesions decreased as lesion age increased.
Study from @SydneySaveSight @Sydney_Uni ▶️ journals.sagepub.com/doi/full/10.1177/20552173251378788 -
MSJ
@MSJ_Research
Genetic risk scores for #multiplesclerosis stratified European and Latino/admixed individuals but not African ancestry, underscoring the need for more ancestry-tailored data.
Study from @CyprienRivier @GuidoFalconeMD @YaleMed ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251377607 -
MSJ
@MSJ_Research
📢October I issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @uOttawa @NDCNOxford @UniofOxford with their review on the spectrum of the antibody-mediated demyelinating diseases ▶️ journals.sagepub.com/doi/10.1177/13524585251367343 -
MSJ
@MSJ_Research
🔊 Listen to @ALugaresi @Unibo on the cascade sign in AQ4+ neuromyelitis optica #nmosd (MRI showing confluent diencephalo-mesencephalic lesions).
📄 And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585251356820
1/🧵
MSJ
@MSJ_Research
...and commentary from @KCH_Research @kingshealth: The cascade sign on MRI, while suggestive, is not pathognomonic for neuro-Behcet’s disease, and #nmosd should also be considered.
🔽
journals.sagepub.com/doi/abs/10.1177/13524585251356838
2/🧵 -
MSJ
@MSJ_Research
New issue of Multiple Sclerosis Journal – Experimental, Translational and Clinical is now available online journals.sagepub.com/toc/msoa/11/3 ▶️ and is full open access 🔓
-
MSJ
@MSJ_Research
Pregnancy was not associated with a significant difference in long-term disability trajectories in women with progressive #multiplesclerosis symptoms.
Multicentre @MSBase_Registry study led by @vjokubaitis @MonashSTM ▶️ journals.sagepub.com/doi/full/10.1177/13524585251368248 -
MSJ reposted
ECTRIMS
@ECTRIMS
How will the 2024 McDonald Criteria be applied in clinical practice worldwide? Two key resources are available to address this:
A 2025 ECTRIMS webinar with Dr. Avinash Chandra (Nepal) & Dr. Sastre-Garriga @cemcat_em:
▶️ ectrims.eu/webinar-highlights-2024-diagnostic-criteria-an…
A new ECTRIMS Spotlight with Prof. Siritho @MahidolU & Prof. Ciampi @uc_chile on access, equity and readiness in places like Thailand & Chile:
▶️ ectrims.eu/insights/applying-the-proposed-2024-mcdonald-c…
#iacctms @mssociety -
MSJ
@MSJ_Research
Choroid plexus enlargement is similar in #multiplesclerosis and its radiological presentations, and is associated with demyelination and neurodegeneration, suggesting it is part of the disease spectrum.
Study from @UnityHealthTO @UofT ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251375365 -
MSJ
@MSJ_Research
Severe course of tick-borne encephalitis in a person with relapsing #multiplesclerosis treated with ocrelizumab.
Case report from @LMU_Muenchen @DZIF_ ▶️ journals.sagepub.com/doi/full/10.1177/13524585251369425
1/🧵
MSJ
@MSJ_Research
...and commentary from @univienna: Rarer but potentially severe complications —particularly infections— present additional complexity, including diagnosis and treatment.
🔽
journals.sagepub.com/doi/abs/10.1177/13524585251369417
2/🧵 -
MSJ reposted
ECTRIMS
@ECTRIMS
🔎Best of #ectrims2025 Slide Deck Spotlight: Dr Engels @LMU_Muenchen et al.: Longer rituximab intervals in NMOSD may cut infection risk without losing efficacy.
👉 Explore, download, and share the Clinical Track here: my.ectrims.eu/bestofslidedecks
@MSJ_Research @ChariteBerlin -
MSJ
@MSJ_Research
Disease reactivation occurred after 40.5 months from only two ocrelizumab courses in 6/19 (32%) participants with #multiplesclerosis vs 0/52 propensity-score-matched participants with continued treatment.
Results of two open-label trials @JohnsHopkins ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251375350 -
MSJ reposted
IJMSC
@IJMSCtweets
"This article reviews key insights gained into[#mogad & #nmosd], tracing timelines that have shaped our knowledge. It outlines evolution of antibody assay techniques, examines their epidemiology & phenotypic presentations & describes predictive factors for clinical outcome."
MSJ
@MSJ_Research
Unraveling the spectrum of the antibody-mediated demyelinating diseases: Antibody assays, epidemiology, clinical presentations, treatments and outcomes.
Review from @uOttawa @NDCNOxford @UniofOxford ▶️ journals.sagepub.com/doi/10.1177/13524585251367343 -
MSJ
@MSJ_Research
In neuromyelitis optica spectrum disorders #nmosd, cognitive impairment was associated with relapses, specifically those with lower education and longer disease duration.
Study from @udg_oficial ▶️ journals.sagepub.com/doi/full/10.1177/20552173251378801 -
MSJ
@MSJ_Research
More data is needed, but in the meanwhile we have anti-CD20 monoclonal antibodies...
MSJ
@MSJ_Research
What do you think? Anti-B-cell CAR-T therapy in #multiplesclerosis is simply a more profound immunoablation?
5/🧵 -
MSJ reposted
Associate Professor Mastura Monif
@MasturaMonif
A commentary regarding #car T cell therapy usage in #mutiple Sclerosis .
MSJ
@MSJ_Research
And commentary from @UNSW @MasturaMonif @MonashSTM: CAR-T cell therapy in #multiplesclerosis remains in its infancy. Clinical trials are urgently needed to establish both the safety and true efficacy of CAR-T in this complex, multifaceted disease.
🔽
journals.sagepub.com/doi/abs/10.1177/13524585251370085
4/🧵 -
MSJ
@MSJ_Research
Elevated GFAP and UCHL-1 (astrocytic activation) and reduced P-Tau181/T-Tau ratio (disrupted neuronal structure) are associated with the risk of progression independent of relapse activity in #multiplesclerosis.
Study from @unimib ▶️ journals.sagepub.com/doi/full/10.1177/20552173251372751 -
MSJ
@MSJ_Research
Unraveling the spectrum of the antibody-mediated demyelinating diseases: Antibody assays, epidemiology, clinical presentations, treatments and outcomes.
Review from @uOttawa @NDCNOxford @UniofOxford ▶️ journals.sagepub.com/doi/10.1177/13524585251367343 -
MSJ
@MSJ_Research
Did you attend #ectrims2025 @ECTRIMS conference?
Abstracts are now available🔽 journals.sagepub.com/toc/msja/31/3_suppl -
MSJ
@MSJ_Research
New controversy available ⚖️
Anti-B-cell CAR-T therapy in #multiplesclerosis is simply a more profound immunoablation?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @UNSW @MasturaMonif @MonashSTM: CAR-T cell therapy in #multiplesclerosis remains in its infancy. Clinical trials are urgently needed to establish both the safety and true efficacy of CAR-T in this complex, multifaceted disease.
🔽
journals.sagepub.com/doi/abs/10.1177/13524585251370085
4/🧵
MSJ
@MSJ_Research
What do you think? Anti-B-cell CAR-T therapy in #multiplesclerosis is simply a more profound immunoablation?
5/🧵 -
MSJ
@MSJ_Research
📢September issue is now available 🔽
journals.sagepub.com/toc/MSJ/current
...and the cover goes to @unige_en with their review on the new insights and clinica implications of immunosenescence in #multiplesclerosis ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251367611 -
MSJ
@MSJ_Research
📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠
Register here to receive our research
🔽
journals.sagepub.com/connected/MSJ -
MSJ reposted
ECTRIMS
@ECTRIMS
Now out! The Best of Slide Deck contains the top abstracts presented at #ectrims2025 – separated by content track, we invite you to download and share the information with your colleagues and peers ➡️ my.ectrims.eu/bestofslidedecks
-
MSJ reposted
Berenice Silva
@bereniceanabel
Congrats to Ethel Ciampi and Adolfo del Canto!
-
MSJ reposted
Joe Sabatino
@jsabatino37
Finite-course ocrelizumab in relapsing multiple sclerosis: Results of two prospective open-label trials with matched controls
journals.sagepub.com/doi/10.1177/13524585251375350 -
MSJ reposted
ECTRIMS
@ECTRIMS
#ectrims2025 | Missed a session during the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and want to follow up? View all sessions on our easy to navigate on demand platform ➡️ ectrims-congress.virtual-meeting.org
#multiplesclerosis #msresearch #ondemand -
MSJ reposted
EthelCiampiSCL
@EthelScl
MSJ
@MSJ_Research
And the winners are...
#ectrims2025 @ECTRIMS -
MSJ reposted
ECTRIMS
@ECTRIMS
Live at #ectrims2025: @KristenKryskoMD from @stmikeshospital, has been awarded the 2025 Rachel Horne Prize for Women’s Research in MS. Join us in congratulating @KristenKryskoMD for her invaluable contributions to women's health & her exemplary leadership in the field of MS research.
#rachelhorneprize #rims
@RachelHorne19 @eurims -
MSJ reposted
Wallace Brownlee
@DrWBRO
Pleased to present our validation of the 2024 revised McDonald criteria earlier this week at #ectrims2025 demonstrating how well the new criteria perform in a real world settting, facilitating earlier MS diagnosis
@UCLHresearch @uclh @UCLIoN
MSJ
@MSJ_Research
Listen to our Editor @DrWBRO on the real-world validation of new #multiplesclerosis diagnostic criteria at #ectrims2026
@ECTRIMS -
MSJ
@MSJ_Research
And the winners are...
#ectrims2025 @ECTRIMS -
MSJ reposted
ECTRIMS
@ECTRIMS
Coming up at 10:30 CEST!
The best Late Breaking Abstracts will be presented in the Auditorium — and online via live stream: ectrims-congress.virtual-meeting.org/programme/session/67943
Don’t miss the latest breakthroughs in #msresearch!
#ectrims2025 #neurology -
MSJ reposted
ECTRIMS
@ECTRIMS
#ectrims2025 | Day two is here! Plan your day with hot topics, scientific sessions, free communications, and more. It’s going to be busy! @eurims
Full programme ➡️ ectrims-congress.virtual-meeting.org -
MSJ
@MSJ_Research
Listen to our Editor @DrWBRO on the real-world validation of new #multiplesclerosis diagnostic criteria at #ectrims2026
@ECTRIMS -
MSJ
@MSJ_Research
Ready for #ectrims2026 ?
@ECTRIMS #msresearch -
MSJ reposted
ECTRIMS
@ECTRIMS
🌟 ECTRIMS Pre-Day is here!
We're thrilled to kick off Pre-Day with a packed agenda filled with cutting-edge research and discussions on MS, NMOSD/MOGAD, auto-immune encephalitis, and more.
👉 Join now: ectrims-congress.virtual-meeting.org
#msresearch #ectrims2025 @eurims @CCIB_Forum -
MSJ reposted
Mar Tintore
@MarTintore
As the local chairs, XavierMontalban and I are so honored to welcome you to #ectrims2025 in beautiful Barcelona our home city.
-
MSJ
@MSJ_Research
Structures in the post-glymphatic system, including parasagittal dural space and arachnoid granulations, are enlarged in pre-clinical and early clinical #multiplesclerosis.
Study from @BagnatoLab @ahmadtubasi99 @VUMCDiscoveries ▶️journals.sagepub.com/doi/full/10.1177/13524585251364720 -
MSJ reposted
Xavier Montalban
@XMontalban
Thrilled to share the 2024 revisions of the diagnostic Mc Donald criteria and companion papers @ECTRIMS @mssociety @MSIntFederation @vallhebron @FundacioEM @esclerosiseme @cemcat_em @ACTRIMS @EuropeanCharcot @TheLancetNeuro @UABBarcelona @u_medicina www.linkedin.com/posts/xaviermontalban_diagnosis-of-multi…
-
MSJ reposted
ECTRIMS
@ECTRIMS
🎧 Special ECTRIMS Podcast! Two authors of the just-published 2024 Revisions of the McDonald Criteria for #ms discuss what the guidelines mean for clinicians & patients. Listen to Prof. @Xmontalban of @cemcat_em & Dr. Jiwon Oh of @uoft. 👉 open.spotify.com/episode/47YidH1nVEWTw4E2i0pXhk
@mssociety -
MSJ
@MSJ_Research
Social determinants of health, including education, employment, healthcare access and social support, and their impact on people living with #multiplesclerosis.
A scoping review from @unige_en ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251353196 -
MSJ
@MSJ_Research
Genomewide association study identified novel variants associated with tumefactive #multiplesclerosis, warranting future validation and functional experiments.
Study from @HZhaoFleming @mayoneurores @MayoClinic ▶️ journals.sagepub.com/doi/full/10.1177/13524585251371984 -
MSJ reposted
Wallace Brownlee
@DrWBRO
1/5 The long-awaited 2024 McDonald criteria are now published! I’m proud to see that our work at @UCLIoN @UCLHresearch has helped to change the way MS is diagnosed, and that our patients will now benefit from earlier diagnosis and treatment @olgacicc
www.thelancet.com/journals/laneur/article/PIIS1474-4422(2… -
MSJ
@MSJ_Research
The 2024 revisions of the McDonald criteria for diagnosis of #multiplesclerosis: What to know more about the CSF analysis? Here is the companion paper on the new definition of positive CSF▶️ www.thelancet.com/journals/ebiom/article/PIIS2352-3964(25…
-
MSJ reposted
The Lancet Neurology
@TheLancetNeuro
Read the latest revision of the McDonald criteria for the diagnosis of multiple sclerosis at: www.thelancet.com/journals/laneur/article/PIIS1474-4422(2…
@XMontalban -
MSJ
@MSJ_Research
The 2024 revisions of the McDonald criteria for diagnosis of #multiplesclerosis: What to know more about the optic nerve? Here is the companion paper on the use of optical coherence tomography and visual evoked potentials▶️ www.sciencedirect.com/science/article/abs/pii/S1474442225…
-
MSJ
@MSJ_Research
The 2024 revisions of the McDonald criteria for diagnosis of #multiplesclerosis: What to know more about the use of MRI? Here is the companion paper on the use of MRI ▶️ www.sciencedirect.com/science/article/abs/pii/S1474442225…
-
MSJ reposted
Celia Oreja-Guevara
@C_OrejaGuevara
McDonald Criteria 2024 published !!!!!!!! 👏👏👏
🚨 A significant landmark for MS diagnosis and treatment in #multiplesclerosis !!
👉Read here:www.thelancet.com/journals/laneur/article/PIIS1474-4422(2…
@lancetneurology @ECTRIMS
#multiplesclerosis #diagnosis -
MSJ reposted
ECTRIMS
@ECTRIMS
📢 Breaking news: The 2024 revised #mcdonaldcriteria have been published in @TheLancetNeuro. Explore the latest evidence shaping #msdiagnosis. Published by the International Advisory Committee for Clinical Trials in #ms.
👉 www.thelancet.com/journals/laneur/article/PIIS1474-4422(2…
@mssociety #msresearch #iacctms -
MSJ reposted
Daniel Ontaneda
@DanOntaneda
Brand new MS diagnostic Criteria. Congratulations to @XMontalban and all involved. A huge step forward towards biologically based diagnosis of #multiplesclerosis @ECTRIMS @ACTRIMS @mssociety @TheLancetNeuro
www.thelancet.com/issue/S1474-4422(25)X0010-7 -
MSJ
@MSJ_Research
The 2024 revisions of the McDonald criteria for diagnosis of #multiplesclerosis are out ▶️ www.thelancet.com/journals/laneur/article/PIIS1474-4422(2…
-
MSJ reposted
Dr. Brandon Beaber
@Brandon_Beaber
The "cascade" (waterfall) sign has been reported in neuro-Behçet’s disease, but beware! This MRI is actually from a case report of a woman with AQP4-IgG+ neuromyelitis optica. journals.sagepub.com/doi/10.1177/13524585251356820
-
MSJ
@MSJ_Research
Financial strain is highly prevalent in neuromyelitis optica spectrum disorder #nmosd, and associated with key clinical (attacks and disability) and sociodemographic features (non-white).
Study from @MGHNeurology ▶️ journals.sagepub.com/doi/full/10.1177/13524585251365139 -
MSJ
@MSJ_Research
The macromolecular-to-free pool size ratio has greater accuracy and effect size than the magnetization transfer ratio for the MRI assessment of myelin injury in early #multiplesclerosis.
Study from @ahmadtubasi99 @BagnatoLab @VanderbiltU ▶️ journals.sagepub.com/doi/full/10.1177/13524585251364766 -
MSJ
@MSJ_Research
🔊 Listen to @unige_en on the new insights and clinical implications of immunosenescence in #multiplesclerosis.
📰 And read the full manuscript ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251367611 -
MSJ
@MSJ_Research
Neuroimmune interactions: How systemic immune activity can initiate/modulate CNS pathology, and how CNS-derived signals may shape peripheral immunity in #multiplesclerosis.
The Kenneth P Johnson Lecture @ACTRIMS from @AdilHarroud @TheNeuro_MNI @mcgillu ▶️ journals.sagepub.com/doi/full/10.1177/13524585251370884 -
MSJ
@MSJ_Research
The prevalence rate of #multiplesclerosis in older adults (65 years and above) increased by 15% in the past decade, from 210.55 (per 100,000) in 2011 to 243.17 in 2021.
Medicare fee-for-service claims study from @AparasuRaj @UH_Pharmacy ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251368687 -
MSJ
@MSJ_Research
Analysis of serum neurofilament light chain can support the identification of disease activity in people with #multiplesclerosis and new symptoms (less so GFAP).
Study from @MScentrum020 ▶️ journals.sagepub.com/doi/10.1177/20552173251370830 -
MSJ
@MSJ_Research
Successful alemtuzumab retreatment in #multiplesclerosis following previous diffuse alveolar haemorrhage.
Case report from @UniofOxford ▶️ journals.sagepub.com/doi/full/10.1177/13524585251365791
1/🧵
MSJ
@MSJ_Research
...and commentary from @cardiffuni: Diffuse alveolar haemorrhage and other autoimmune adverse effects of alemtuzumab remain poorly understood, but most can be treated and should not necessarily contraindicate treatment cycles.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251365794
2/🧵 -
MSJ
@MSJ_Research
Cautious approach is recommended
MSJ
@MSJ_Research
What do you think? Patients with rheumatological diseases should routinely be tested for #aqp4 antibodies for #nmosd?
5/🧵 -
MSJ
@MSJ_Research
...and letter from @blasco_borras: Incorporating validated adherence measures alongside persistence assessments would provide a more accurate and clinically meaningful interpretation of real-world treatment dynamics.
🔽
journals.sagepub.com/doi/full/10.1177/20552173251370841
MSJ
@MSJ_Research
People with #multiplesclerosis are more persistent to B cell depleting therapies, than to other treatments, possibly reflecting better clinical outcomes.
Swiss MS Cohort study @EnteOspedaliero @GDSC_usi @JensKuhle @RC2NB @UniBasel_en ▶️ journals.sagepub.com/doi/full/10.1177/20552173251315457 -
MSJ
@MSJ_Research
Diffusion tensor imaging of the cingulum and cerebellar peduncles may be useful target outcome metrics in neuroprotective trials in progressive #multiplesclerosis.
Re-analysis of the SPRINT-MS trial @ClevelandClinic ▶️ journals.sagepub.com/doi/full/10.1177/20552173251361225 -
MSJ
@MSJ_Research
New controversy available ⚖️
Patients with rheumatological diseases should routinely be tested for aquaporin-4 #aqp4 antibodies for neuromyelitis optica spectrum disorder #nmosd?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @MonashUni: AQP4-IgG testing should be standard practice in patients presenting with neurological symptoms suggestive of #nmosd, and other neurological diseases should be ruled out, such as vasculitis or lupus cerebritis.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251367335
4/🧵
MSJ
@MSJ_Research
What do you think? Patients with rheumatological diseases should routinely be tested for #aqp4 antibodies for #nmosd?
5/🧵 -
MSJ
@MSJ_Research
The lifetime risk of suicidal ideation in persons with #multiplesclerosis is 30%, and can be predicted using low-burden self-report tools and electronic health record information.
Study from @umiamimedicine @ClevelandClinic ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251365207 -
MSJ
@MSJ_Research
Deep cervical lymph node volume decreased following B-cell depletion therapy with ocrelizumab in #multiplesclerosis, warranting further investigation for pharmacological or clinical utility.
Study from @UMassChan ▶️ journals.sagepub.com/doi/full/10.1177/20552173251371743 -
MSJ reposted
Rachel Horne
@RachelHorne19
👏🏆Congrats to @KristenKryskoMD 2025 winner of the #rachelhorneprize for Women's Research in MS for her outstanding work on how best to guide/treat women with #ms during pregnancy & breastfeeding!
@UnityHealthTO,@SMHNeurology,@UofTNeurology
Tx to @ECTRIMS,@ACTRIMS,@IntNatlWiMS -
MSJ
@MSJ_Research
Fingolimod treatment in #multiplesclerosis is associated with range of dermatologic findings, including melanocytic nevus (65%) as well as refractory genital HPV, dysplastic nevi and fibrous papules.
A 5-year real-world study from @RoyanInstitute ▶️ journals.sagepub.com/doi/full/10.1177/20552173251369990 -
MSJ
@MSJ_Research
In this prospective study, high serum GFAP levels – more than NfL levels – were associated with retinal layer thinning in relapsing #multiplesclerosis.
Study from @KrajncNik93 @MedUni_Wien ▶️ journals.sagepub.com/doi/full/10.1177/13524585251360972 -
MSJ
@MSJ_Research
Multimodal imaging of the optic nerve (OCT and VEP) can demonstrate myelination, a key outcome in remyelination trials.
Case report from @NickGCunniffe @Cambridge_Uni ▶️ journals.sagepub.com/doi/full/10.1177/13524585251365793
1/🧵
MSJ
@MSJ_Research
...and commentary from @UCSF @unige_en: This finding offers a rare example of possible gain-of-function in the human visual system independent of therapeutically induced remyelination, but definitely needs replication.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251365792
2/🧵 -
MSJ
@MSJ_Research
The definition of acute disseminated encephalomyelitis #adem need to be updated to be applied to attacks at any time during the disease course of associated disease #mogad.
Study from @EoinFlanagan14 @MayoClinicNeuro ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251359450 -
MSJ
@MSJ_Research
Misapplication of the 2015 criteria for neuromyelitis optica #nmosd is common, and alternative explanations in seronegative #nmosd should be considered, including multiple sclerosis and functional neurologic disorder.
Study from @chenmayo @MayoClinic▶️ journals.sagepub.com/doi/abs/10.1177/13524585251360648 -
MSJ reposted
ECTRIMS
@ECTRIMS
⏳ Countdown to #ectrims2025!
Just 1 month to go until the 41st ECTRIMS Congress and 30th Conference of Rehabilitation in #multiplesclerosis!
💻 If you can’t attend in person, don’t worry! You can join us ONLINE from wherever you are.
👉 Register today: ectrims.eu/ectrims2025-registration/ -
MSJ
@MSJ_Research
Cognitive data should be assessed as continuous variables to enhance statistical sensitivity and to provide a more nuanced understanding of cognitive impairment in #multiplesclerosis.
Viewpoint from @Jeroen_VS @vub_etro @AIMS_VUB @VUBrussel @uabsoph ▶️ journals.sagepub.com/doi/10.1177/13524585251363747 -
MSJ
@MSJ_Research
A personalised digital lifestyle management app (levidex) did not show effect on relapse and/or new T2 lesion, compared with a non-personalised app (dexilev), in early #multiplesclerosis.
Results of the randomised controlled POWER@MS1 trial ▶️ journals.sagepub.com/doi/full/10.1177/13524585251356410 -
MSJ
@MSJ_Research
📢August issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @BoveRiley @UCSF with their review on the management of gynecological health within comprehensive treatment monitoring for #multiplesclerosis ▶️ journals.sagepub.com/doi/full/10.1177/13524585251346371 -
MSJ
@MSJ_Research
Standard premedication for people with #multiplesclerosis treated with ocrelizumab demonstrated more efficacy in reducing infusion-related reactions than low-dose regimen.
A randomized controlled trial from @TumsIPR ▶️ journals.sagepub.com/doi/full/10.1177/20552173251359074 -
MSJ reposted
ECTRIMS
@ECTRIMS
1 week away! Don't miss the deadline to submit a nomination to be a member of the distinguished International Advisory Committee on Clinical Trials in Multiple Sclerosis.
📮Submit your nomination by 29 August: ectrims.eu/insights/call-for-nominations/ -
MSJ
@MSJ_Research
📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠
Register here to receive our research
🔽
journals.sagepub.com/connected/MSJ -
MSJ
@MSJ_Research
Percutaneous epidural spinal cord stimulation can immediately reduce clonus in #multiplesclerosis.
Case report from @MayoClinic ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251357143 -
MSJ reposted
IJMSC
@IJMSCtweets
"The most common reason for #delayed #dmt initiation or not initiating a DMT at all was refusal."
#multiplesclerosis #finland
MSJ
@MSJ_Research
Among 2363 people with relapsing #multiplesclerosis, 193 never started a disease modifying treatment and 88 initiated after 1 year, in relation to age, optic neuritis, inactivity and refusal.
A nationwide population-based study @SiniLaakso @helsinkiuni ▶️ journals.sagepub.com/doi/full/10.1177/20552173251360358 -
MSJ
@MSJ_Research
Among 2363 people with relapsing #multiplesclerosis, 193 never started a disease modifying treatment and 88 initiated after 1 year, in relation to age, optic neuritis, inactivity and refusal.
A nationwide population-based study @SiniLaakso @helsinkiuni ▶️ journals.sagepub.com/doi/full/10.1177/20552173251360358 -
MSJ
@MSJ_Research
Whole brain volume is already reduced in children with radiologically isolated syndrome (#ris), and further reduces over time, as in children with clinical #multiplesclerosis.
Study from @carstenfinke @ChariteBerlin @UniWHgch ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251359066 -
MSJ
@MSJ_Research
People with #multiplesclerosis and epilepsy have worse processing speed and visuospatial memory, alongside psychological distress, highlighting the need for targeted multidisciplinary care.
Study from @VPozzilli @PoliclinCampus @univUda ▶️ journals.sagepub.com/doi/full/10.1177/20552173251359061 -
MSJ
@MSJ_Research
Lateral switching between ocrelizumab and ofatumumab does not affect effectiveness outcomes in #multiplesclerosis, with some caveats over increased loss of IgG.
Matched real-world cohort from Justus-Liebig-Universität Giessen ▶️ journals.sagepub.com/doi/full/10.1177/13524585251361330 -
MSJ reposted
Gary Álvarez.•.
@garinho29
The effect of LET/MET DMTs is less pronounced in older adults and may not significantly impact long-term disability outcomes.
MSJ
@MSJ_Research
In 63 people with #multiplesclerosis onset after 50 years, low/moderate efficacy treatments did not significantly impact long-term disability outcomes, compared with no treatment.
Study from @NorthwesternU @unlvmedicine ▶️ journals.sagepub.com/doi/full/10.1177/20552173251360357 -
MSJ
@MSJ_Research
In 63 people with #multiplesclerosis onset after 50 years, low/moderate efficacy treatments did not significantly impact long-term disability outcomes, compared with no treatment.
Study from @NorthwesternU @unlvmedicine ▶️ journals.sagepub.com/doi/full/10.1177/20552173251360357 -
MSJ
@MSJ_Research
Yes, high-risk populations should be screened for #multiplesclerosis but considerations apply at individual level.
MSJ
@MSJ_Research
What do you think? High-risk populations should be screened for #multiplesclerosis?
5/🧵 -
MSJ
@MSJ_Research
Higher Anti-Müllerian hormone levels, reflecting ovarian reserve, were associated with more #multiplesclerosis relapses, independently of chronological age.
Study from @mariacellerino1 @maclaudiaa @MatildeInglese @UniGenova ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251356384 -
MSJ
@MSJ_Research
Ozanimod reduced brain atrophy rates in #multiplesclerosis over 7 years, with faster cognitive processing speed and slower physical disability progression.
Results from phase 3 and open-label extension trials from @JeffCohenMD @ClevelandClinic @UCSF ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251355842 -
MSJ
@MSJ_Research
Embracing the complexity of rehabilitation in #multiplesclerosis empowered by the resolution of the World Health Organization to strengthen rehabilitation in the health systems.
Future perspectives from @peterfeys_ @uhasselt @UBC ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251356967 -
MSJ
@MSJ_Research
New controversy available ⚖️
📢High-risk populations should be screened for #multiplesclerosis?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @karolinskainst: The challenge is not simply whether to screen, but how, when, and for whom.
🔽
journals.sagepub.com/doi/abs/10.1177/13524585251353029
4/🧵
MSJ
@MSJ_Research
What do you think? High-risk populations should be screened for #multiplesclerosis?
5/🧵 -
MSJ reposted
The Sumaira Foundation
@TheSumairaFDN
This is such important work. Thank you @farrahmateen!
-
MSJ reposted
MS Int'l Federation
@MSIntFederation
A recent MSIF visit to MS South Africa and MS Namibia offered insights into the lived experiences of people with MS in the region. The trip showcased the incredible impact of community-driven action and highlighted the need for better MS awareness. 👉 msintfederation.org/4kT8xkD
-
MSJ
@MSJ_Research
Among 897 participants with neuromyelitis optica spectrum disorder #nmosd, employment dropped from 62.6% before diagnosis to 36.3% after.
An international, multicentered, cross-sectional study from @FarrahMateen @MassGeneralNews ▶️ journals.sagepub.com/doi/full/10.1177/13524585251349139 -
MSJ reposted
ECTRIMS
@ECTRIMS
👉 The application period for the 2026 #ectrimsfellowship Programmes opens today! Advance your knowledge and expertise in the field of #multiplesclerosis and related neurological conditions.
⏳ Deadline: 1 Dec 2025
Learn more ➡️ ectrims.eu/fellowships
#ectrimsnextgen -
MSJ
@MSJ_Research
Music therapy with a monochord (figure below) showed improvements on fatigue, pain and body perception in people with #multiplesclerosis.
A randomized, controlled, rater-blinded trial from @RC2NB @UniBasel_en ▶️ journals.sagepub.com/doi/full/10.1177/20552173251352712 -
MSJ
@MSJ_Research
Gadolinium enhancement lasted 14 months in a patient with aquaporin-4-positive myelitis #nmosd, suggesting long-lasting enhancement could be crucial for diagnostic accuracy.
Case report from @APHP @HopPitieSalpe ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251352315
1/🧵
MSJ
@MSJ_Research
...and commentary from @INECOArgentina: In #nmosd follow-up MRI beyond the acute phase may be warranted to persisting subclinical disease activity and guide timely treatment optimization.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251352317
2/🧵 -
MSJ
@MSJ_Research
Efficacy and safety of autologous haematopoietic stem cell transplantation #hsct for aggressive #multiplesclerosis
Review from @giackbo @unige_en @RaffaellaGrecoM @SanRaffaeleMI on the behalf of @TheEBMT ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251349129 -
MSJ
@MSJ_Research
Improving survival in people with #multiplesclerosis may require a focus on quality and content of care and proactive management of comorbidities.
Registry study from @ZealandEp @MORTENDAHL14 @UCPH_Research ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251353079 -
MSJ reposted
NYU Langone Neuromodulation Lab
@NYUNeuromod
🤩 Exciting new study published in @MSJ_Research
💻 See how we significantly enhanced the cognitive outcomes of patients with multiple sclerosis using a non-invasive #telehealth intervention
doi.org/10.1177/20552173251356704 -
MSJ
@MSJ_Research
From 2020 to 2024, there has been increasing number of pregnancies in women with #multiplesclerosis being conceived on monoclonal antibody therapies, without overt safety signals.
Study from @vjokubaitis @MonashUni @drorlagray @setrust @MSBase_Registry ▶️ journals.sagepub.com/doi/full/10.1177/13524585251349125 -
MSJ
@MSJ_Research
Real-world occurrence and management of ofatumumab injection-related reactions among healthcare providers of people with relapsing #multiplesclerosis.
Delphi panel from @HopkinsMedicine @UTSWMedCenter ▶️ journals.sagepub.com/doi/full/10.1177/20552173251355677 -
MSJ reposted
Nat Rev Neurology
@NatRevNeurol
New online! Advancing multiple sclerosis management in older adults idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nat…
-
MSJ
@MSJ_Research
📢July issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @UMontreal @chumontreal @UQAM with their review on subjective cognitive impairment in #multiplesclerosis ▶️journals.sagepub.com/doi/abs/10.1177/13524585251334488 -
MSJ
@MSJ_Research
📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠
Register here to receive our research
🔽
journals.sagepub.com/connected/MSJ -
MSJ reposted
ECTRIMS
@ECTRIMS
Our latest #msresearch Spotlight focuses on global perspectives on the proposed 2024 McDonald Criteria. #ms experts from Thailand and Chile share real-world insights on applying the criteria across diverse healthcare systems. Read more: ectrims.eu/insights/applying-the-proposed-2024-mcdonald-c…
@MahidolU -
MSJ
@MSJ_Research
There is high frequency of co-occurrence of #multiplesclerosis with several autoimmune diseases, suggesting shared genetic susceptibility factors.
A population-based study with genetic linkage from @regionepiemonte ▶️ journals.sagepub.com/doi/full/10.1177/20552173251349671 -
MSJ
@MSJ_Research
Estimates of #multiplesclerosis disability and predictions of its progression using routinely collected healthcare data.
Advanced data analytics from @giuseppinaaffi3 @RPalladino84 @UninaIT ▶️ journals.sagepub.com/doi/full/10.1177/13524585251347513 -
MSJ
@MSJ_Research
The importance of patient-reported outcomes: A call for their integration in the routine care of patients with #multiplesclerosis.
Review from @drmelcalvert @CPROR_UoB @unibirmingham ▶️ journals.sagepub.com/doi/full/10.1177/13524585251349354 -
MSJ
@MSJ_Research
Did you publish your first article as first author in 2024 on our journals?
Apply to the 2025 F2 Award of @MSJ_Research and @ECTRIMS with a cash prize and one year access to the #msj (stay tuned at the #ectrims2025 Closing Ceremony) ▶️ journals.sagepub.com/msj/researcherprize
Deadline: TODAY -
MSJ
@MSJ_Research
New issue of Multiple Sclerosis Journal – Experimental, Translational and Clinical is now available online journals.sagepub.com/toc/msoa/11/2 ▶️ and is full open access 🔓
-
MSJ
@MSJ_Research
Did you publish your first article as first author in 2024 on our journals?
Apply to the 2025 F2 Award of @MSJ_Research and @ECTRIMS with a cash prize and one year access to the #msj (stay tuned at the #ectrims2025 Closing Ceremony) ▶️ journals.sagepub.com/msj/researcherprize
Deadline: TOMORROW -
MSJ
@MSJ_Research
People with #multiplesclerosis using disease-modifying therapies have disproportionately high malignant melanoma reporting compared to all other medications.
A disproportionality analysis of the @FDA adverse event reporting system @harvardmed ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251342725 -
MSJ
@MSJ_Research
🔊 Listen to @CagolAlessandr0 @RC2NB @alexrovirarayos @vallhebron: PRLs are reliable across diverse #multiplesclerosis populations and imaging platforms, reinforcing readiness for real-world application.
📰 And read the editorial ▶️journals.sagepub.com/doi/full/10.1177/13524585251349971 -
MSJ
@MSJ_Research
Out of 856 people with #multiplesclerosis, 38.4% had at least one comorbidity (from 24.0% at age 15–29 years to 52.6% at 50–76 years, which was in turn associated with disability.
Study from @IsfUniversity @UniSouthDenmark ▶️ journals.sagepub.com/doi/full/10.1177/20552173251352735 -
MSJ
@MSJ_Research
So it is no, or at least not now.
MSJ
@MSJ_Research
What do you think? Should natalizumab be used in #multiplesclerosis despite JC virus positivity?
5/🧵 -
MSJ
@MSJ_Research
Did you publish your first article as first author in 2024 on our journals?
Apply to the 2025 F2 Award of @MSJ_Research and @ECTRIMS with a cash prize and one year access to the #msj (stay tuned at the #ectrims2025 Closing Ceremony) ▶️ journals.sagepub.com/msj/researcherprize
Deadline: Jul 19 -
MSJ
@MSJ_Research
The benefit of initial high-efficacy treatment for #multiplesclerosis diminishes with age, but, at individual level, exposure to treatment reduces risks of disability, suggesting prolonged treatment is needed.
Real-world study from @UNI_FIRENZE ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251345317 -
MSJ
@MSJ_Research
Validation studies on the BICAMS in LATAM for cognitive assessment in #multiplesclerosis, included a greater proportion of relapsing patients and middle-aged adults, thus requiring further evaluations.
Review from @udg_oficial ▶️ journals.sagepub.com/doi/full/10.1177/20552173251350724 -
MSJ
@MSJ_Research
New controversy available ⚖️
📢Should natalizumab be used in #multiplesclerosis despite JC virus positivity?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @karolinskainst: Large-scale observational studies and biomarker research may help clarify when, and for whom, natalizumab can be used safely in the context of JCV seropositivity.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251346378
4/🧵
MSJ
@MSJ_Research
What do you think? Should natalizumab be used in #multiplesclerosis despite JC virus positivity?
5/🧵 -
MSJ
@MSJ_Research
The EXOPULSE Mollii showed motor improvements in people with #multiplesclerosis, including balance, spasticity, mobility and fatigue.
A randomized sham-controlled crossover trial ▶️ journals.sagepub.com/doi/full/10.1177/20552173251348304 -
MSJ
@MSJ_Research
κ-FLC index >100 at #multiplesclerosis diagnosis predicts risk of relapse and disability accumulation after 10 years.
Study from Medizinische Universitaet Innsbruck ▶️ journals.sagepub.com/doi/full/10.1177/13524585251344807 -
MSJ
@MSJ_Research
Did you publish your first article as first author in 2024 on our journals?
Apply to the 2025 F2 Award of @MSJ_Research and @ECTRIMS with a cash prize and one year access to the #msj (stay tuned at the #ectrims2025 Closing Ceremony) ▶️ journals.sagepub.com/msj/researcherprize
Deadline: Jul 19 -
MSJ reposted
Yi Chao Foong
@foongahh
Thoroughly enjoyed the opportunity to write this controversy in MS article! #ms #multiplesclerosis
MSJ
@MSJ_Research
No 👎 from @foongahh @UTAS_ @MonashUni: Trials and real-world evidence showed that unselected treatment-cessation approach carries an unacceptable risk of disease reactivation.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251344805
3/🧵 -
MSJ
@MSJ_Research
Black African people born and evaluated in Zambia experienced prolonged #multiplesclerosis diagnostic delays when compared to non-black Zambians born and/or evaluated outside Zambia.
Study from @DeannaSaylor1 @UnzaOfficial @UniversityofNo7 ▶️journals.sagepub.com/doi/full/10.1177/13524585251344832 -
MSJ reposted
Malya Sahu, MD
@MSahuMD
Excited to share this important work on delays to diagnosis of MS in Zambia that underscores the need for improved awareness, especially amongst HCWs @MSJ_Research @DeannaSaylor1
journals.sagepub.com/doi/full/10.1177/13524585251344832 -
MSJ
@MSJ_Research
Gynecological health within comprehensive treatment monitoring for #multiplesclerosis.
Topical review from @BoveRiley @UCSF ▶️journals.sagepub.com/doi/full/10.1177/13524585251346371 -
MSJ
@MSJ_Research
By testing the SDMT monthly across 3 years, the plateau of practice effects was reached after 18 repetitions, suggesting that alternate versions and reliable-change methodologies should be considered.
Study from @goteborgsuni @sahlgrenska ▶️ journals.sagepub.com/doi/full/10.1177/13524585251344794 -
MSJ
@MSJ_Research
Rituximab showed superior effectiveness on MRI and clinical activity, compared to cladribine, over 4.5 years.
Observational data from the Norwegian #multiplesclerosis Registry and Biobank @UiB @UniOslo ▶️ journals.sagepub.com/doi/full/10.1177/13524585251342727 -
MSJ
@MSJ_Research
Depression and fatigue should be addressed in the context of lifestyle recommendations in #multiplesclerosis, to maximise the effect of cognitively enriching leisure activities.
Study from @ucddublin ▶️ journals.sagepub.com/doi/full/10.1177/13524585251338757 -
MSJ reposted
Nabeela Nathoo, MD, PhD, FRCPC
@neuronathoo
Proud to be one of the co-authors of this series on gender affirming care and interventions in MS. Without trying to understand all types of people living with MS, we cannot claim to provide equitable care to all.
MSJ
@MSJ_Research
For the International #lgbt Pride Day 🌈 have a look at the case series from @nurneyal @MayoClinic on gender-affirming interventions and prognosis in #multiplesclerosis.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251341174
1/🧵 -
MSJ
@MSJ_Research
Dynamic contrast-enhanced MRI was used to evaluate blood–brain barrier permeability in #multiplesclerosis, in relation to severity and timing of optic neuritis.
Study from @lina_passali @koebenhavns_uni @Rigshospitalet ▶️ journals.sagepub.com/doi/full/10.1177/20552173251346979 -
MSJ
@MSJ_Research
For the International #lgbt Pride Day 🌈 have a look at the case series from @nurneyal @MayoClinic on gender-affirming interventions and prognosis in #multiplesclerosis.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251341174
1/🧵
MSJ
@MSJ_Research
...and commentary from @MarcelloMoccia_ @UninaIT: We really hope this case series can support our clinical decisions and ultimately improve quality of life and health outcomes of gender-diverse people with #multiplesclerosis.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251341177
2/🧵 -
MSJ
@MSJ_Research
Did you publish your first article as first author in 2024 on our journals?
Apply to the 2025 F2 Award of @MSJ_Research and @ECTRIMS with a cash prize and one year access to the #msj (stay tuned at the #ectrims2025 Closing Ceremony) ▶️ journals.sagepub.com/msj/researcherprize
Deadline: Jul 19 -
MSJ reposted
ECTRIMS
@ECTRIMS
New article in the @MSJ_Research: A newly introduced JC virus assay classified 61.4% of MS patients as seropositive compared to just 23.6% with the reference test. The high rate of discrepancy challenges clinical decision-making. 🔗 Read the article here: journals.sagepub.com/doi/full/10.1177/13524585251322683
-
MSJ reposted
ECTRIMS
@ECTRIMS
📰 Our latest newsletter is here!
We’ve packed this edition with all the essentials for your #ectrims2025 planning. 📬 Catch up on important dates, recent activities, and educational content from the last three months. Read the newsletter ➡️ ectrims.eu/june-2025-newsletter/ -
MSJ
@MSJ_Research
Plasma 4S-hydroxycholesterol provides a minimally invasive biomarker of brain cholesterol metabolism and follows the effects of treatment with the remyelinating antibody rHIgM22 in #multiplesclerosis.
Study from @UCBerkeley▶️ journals.sagepub.com/doi/full/10.1177/20552173251344555 -
MSJ reposted
The Sumaira Foundation
@TheSumairaFDN
🇺🇬 Rita from Kampala, Uganda, lives with #nmosd. Symptoms began in May 2022 with vision loss and paralysis.
After struggling to afford her treatment, she now receives care at @MulagoReferral.
Inspired by TSF, she’s raising NMO awareness in Uganda. www.sumairafoundation.org/ritas-nmosd-story-a-surprise-co… -
MSJ reposted
IJMSC
@IJMSCtweets
"The [#family Reported Outcome Measure] FROM-16 could be used to measure the [#multiplesclerosis] family #impact in routine practice to support family members appropriately and to include this impact in health economic appraisal and therapeutic clinical trials."
MSJ
@MSJ_Research
#multiplesclerosis substantially impacts the quality of life of family members/partners of people with MS, indicating a need to assess this impact routinely.
Evidence using the Family Reported Outcome Measure @cardiffuni ▶️ journals.sagepub.com/doi/full/10.1177/20552173251338762 -
MSJ
@MSJ_Research
📢 June issue is now available ▶️journals.sagepub.com/toc/MSJ/current
...and the cover goes to @ki_elements @TjalfZiemssen @tudresden_de with their study on speech analysis in #multiplesclerosis▶️journals.sagepub.com/doi/abs/10.1177/13524585251329801 -
MSJ
@MSJ_Research
#multiplesclerosis substantially impacts the quality of life of family members/partners of people with MS, indicating a need to assess this impact routinely.
Evidence using the Family Reported Outcome Measure @cardiffuni ▶️ journals.sagepub.com/doi/full/10.1177/20552173251338762 -
MSJ
@MSJ_Research
Case-by-case decisions look the most sensible.
MSJ
@MSJ_Research
What do you think? Should disease-modifying therapy be discontinued in older patients with stable #multiplesclerosis after long-term clinical and radiological stability?
5/🧵 -
MSJ reposted
ECTRIMS
@ECTRIMS
🧪 A new study in @MSJ_Research highlights major discrepancies between two JC virus antibody assays used to assess PML risk in MS. In a French cohort, 37.8% patients showed binary discordance between the new and reference tests. Read the article here: journals.sagepub.com/doi/full/10.1177/13524585251322683
-
MSJ reposted
MS Int'l Federation
@MSIntFederation
MSIF is proud to announce Professor Ludwig Kappos as the 2025 #charcotaward recipient, honouring a lifetime of impact in #msresearch. 🏆🔬
From pioneering treatments to mentoring researchers worldwide, his legacy is global. 🌎
Read more: msintfederation.org/4ncra5K
@RC2NB -
MSJ
@MSJ_Research
🔊 Listen to @andreuvilaseca7 @AVidalJordana @XMontalban @cemcat_em on how we could accurately diagnose a subclinical period of #multiplesclerosis.
📰 And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585251332115 -
MSJ
@MSJ_Research
Vitamin D receptor binding variants are associated with pediatric-onset #multiplesclerosis.
Mendelian randomization from the Network of Pediatric Multiple Sclerosis Centers @UCBerkeley ▶️ journals.sagepub.com/doi/full/10.1177/20552173251335625 -
MSJ
@MSJ_Research
New controversy available ⚖️
📢Should disease-modifying therapy be discontinued in older patients with stable #multiplesclerosis after long-term clinical and radiological stability?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
No 👎 from @foongahh @UTAS_ @MonashUni: Trials and real-world evidence showed that unselected treatment-cessation approach carries an unacceptable risk of disease reactivation.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251344805
3/🧵
MSJ
@MSJ_Research
And commentary from @karolinskainst: The most sensible path lies on a flexible, individual approach, accounting for age, disease course, treatment type, duration of stability, comorbidities, and patient preference.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251344786
4/🧵
MSJ
@MSJ_Research
What do you think? Should disease-modifying therapy be discontinued in older patients with stable #multiplesclerosis after long-term clinical and radiological stability?
5/🧵 -
MSJ
@MSJ_Research
Phonatory instabilities, changes in pitch and loudness, and reduced speech time are associated with #multiplesclerosis severity, motor and cognitive symptoms.
Speech analysis using the SIGMA library from
@ki_elements @TjalfZiemssen @tudresden_de ▶️journals.sagepub.com/doi/abs/10.1177/13524585251329801 -
MSJ
@MSJ_Research
Did you publish your first article as first author in 2024 on our journals?
Apply to the 2025 F2 Award of @MSJ_Research and @ECTRIMS with a cash prize and one year access to the #msj (stay tuned at the #ectrims2025 Closing Ceremony) ▶️ journals.sagepub.com/msj/researcherprize
Deadline: Jul 19 -
MSJ reposted
ECTRIMS
@ECTRIMS
The International Advisory Committee on Clinical Trials in #ms met in May to discuss a topic that could reshape the landscape of MS care and research: the revision of MS course descriptors. Learn why this is an important step forward in #msresearch: ➡️ ectrims.eu/insights/rethinking-the-way-we-define-multiple…
-
MSJ
@MSJ_Research
Lumbar puncture opening pressure was raised in 17% patients with #nmosd and 11% with #multiplesclerosis within 30 days of an attack, but did not require treatment.
Study from @RostonSydney @chenmayo @umnmedschool @UofMaryland ▶️ journals.sagepub.com/doi/full/10.1177/13524585251340841 -
MSJ
@MSJ_Research
The path to prevention of #multiplesclerosis: Considerations for Epstein-Barr virus vaccine-based prevention studies.
Future perspective from @UW @BeboBruce @mssociety ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251340812 -
MSJ
@MSJ_Research
HLA-DQB1*04 allele may increase susceptibility to neuromyelitis optica #nmosd, while DQB1*03 allele could exert a protective effect in our population.
A case–control study considering genetic ancestry from @U_ElBosque @Uniandes @santa_bogota ▶️journals.sagepub.com/doi/abs/10.1177/13524585251336641 -
MSJ
@MSJ_Research
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in #multiplesclerosis.
A modified Delphi Study from @LGHemkens @JensKuhle @UniBasel_en @RC2NB ▶️ journals.sagepub.com/doi/full/10.1177/13524585251335466 -
MSJ reposted
Sharon Roman (n of 1)
@SRoman_SPQR
If I may, @MSJ_Research, it's⬇️for the folks who would like it explained in plain language.
tremlettsmsresearchexplained.wordpress.com/2025/06/02/hea…
MSJ
@MSJ_Research
In 451 individuals with pediatric-onset #multiplesclerosis, there was higher healthcare use from birth, suggesting early life as a risk period.
A population-based study from @DalhousieU @UBC ▶️ journals.sagepub.com/doi/full/10.1177/13524585251338745 -
MSJ
@MSJ_Research
In 451 individuals with pediatric-onset #multiplesclerosis, there was higher healthcare use from birth, suggesting early life as a risk period.
A population-based study from @DalhousieU @UBC ▶️ journals.sagepub.com/doi/full/10.1177/13524585251338745 -
MSJ
@MSJ_Research
📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠
Register here to receive our research
🔽
journals.sagepub.com/connected/MSJ -
MSJ
@MSJ_Research
Ellagic acid, a strong and polyphenolic antioxidant, alleviated fatigue, depression, and anxiety in people with #multiplesclerosis.
Randomized clinical trial from @IAUniversity82 ▶️ journals.sagepub.com/doi/full/10.1177/20552173251331524 -
MSJ
@MSJ_Research
Did you publish your first article as first author in 2024 on our journals?
Apply to the 2025 F2 Award of @MSJ_Research and @ECTRIMS with a cash prize and one year access to the #msj (stay tuned at the #ectrims2025 Closing Ceremony) ▶️ journals.sagepub.com/msj/researcherprize
Deadline: Jul 19 -
MSJ reposted
IJMSC
@IJMSCtweets
#multiplesclerosis #hcps "should develop strong #multicultural training around diagnosis, treatment, prognosis, and the needs of minoritized patients."
MSJ
@MSJ_Research
White people with #multiplesclerosis reported on ease to access to providers, while Black discussed health insurance and facing discrimination.
Qualitative study from @k_bhattiprolu @JBhattaraiPhD @udcadlab @UVAPsyc @HopkinsMedicine @MSRehabResearch ▶️ journals.sagepub.com/doi/full/10.1177/20552173251336753 -
MSJ
@MSJ_Research
Cirrus HD-OCT showed excellent reliability of GCIPL and pRNFL thicknesses and inter-eye differences to identify unilateral optic neuritis.
Test–retest study from @HopkinsNeuro ▶️ journals.sagepub.com/doi/full/10.1177/20552173251340957 -
MSJ
@MSJ_Research
White people with #multiplesclerosis reported on ease to access to providers, while Black discussed health insurance and facing discrimination.
Qualitative study from @k_bhattiprolu @JBhattaraiPhD @udcadlab @UVAPsyc @HopkinsMedicine @MSRehabResearch ▶️ journals.sagepub.com/doi/full/10.1177/20552173251336753 -
MSJ
@MSJ_Research
In 2 years, 255 people with progressive #multiplesclerosis had stable cognitive scores, while disability and brain and optic nerve atrophy progressed, suggesting that cognitive instruments are flawed.
SPRINT-MS analysis from @ColumbiaMed @UCalgary ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251335213 -
MSJ
@MSJ_Research
Falls in people with #multiplesclerosis are more frequent in patients who are older, have higher disability, slower walking, and worse balance.
Study using patient-reported outcomes and wearable gait metrics from @SamanthaBanksMD @MayoClinicNeuro ▶️ journals.sagepub.com/doi/full/10.1177/20552173251329825 -
MSJ reposted
ECTRIMS
@ECTRIMS
Don't Miss ECTRIMS Pre-Day!
✅ Insights into rare neuroimmune diseases
✅ In-depth sessions on NMOSD, MOGAD, autoimmune encephalitis & HSV encephalitis + more
✅ Happening in beautiful Barcelona on 23 Sept
✍️ Book your seat now! ectrims.eu/ectrims2025-registration/
#ectrims2025 -
MSJ reposted
Jaime Imitola MD., FAAN
@DrJim4MS
MSJ
@MSJ_Research
A young woman with #multiplesclerosis treated with ocrelizumab developed severe coxsackie virus B5 encephalitis, mimicking autoimmune limbic encephalitis (good response to ribavirin/favipiravir and immunoglobulins).
Case report from @Saar_Uni ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251322327 -
MSJ
@MSJ_Research
Acute retinal necrosis due to varicella zoster virus #vzv infection in a person with #multiplesclerosis treated with dimethyl fumarate.
Case report from @NorthBristolNHS ▶️ journals.sagepub.com/doi/full/10.1177/13524585251326475
1/🧵
MSJ
@MSJ_Research
...and commentary from @AVidalJordana @neurosantpau: Serological testing to determine immune status against #vzv and other viruses, coupled with appropriate vaccinations, is essential in #multiplesclerosis.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251326475
2/🧵 -
MSJ reposted
ECTRIMS
@ECTRIMS
What's new in the Multiple Sclerosis Journal @MSJ_Research? A pilot study from Sapienza University @unirome1 & @NeuromedIRCCS on the potential of tACS as a non-invasive clinical intervention to help manage cognitive impairment in #ms. Read 👉 journals.sagepub.com/home/MSJ
#msresearch -
MSJ
@MSJ_Research
...and commentary from @olgacicc @QSMSCENTRE @UCLIoN @UCLBrainScience @SapienzaRoma: The potential of regional grey matter measurements to investigate the mechanisms of action of disease-modifying treatments in #multiplesclerosis.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251338772
MSJ
@MSJ_Research
Treatment with cladribine tablets reduced neurodegeneration in deep grey matter, thalamus, and brainstem in #multiplesclerosis
Analysis of the CLARITY study from @marbarrace @Mennoke @MScentrum020 ▶️ journals.sagepub.com/doi/full/10.1177/13524585251314779 -
MSJ reposted
Sarah Levy
@SarahLevyPhD
Patient-reported cognitive concerns in MS can be tricky to assess. This timely review covers key measures and notes the MS Cognitive Scale (MSCS), developed by @JimSumowski, for its stronger links to objective cognition, which is freely available: labs.icahn.mssm.edu/sumowskilab/wp-content/uploads/sites/…
MSJ
@MSJ_Research
Subjective cognitive impairment has a significant impact on day-to-day quality of life of people with #multiplesclerosis, and needs to be efficiently evaluated and managed.
Review from @UMontreal @chumontreal @UQAM ▶ journals.sagepub.com/doi/abs/10.1177/13524585251334488 -
MSJ
@MSJ_Research
Subjective cognitive impairment has a significant impact on day-to-day quality of life of people with #multiplesclerosis, and needs to be efficiently evaluated and managed.
Review from @UMontreal @chumontreal @UQAM ▶ journals.sagepub.com/doi/abs/10.1177/13524585251334488 -
MSJ reposted
The MOG Project
@TheMOGProject
Extremely important. 24% of relapsing #mogad pts relapsed after discontinuation of treatment after 2 years. Relapsing MOGAD pts whose treatments were discontinued after a short period of time, also experienced higher risk of relapse, compared to monophasic patients.
We really need to think about where we are in terms of keeping relapsing pts on treatment & taking them off. Does the risk outweigh the benefits? 🤷🏻♀️
MSJ
@MSJ_Research
🔊 Listen to @SKKUni1398 on discontinuation of immunosuppressive therapy in people with MOG antibody-associated disease #mogad.
📄And read the full manuscript▶️ journals.sagepub.com/doi/abs/10.1177/13524585251320046This media couldn't be displayed. See it on the original post. -
MSJ
@MSJ_Research
Did you publish your first article as first author in 2024 on our journals?
Apply to the 2025 F2 Award of @MSJ_Research and @ECTRIMS with a cash prize and one year access to the #msj (stay tuned at the #ectrims2025 Closing Ceremony) ▶️ journals.sagepub.com/msj/researcherprize
Deadline: Jul 19 -
MSJ
@MSJ_Research
🔊 Listen to @SKKUni1398 on discontinuation of immunosuppressive therapy in people with MOG antibody-associated disease #mogad.
📄And read the full manuscript▶️ journals.sagepub.com/doi/abs/10.1177/13524585251320046This media couldn't be displayed. See it on the original post. -
MSJ
@MSJ_Research
Over 5 years, serum neurofilament light chain decreased after the initiation of high-efficacy and low-efficacy early therapy in #multiplesclerosis, while GFAP was not substantially impacted.
Study from @es_madill @BrighamWomens @harvardmed ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251335521 -
MSJ reposted
World MS Day
@WorldMSDay
🧠 The first symptoms of MS can look very different from person to person. Thousands have shared their diagnosis journeys through the #worldmsday poster maker, helping raise awareness & build understanding. 🌍💬
🎨 Create your own poster & add your voice: worldmsday.org/poster-maker/ -
MSJ
@MSJ_Research
Yes, treating comorbidities in #multiplesclerosis is disease modifying
MSJ
@MSJ_Research
What do you think? Treating comorbidities in #multiplesclerosis is disease modifying?
5/🧵 -
MSJ
@MSJ_Research
Pre-pubertal onset #multiplesclerosis was associated with severe symptoms, greater lesion burden, higher 10-year disability, and increased relapse rates when transitioning to peri- or post-puberty.
Study from @melindamagyari @Rigshospitalet @univca ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251335476 -
MSJ
@MSJ_Research
#worldmsday2025: The #multiplesclerosis disease activity (MSDA) test, measuring 18 proteins, showed potential impact on real-world longitudinal decision-making.
Retrospective chart review with a pre-post test design component @OctaveBiostudy▶️ journals.sagepub.com/doi/10.1177/20552173251331030 -
MSJ
@MSJ_Research
#worldmsday2025: Testing for myelin oligodendrocyte glycoprotein #mogad antibodies: Who, what, where, when, why, and how!
Review from @adrianbudhram1 @LHSCCanada @WesternU @EoinFlanagan14 @MayoClinicNeuro ▶️ journals.sagepub.com/doi/full/10.1177/13524585251313744 -
MSJ
@MSJ_Research
#worldmsday2025: Nabiximols was the most common cannabinoid to treat spasticity in #multiplesclerosis, and proved effective in the real world.
A systematic review with 31 studies and meta-analysis @TumsIPR ▶️ journals.sagepub.com/doi/full/10.1177/20552173241282379 -
MSJ
@MSJ_Research
#worldmsday2025: Studies on pharmacological and nonpharmacological interventions for fatigue in #multiplesclerosis have provided inconclusive evidence, and comprehensive and interdisciplinary approach is required.
Scoping review from @URosario ▶️ journals.sagepub.com/doi/full/10.1177/20552173241312527 -
MSJ
@MSJ_Research
#worldmsday2025: The refined Pathways to Cures Research Roadmap provides a strategic framework for tackling the complexities of #multiplesclerosis and advancing prevention, treatment and cure.
Global effort lead by @BeboBruce @mssociety @UCLBrainScience ▶️journals.sagepub.com/doi/abs/10.1177/13524585241266483 -
MSJ reposted
Kavya Bhattiprolu
@k_bhattiprolu
I'm excited to share that my first first-author paper is now published in MSJ-ETC @MSJ_Research! We examined race- and place-based disparities in experiences with multiple sclerosis care.
Thanks to the team for all their hard work!
doi.org/10.1177/20552173251336753 -
MSJ
@MSJ_Research
#worldmsday2025: In people with #multiplesclerosis treated with ocrelizumab, progression independent of relapses occurred within suboptimal B-cell depletion, highlighting the need for monitoring and adjusted infusion intervals.
Study from @uni_muenster ▶️ journals.sagepub.com/doi/full/10.1177/13524585251329849 -
MSJ
@MSJ_Research
Today is World #multiplesclerosis Day: We will be sharing our most read articles from the past 12 months, with the hope to uncover the most controversial aspects of the disease.
More information on the #worldmsday2025
🔽
worldmsday.org -
MSJ
@MSJ_Research
The Symbol Digit Modalities Test is affected by motor disability if written or electronic, and is more sensitive to age and education if electronic, than oral or written, requiring version-specific normative in #multiplesclerosis.
Study from @NIH_NINDS ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251330961 -
MSJ
@MSJ_Research
New controversy available ⚖️
📢 Treating comorbidities in #multiplesclerosis is disease modifying?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @UninaIT @imperialcollege: While the #multiplesclerosis specialist remains central to patient care, an integrated care model should be prioritized, pending high-quality data to establish priorities for effective intervention.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251338755
4/🧵
MSJ
@MSJ_Research
What do you think? Treating comorbidities in #multiplesclerosis is disease modifying?
5/🧵 -
MSJ
@MSJ_Research
Baló’s concentric sclerosis successfully treated with alemtuzumab, with clinical and radiological follow-up over 6 years.
Case report from @CRFSheffield @ConcordHospital ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251331536 -
MSJ
@MSJ_Research
Did you publish your first article as first author in 2024 on our journals?
Apply to the 2025 F2 Award of @MSJ_Research and @ECTRIMS with a cash prize and one year access to the #msj (stay tuned at the #ectrims2025 Closing Ceremony) ▶️ journals.sagepub.com/msj/researcherprize
Deadline: Jul 19 -
MSJ
@MSJ_Research
Switching to siponimod from other #multiplesclerosis treatments was generally well tolerated (list of most common side effects 🔽), especially when from fingolimod due to lack of changes in heart rate.
The EXCHANGE study from @ClevelandClinic @Penn ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251330085 -
MSJ
@MSJ_Research
Functional System scores and their corresponding subscores, Ambulation scores and EDSS scores revealed different patterns of disability in #multiplesclerosis.
Machine learning study using EXPAND trial from @RC2NB @UniBasel_en @UniSpitalBasel ▶️ journals.sagepub.com/doi/full/10.1177/13524585251327300 -
MSJ
@MSJ_Research
Switching to siponimod from other #multiplesclerosis treatments was generally well tolerated (list of most common side effects 🔽), especially when from fingolimod due to lack of changes in heart rate.
The EXCHANGE study from @ClevelandClinic @Penn ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251330085 -
MSJ
@MSJ_Research
Among 1745 mothers with #multiplesclerosis, higher area-level deprivation and disability levels were associated with an increased incidence of peripartum mental illness.
Population-based study from @DalhousieU @UWaterloo ▶️ journals.sagepub.com/doi/full/10.1177/13524585251330109 -
MSJ reposted
ECTRIMS
@ECTRIMS
🚨 Happening today (20 May)! Don't miss our first Clinical Case Neurowebinar, where experts analyse a real-life case on rapid progression and neuroprotection. It's not too late to register ➡️ my.ectrims.eu/webinars/108
🕕 18:00-19:00 CEST
#msresearch #neurology #ms #webinar -
MSJ reposted
IJMSC
@IJMSCtweets
Pw #ms "assigned to [#hyphosis] & [#meditation] conditions reported significantly greater reductions in #fatigue impact, #sleep disturbance & depressive symptom severity than participants assigned to TAU condition after 4 weeks of access to audio recordings of...interventions."
MSJ
@MSJ_Research
4w hypnosis (HYP) and mindfulness (MM) audio recordings improved fatigue impact, sleep disturbance and depressive symptoms in people with #multiplesclerosis, compared with treatment as usual (TAU).
A randomized controlled study from @KevinAlschuler @UW ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251329820 -
MSJ
@MSJ_Research
Cervical spine MRI showed asymptomatic lesions in 5-12% of people with #multiplesclerosis, especially if Black/African American, but only half also had brain lesions.
Study from @EllenMowryMD @HopkinsMedicine @HopkinsNeuro @JohnsHopkinsSPH @UW ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251331405 -
MSJ
@MSJ_Research
4w hypnosis (HYP) and mindfulness (MM) audio recordings improved fatigue impact, sleep disturbance and depressive symptoms in people with #multiplesclerosis, compared with treatment as usual (TAU).
A randomized controlled study from @KevinAlschuler @UW ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251329820 -
MSJ
@MSJ_Research
📢May issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @SapienzaRoma @NeuromedIRCCS with their pilot study on aerobic capacity, spinal cord atrophy and clinical disability in #multiplesclerosis ▶️ journals.sagepub.com/doi/full/10.1177/13524585251333575 -
MSJ
@MSJ_Research
A 17-year-old boy with AQ4+ #nmosd and treated with rituximab, had JCV+ progressive multifocal leukoencephalopathy #pml, which resulted into death.
Case report from @TheWaltonCentre @MonashUni ▶️journals.sagepub.com/doi/full/10.1177/13524585251331855
1/🧵
MSJ
@MSJ_Research
...and commentary from @UnivParisSaclay: We need to identify pediatric-specific risk factors for #pml and refine treatment strategies that balance effective immunosuppression with minimal adverse effects.
🔽
journals.sagepub.com/doi/abs/10.1177/13524585251331875
2/🧵 -
MSJ
@MSJ_Research
40% of people with #multiplesclerosis reported misdiagnosis of their symptoms, which was in turn associated with longer diagnostic time, suggesting we need to trace the diagnostic journey to understand/prevent delays.
Registry study from @UVMLarnerMed
▶️ journals.sagepub.com/doi/full/10.1177/20552173251333390 -
MSJ
@MSJ_Research
Did you attend #actrims Forum 2025?
@ACTRIMS
Abstracts are now available ▶️ journals.sagepub.com/toc/msja/31/2_suppl -
MSJ
@MSJ_Research
In steroid-refractory #multiplesclerosis attacks, immunoadsorption reduced B-cell derived inflammation more effectively than plasma exchange.
Study using immunological markers from @uni_ulm ▶️ journals.sagepub.com/doi/full/10.1177/20552173251321797 -
MSJ
@MSJ_Research
Digital and holistic interventions were associated with positive trends in #multiplesclerosis care delivery, including reduced time from diagnosis to treatment and in admissions and healthcare costs.
Study from @AgneStraukiene @TorbaySDevonNHS @PlymUni ▶️ journals.sagepub.com/doi/full/10.1177/20552173251317020 -
MSJ reposted
ECTRIMS
@ECTRIMS
🎉We’re thrilled to announce the recipients of the 2025 ECTRIMS Fellowship Awards. 👏 Join us in congratulating this year’s fellows as they take the next big step in advancing MS science and treatment! Read more ➡️ ectrims.eu/ectrims-fellowship-2025-winners/
-
MSJ
@MSJ_Research
Telehealth-based cognitive intervention is well accepted by people with #multiplesclerosis and may improve memory and functional status.
A pilot study of a metacognitive strategy-based intervention from @nyuniversity ▶️ journals.sagepub.com/doi/full/10.1177/20552173251333383 -
MSJ
@MSJ_Research
Gamma-transcranial alternating current stimulation transiently improved cognitive impairment in #multiplesclerosis, deserving further investigations.
A randomized, double-blind, sham-controlled, pilot study from @SapienzaRoma @NeuromedIRCCS ▶️ journals.sagepub.com/doi/full/10.1177/13524585251333575 -
MSJ
@MSJ_Research
The #multiplesclerosis disease activity (MSDA) test, measuring 18 proteins, showed potential impact on real-world decision-making, especially with longitudinal use.
Retrospective chart review with a pre-post test design component ▶️ journals.sagepub.com/doi/full/10.1177/20552173251331030 -
MSJ reposted
Service de neurologie du CHUM
@ChumNeuro
Une explication approfondie sur la complexité de l’interprétation des troubles cognitifs en #scleroseenplaques dans cet article de @GMacaronMD publié ce mois dans @MSJ_Research 👏🏼
pubmed.ncbi.nlm.nih.gov/40247705/ -
MSJ
@MSJ_Research
Early treatment with ocrelizumab in relapsing and progressive #multiplesclerosis helps to prevent additional cerebellar volume loss compared with delayed switching to ocrelizumab.
Re-analysis of phase III trials from @NeuroRxResearch @mcgillu @Roche ▶️ journals.sagepub.com/doi/full/10.1177/13524585251325086 -
MSJ
@MSJ_Research
Slower retinal thinning over a year predicts continuous NEDA (no relapses, disability progression and active MRI) in #multiplesclerosis, suggesting it could be used for prognosis and monitoring.
A longitudinal OCT study from @SamiaKhoury3 @AUB_Lebanon ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251332499 -
MSJ
@MSJ_Research
Among 110 people with #multiplesclerosis, 87.3% had at least 1 paramagnetic rim lesion, which was associated with EDSS, SDMT, total lesion count, and volume.
Study from 🇨🇳 Capital Medical University ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251328902 -
MSJ
@MSJ_Research
🔊 Listen to @MedUni_Wien on the diagnostic accuracy of OCT in identifying optic neuritis in #multiplesclerosis.
📄 And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585251332895 -
MSJ
@MSJ_Research
In people with #multiplesclerosis treated with ocrelizumab, progression independent of relapse activity occurred within suboptimal B-cell depletion, highlighting the need for monitoring and adjusted infusion intervals.
Study from @uni_muenster ▶️ journals.sagepub.com/doi/full/10.1177/13524585251329849 -
MSJ
@MSJ_Research
Medicaid coverage was associated with worse clinical outcomes in #multiplesclerosis, including more clinical relapses and disability progression, compared to privately insured patients, indicating socioeconomic disparities.
Study from @RushMedical ▶️ journals.sagepub.com/doi/10.1177/20552173251318034 -
MSJ reposted
Paolo Preziosa
@paolopreziosa
Thanks to @MSJ_Research for having selected our figure for the cover for the April issue!
@AlbergoniMatteo
MSJ
@MSJ_Research
📢April issue (II) is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @AlbergoniMatteo @NRU_SanRaffaele @SanRaffaeleMI @MyUniSR with their study on aerobic capacity, spinal cord atrophy and clinical disability in #multiplesclerosis ▶️ journals.sagepub.com/doi/full/10.1177/13524585251318647 -
MSJ reposted
ECTRIMS
@ECTRIMS
⏰ Just 1 day to go! Join global experts from @cemcat_em, @ClevelandClinic, @UofT, @CHUdeNice in a #webinar on the proposed revisions to the McDonald Diagnostic Criteria for #ms. 👉 Register now via myECTRIMS: my.ectrims.eu/webinars/119
📆 30 April 15:00-16:00 CEST -
MSJ
@MSJ_Research
In people with #multiplesclerosis, fatigue is intercorrelated with anxiety, depression and pain, and could be affected by imbalanced pro- and anti-angiogenic signaling.
Study from @PennStHershey ▶️ journals.sagepub.com/doi/10.1177/20552173251329904 -
MSJ
@MSJ_Research
📢April issue (II) is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @AlbergoniMatteo @NRU_SanRaffaele @SanRaffaeleMI @MyUniSR with their study on aerobic capacity, spinal cord atrophy and clinical disability in #multiplesclerosis ▶️ journals.sagepub.com/doi/full/10.1177/13524585251318647 -
MSJ
@MSJ_Research
MSReactor, a web-based test evaluating processing speed, attention and working memory in #multiplesclerosis, was highly acceptable for long-term digital cognitive monitoring.
Study from @MonashUni ▶️ journals.sagepub.com/doi/full/10.1177/13524585251329035 -
MSJ
@MSJ_Research
Quantitative dried blood spot sampling technique had 100% sensitivity and specificity for reaching >10 × 10*6 cells/L, and could be used to tailor anti-CD20 therapies in #multiplesclerosis.
Study from @ETallantyre @cardiffuni @crf_cardiff ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251330962 -
MSJ reposted
EthelCiampiSCL
@EthelScl
MSJ
@MSJ_Research
Practical issues concerning the use of optical coherence tomography in #multiplesclerosis diagnosis, prognosis and monitoring in Latin America.
Discussion from 19 centres on behalf of the Foro Latam EM study group @uc_chile ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251329159 -
MSJ
@MSJ_Research
Practical issues concerning the use of optical coherence tomography in #multiplesclerosis diagnosis, prognosis and monitoring in Latin America.
Discussion from 19 centres on behalf of the Foro Latam EM study group @uc_chile ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251329159 -
MSJ reposted
大橋 高志
@ULLR64_1
NMOSDの人種・民族グループ間での感受性の違いを厳密に評価することを目的に、カイザー・パーマネンテ南カリフォルニアの会員データを用いて行った後ろ向きコホート研究。
NMOSDの発症率は、黒人で最も高く (0.90/10万人年)、アジア系/太平洋諸島系とヒスパニック系が同程度で、白人で最も低かった。
MSJ
@MSJ_Research
The risk of neuromyelitis optica spectrum disorder #nmosd is highest in Black people, followed by Asian/Pacific Islands, then Hispanic people, and lowest in White people.
A contemporary, multi-ethnic cohort study from @KPLACounty ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251328554 -
MSJ
@MSJ_Research
The risk of neuromyelitis optica spectrum disorder #nmosd is highest in Black people, followed by Asian/Pacific Islands, then Hispanic people, and lowest in White people.
A contemporary, multi-ethnic cohort study from @KPLACounty ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251328554 -
MSJ
@MSJ_Research
Apnea–hypopnea index was associated with the number of and presence of brainstem #multiplesclerosis lesions, independently of age and BMI.
Polysomnography and MRI study from @uvermont @Yale ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251327875 -
MSJ reposted
Peter Foley
@foley_p_neuro
doi.org/10.1016/j.msard.2022.104429
Similar findings to our study of ~320 people with RRMS taking part in #futurems study 🏴🧠.
Fatigue strongly related to physical disability and mood.
We found lack of links to MRI metrics or objective cog tests
@MSImaGE2 @AnneRowlClinic @dr_niall
MSJ
@MSJ_Research
In this cross-sectional study, 47% of the people with #multiplesclerosis reported fatigue, which was related to higher disability, lower education, and smoking.
Finnish registry study from @neuroliitto @AnnikaHulten @UniEastFinland ▶️ journals.sagepub.com/doi/full/10.1177/20552173251325098 -
MSJ
@MSJ_Research
In this cross-sectional study, 47% of the people with #multiplesclerosis reported fatigue, which was related to higher disability, lower education, and smoking.
Finnish registry study from @neuroliitto @AnnikaHulten @UniEastFinland ▶️ journals.sagepub.com/doi/full/10.1177/20552173251325098 -
MSJ
@MSJ_Research
Lower copies at the complement C4 locus confer risk for #multiplesclerosis, similar to other autoimmune disorders.
Next-generation sequencing study from @UCSF ▶️ journals.sagepub.com/doi/10.1177/13524585251324850 -
MSJ reposted
ECTRIMS
@ECTRIMS
🎇 A big thank you to all #ms researchers who submitted an abstract during our general abstract period, which closed on 10 April.
We received over 2,200 submissions for #ectrims2025 -- 25% more than last year! Best of luck to all & we look forward seeing your work in Barcelona! -
MSJ
@MSJ_Research
Cut-points discriminating people with #multiplesclerosis with or without walking impairments were 446 m for 6MWT, 8.3 s for SSST, and 5.5 s for T25FWT.
Study from @AarhusUni_int ▶️ journals.sagepub.com/doi/10.1177/20552173251324600 -
MSJ
@MSJ_Research
People with #multiplesclerosis showed decreased levels of phosphatidylcholines and different amino acids, with potential associations with worse motor function.
Study from @KateFitzg @HopkinsMedicine ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251325468 -
MSJ
@MSJ_Research
There are no fluctuations in daily step count following anti-CD20 infusion in people with #multiplesclerosis, thus suggesting stability between infusions.
Prospective study using Fitbit from @ValerieBlock1 @BoveRiley @UCSF ▶️ journals.sagepub.com/doi/10.1177/20552173251329817 -
MSJ
@MSJ_Research
Maximal muscle strength and aerobic capacity are preferentially associated with different lower extremity physical functions in people with #multiplesclerosis, suggesting the need of tailored intervention.
Cross-sectional study from @AarhusUni_int ▶️ journals.sagepub.com/doi/full/10.1177/20552173251326171 -
MSJ reposted
ECTRIMS
@ECTRIMS
🏃 Science is moving fast in #ms care. Now let’s make sure access keeps up! The new issue of @MSJ_Research presents a practical roadmap to ensure the availability of essential DMTs for people with MS living in resource-limited settings. Read more➡️ journals.sagepub.com/doi/full/10.1177/13524585251326843
-
MSJ
@MSJ_Research
📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠
Register here to receive our research
🔽
journals.sagepub.com/connected/MSJ -
MSJ
@MSJ_Research
In cellular and animal models of demyelination, evobrutinib increased 1.59x the number of microglia/macrophages with beneficial effect on remyelination, in the absence of added benefits from clemastine.
Study from @Sorbonne_Univ_ @HopPitieSalpe @Inserm ▶️ journals.sagepub.com/doi/full/10.1177/20552173251326913 -
MSJ
@MSJ_Research
A safety nurse navigator successfully identified incomplete safety monitoring for infusion therapies for #multiplesclerosis, including outdated lab, appointments and imaging, to avoid drug-related complications.
Study from @ShuvroRoy @hopkinsneurons ▶️ journals.sagepub.com/doi/full/10.1177/20552173251320791 -
MSJ
@MSJ_Research
Cognitive deficits, fatigue and dysarthria contribute to communication difficulties in people with #multiplesclerosis, highlighting the need for targeted interventions.
Cross-sectional study from @Aristoteleio ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251328556 -
MSJ
@MSJ_Research
...and editorial from @FleniOficial: There is reason for optimism the #multiplesclerosis community is paving the way for more sustainable solutions, with equitable access to treatments, driven by scientific advances, advocacy and global collaboration.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251326843
MSJ
@MSJ_Research
Recommendations for essential medicines for #multiplesclerosis in low-resource settings.
A @MSIntFederation initiative including @DeannaSaylor1 @JohnsHopkins @twpiggott @QueensKingston @Ptbohealth ▶️ journals.sagepub.com/doi/full/10.1177/13524585241308134 -
MSJ
@MSJ_Research
📢April issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @UCSF with innovative and collaborative multi-disciplinary research as the key to stop, restore, and end #multiplesclerosis ▶️ journals.sagepub.com/doi/full/10.1177/13524585251314756 -
MSJ reposted
IJMSC
@IJMSCtweets
"Exit or #lasttherapy with #cladt seems to avoid [#multiplesclerosis] disease reactivation in older PWMS irrespective of prior PLT, HET, or no DMT. A longer follow-up will determine whether these patients will need to be retreated in subsequent years."
MSJ
@MSJ_Research
Among 129 people with #multiplesclerosis >45 yo treated with cladribine, only 3 had relapses over 2.4 years, thus suggesting this could be their last/exit therapy.
Retrospective multicentre study from @CHULiege ▶️ journals.sagepub.com/doi/full/10.1177/20552173251321810 -
MSJ
@MSJ_Research
History of seizures independently predicts reduced cognition in people with #multiplesclerosis, deserving further investigations on mechanisms and potential treatments.
Study from @DavidEFreedman @UofTPsych @Sunnybrook ▶️ journals.sagepub.com/doi/full/10.1177/13524585251326841 -
MSJ reposted
Sharon Roman (n of 1)
@SRoman_SPQR
If I may, it’s ⬇️ for the folks who would like it explained in plain language.
tremlettsmsresearchexplained.wordpress.com/2025/03/20/cha…
MSJ
@MSJ_Research
Among 259 Canadian studies from 2010 to 2024, 24.3% evaluated therapies and 20.9% access to care, ≤10% reported race or ethnicity, and none religion, sexual orientation and language.
Scoping review @MLFinlayson @queensu @DalhousieU @UM_RadyFHS ▶️ journals.sagepub.com/doi/full/10.1177/20552173251321814 -
MSJ
@MSJ_Research
Among 129 people with #multiplesclerosis >45 yo treated with cladribine, only 3 had relapses over 2.4 years, thus suggesting this could be their last/exit therapy.
Retrospective multicentre study from @CHULiege ▶️ journals.sagepub.com/doi/full/10.1177/20552173251321810 -
MSJ
@MSJ_Research
Among 259 Canadian studies from 2010 to 2024, 24.3% evaluated therapies and 20.9% access to care, ≤10% reported race or ethnicity, and none religion, sexual orientation and language.
Scoping review @MLFinlayson @queensu @DalhousieU @UM_RadyFHS ▶️ journals.sagepub.com/doi/full/10.1177/20552173251321814 -
MSJ
@MSJ_Research
#multiplesclerosis incidence and prevalence increased significantly from 1974 to 2021, especially after incorporation of MRI in criteria, but prevalence stabilised in 2000s.
Nationwide population-based registry study from @HkiBrainMind @helsinkiuni ▶️ journals.sagepub.com/doi/full/10.1177/20552173251326173 -
MSJ
@MSJ_Research
New issue of Multiple Sclerosis Journal – Experimental, Translational and Clinical is now available online journals.sagepub.com/toc/msoa/11/1 ▶️ and is full open access 🔓
-
MSJ reposted
Fiona Chan
@dr_fiona_c
New Findings Alert
Our study reveals how smoking and vascular risk factors may affect recovery in #nmosd and #mogad. Grateful to my supervisors in @NDCNOxford and @Sydney_Uni for this opportunity. A great souvenir from my Oxford fellowship!
Introductory video below ⬇️
MSJ
@MSJ_Research
🔊 Listen to @dr_fiona_c @david_berhanu @NDCNOxford @Sydney_Uni @OUHospitals on the detrimental effects of smoking and other vascular risk factors on recovery from onset attack of AQ4 #nmosd and #mogad.
📄And read the full manuscript ▶️ journals.sagepub.com/doi/10.1177/13524585251325069 -
MSJ reposted
Fiona Chan
@dr_fiona_c
Thank you for the feature. A result of amazing teamwork.
-
MSJ
@MSJ_Research
🔊 Listen to @dr_fiona_c @david_berhanu @NDCNOxford @Sydney_Uni @OUHospitals on the detrimental effects of smoking and other vascular risk factors on recovery from onset attack of AQ4 #nmosd and #mogad.
📄And read the full manuscript ▶️ journals.sagepub.com/doi/10.1177/13524585251325069 -
MSJ reposted
Rohit Sharma
@piandro3142
You may have already come across this Chee, but this is a nice review that includes extra-CNS manifestations of NMOSD link.springer.com/article/10.1007/s11882-016-0619-4
-
MSJ
@MSJ_Research
Commentary from @marignierro: Recognizing AQP4-Ab-related pneumonia is crucial for optimal management, especially in people with #nmosd on immunosuppressive therapy.
MSJ
@MSJ_Research
A 80-year-old man with AQ4+ #neuromyelitisoptica presented with cough and hiccups, and was found to have organizing pneumonia with AQ4 loss, IgG-binding, and complement deposits, akin to central nervous system lesions.
Case report from @Fukuoka_Univ_PR ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241310397 -
MSJ
@MSJ_Research
Sacral neuromodulation was effective on neurogenic overactive bladder in #multiplesclerosis, with sustained reductions of urinary urgency and incontinence over 5 years.
Retrospective study from @BiardeauX @CHU_Lille @univ_lille▶️ journals.sagepub.com/doi/abs/10.1177/13524585251323178 -
MSJ
@MSJ_Research
Vaccination in #multiplesclerosis: Tackling challenges and paving the way for effective immunization.
Review from @ReneCarvajalMD @MarTintore @cemcat_em @vallhebron ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251318513 -
MSJ
@MSJ_Research
Women with #multiplesclerosis have reduced rates of childbirth compared with controls, from 3 years before onset.
Population-based cohort study from @VestreViken @CeliusElisabeth ▶️ journals.sagepub.com/doi/full/10.1177/13524585251315077 -
MSJ reposted
ECTRIMS
@ECTRIMS
Latest from @MSJ_Research: 🚭Smoking has detrimental effects on people with #mogad or #nmosd. Current smokers with MOGAD or NMOSD are more likely to experience lasting disability from their onset attack. Read more: journals.sagepub.com/doi/10.1177/13524585251325069 #ms
-
MSJ reposted
EthelCiampiSCL
@EthelScl
We are pleased to invite you to our first @IntNatlWiMS Global Epidemiology meeting of 2025! We'll have ✌️amazing speakers from Brazil and Italy, covering the gradient distribution of ADS in children, and SDOH in MS! Mark your 🗓 Monday, 24th, 21hr CET 🌍🌎🌏 @anazabalza
-
MSJ
@MSJ_Research
📢March issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @umassmemorial @UMassChan @NIH_NINDS with their paper on predictors of paramagnetic rim formation in #multiplesclerosis ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241310764 -
MSJ
@MSJ_Research
Interdisciplinary approach is necessary in the treatment of cognitive decline in #multiplesclerosis, though possibly not always available in clinical practice.
MSJ
@MSJ_Research
What do you think? Is an interdisciplinary approach necessary in the treatment of cognitive decline in #multiplesclerosis ?
5/🧵 -
MSJ reposted
Francisco Caiza Zambrano
@panchoCZ
MSJ
@MSJ_Research
The radiologically isolated syndrome: Diagnosis, prognosis and perspectives within new #multiplesclerosis criteria.
The @ECTRIMS Confavreux lecture from @XtineLebrunF ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241311217 -
MSJ
@MSJ_Research
Climate change poses significant challenges for people with #multiplesclerosis, with heat exacerbating symptoms, air pollution contributing to neuroinflammation, and mobility impairments complicating resource access.
Topical review from @harvardmed ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251322664 -
MSJ
@MSJ_Research
A young woman with #multiplesclerosis treated with ocrelizumab developed severe coxsackie virus B5 encephalitis, mimicking autoimmune limbic encephalitis (good response to ribavirin/favipiravir and immunoglobulins).
Case report from @Saar_Uni ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251322327 -
MSJ
@MSJ_Research
People with #multiplesclerosis are more persistent to B cell depleting therapies, than to other treatments, possibly reflecting better clinical outcomes.
Swiss MS Cohort study @EnteOspedaliero @GDSC_usi @JensKuhle @RC2NB @UniBasel_en ▶️ journals.sagepub.com/doi/full/10.1177/20552173251315457 -
MSJ reposted
IJMSC
@IJMSCtweets
"#migraine was associated with an increased odds of MS only when co-occurrence was considered. These findings imply that migraines are part of the constellation of [#multiplesclerosis] onset symptoms rather than a risk factor for or prodromal symptom of MS."
MSJ
@MSJ_Research
People at the time of clinical onset of #multiplesclerosis developed migraines more often than expected in the general population, thus suggesting that migraines are not a prodromal symptom.
Study from @UCSF @KPWestLA ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251318293 -
MSJ
@MSJ_Research
New controversy available ⚖️
📢 Is an interdisciplinary approach necessary in the treatment of cognitive decline in #multiplesclerosis?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @KesslerFdn: Treating cognitive dysfunction requires a team of professionals and community partners with a true interdisciplinary approach to treat the complexities of cognitive dysfunction in #multiplesclerosis.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251315357
4/🧵
MSJ
@MSJ_Research
What do you think? Is an interdisciplinary approach necessary in the treatment of cognitive decline in #multiplesclerosis ?
5/🧵 -
MSJ
@MSJ_Research
Treatment with cladribine tablets reduced neurodegeneration in deep grey matter, thalamus, and brainstem in #multiplesclerosis
Analysis of the CLARITY study from @marbarrace @Mennoke @MScentrum020 ▶️ journals.sagepub.com/doi/full/10.1177/13524585251314779 -
MSJ
@MSJ_Research
🔊 Listen to @UMich @kearaginell @waynestate on the feasibility, reliability, and validity of ambulatory smartphone-administered cognitive tests in #multiplesclerosis.
📄 And read the full manuscript ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251320814 -
MSJ
@MSJ_Research
People at the time of clinical onset of #multiplesclerosis developed migraines more often than expected in the general population, thus suggesting that migraines are not a prodromal symptom.
Study from @UCSF @KPWestLA ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251318293 -
MSJ
@MSJ_Research
In Afro-descendants, optic neuritis incidence was 1.61/100,000 person-years, and was due to #nmosd (10%), #mogad (20%), #multiplesclerosis (35%), isolated (24%) or relapsing optic neuritis (7%) and unclassified (4%).
Study from Martinique ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251317339 -
MSJ
@MSJ_Research
Deteriorating quality of life in early relapsing #multiplesclerosis is associated with subsequent progression independent of relapse activity.
Prospective observational study from @goteborgsuni @sahlgrenska ▶️ journals.sagepub.com/doi/full/10.1177/13524585251318516 -
MSJ
@MSJ_Research
Characterizing gait in people with #multiplesclerosis using digital data from smartphone sensors, including pace, rhythm, stability, symmetry, variability, smoothness, complexity and fatigability.
Proposed framework from @Karatsidis @biogen @Roche ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251316242 -
MSJ
@MSJ_Research
Among 96 people with #multiplesclerosi treated with autologous hematopoietic stem cell transplantation, about 60% improved in physical and psychological quality of life.
Data from Swedish MS registry @UU_University▶️ journals.sagepub.com/doi/full/10.1177/13524585251315363 -
MSJ
@MSJ_Research
It seems a combination of expert and representative patients would be the most sensible approach (for our readers) to increase impact of #multiplesclerosis research!
MSJ
@MSJ_Research
What do you think? Who do we need to engage to increase impact of #multiplesclerosis research in the era of personalized medicine?
5/🧵 -
MSJ
@MSJ_Research
People with #multiplesclerosis have more frequent personality disorders, are more often diagnosed with Lyme disease, and have less tonsillitis than controls and people with other autoimmune diseases.
Retrospective cohort study from @TU_Muenchen ▶️ journals.sagepub.com/doi/full/10.1177/20552173251315458 -
MSJ reposted
Jaume Sastre-Garriga
@J_SastreGarriga
Muy honrado y feliz de participar en el curso anual de formación en #esclerosismultiple para residentes de #neurologia junto a excelentes ponentes, organizado por @seneurologia este año en colaboración con @UNIEMTGirona ¡Gracias a @garinho29 por la invitación!
-
MSJ reposted
ECTRIMS
@ECTRIMS
🏆 The 2025 @RachelHorne19 Prize (US$40,000) honours a rising star female scientist in #ms research. Are you an early to mid-career researcher making an impact in MS research? Apply now! 🔗 www.rachelhorneprize.com/dr-kristen-krysko-2025-winner
#rachelhorneprize #womeninmsmatter #iwd -
MSJ
@MSJ_Research
Slowly expanding lesions in #multiplesclerosis showed progressive demyelination within lesions and normal-appearing tissue over time, as from chronic diffuse inflammation.
Study from @UBC ▶️ journals.sagepub.com/doi/full/10.1177/13524585251316519 -
MSJ reposted
大橋 高志
@ULLR64_1
フマル酸エステル系薬剤に伴う重篤な消化器系有害反応(穿孔、潰瘍、出血、閉塞)について、FDAの有害事象報告システムと医学文献のレビューにより調査した。
49件(うちフマル酸ジメチルが44件)で因果関係があると評価された。多くが治療開始後4か月以内に発症し、消化管出血(36件)が最多だった。
MSJ
@MSJ_Research
There were 49 cases of severe gastrointestinal adverse reactions to fumaric acid ester class in #multiplesclerosis, including perforation, ulceration, hemorrhage, and obstruction, mostly within 4 months from initiation.
Review from @FDA ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251316518 -
MSJ
@MSJ_Research
Studies on pharmacological and nonpharmacological interventions for fatigue in #multiplesclerosis have provided inconclusive evidence, and comprehensive and interdisciplinary approach is required.
Scoping review from @URosario ▶️ journals.sagepub.com/doi/full/10.1177/20552173241312527 -
MSJ
@MSJ_Research
New controversy available ⚖️
📢 Do we need to engage representative patients’ community rather than ‘expert patients’ to increase impact of #multiplesclerosis research in the era of personalized medicine?
1/🧵Post not available here, view on X
MSJ
@MSJ_Research
And commentary from @paolazaratin @aism_nazionale : We need multi-stakeholder participatory governance in patient engagement in health research, with people living with #multiplesclerosis sharing their experiential knowledge.
🔽
journals.sagepub.com/doi/full/10.1177/13524585251315364
4/🧵
MSJ
@MSJ_Research
What do you think? Who do we need to engage to increase impact of #multiplesclerosis research in the era of personalized medicine?
5/🧵 -
MSJ
@MSJ_Research
There were 49 cases of severe gastrointestinal adverse reactions to fumaric acid ester class in #multiplesclerosis, including perforation, ulceration, hemorrhage, and obstruction, mostly within 4 months from initiation.
Review from @FDA ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251316518 -
MSJ
@MSJ_Research
🔊 Listen to @AlbergoniMatteo @NRU_SanRaffaele @SanRaffaeleMI @MyUniSR on aerobic capacity, spinal cord atrophy and clinical disability in #multiplesclerosis.
📄 And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.1177/13524585251318647 -
MSJ
@MSJ_Research
📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠
Register here to receive our research
🔽
journals.sagepub.com/connected/MSJ -
MSJ
@MSJ_Research
Treatment response scoring systems predicted relapses, MRI lesions and progression in people with #multiplesclerosis on high-efficacy therapies.
Study from @marianomarrodan @LusolMF @XMontalban @cemcat_em @vallhebron @FleniOficial ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251316471 -
MSJ reposted
NeurologyLive®
@neurology_live
In a recent interview, @BeboBruce, of @mssociety, discussed how our understanding of #ms has evolved over the last decade based on the sessions topics being presented at the 2025 #actrimsforum. Check out the interview on the site now! @ACTRIMS
-
MSJ
@MSJ_Research
The Swedish registry provides valid, real-world data on pediatric-onset #multiplesclerosis, though missing data exceeded 30% for rituximab infusions, magnetic resonance imaging, and relapses.
Validation study from @karolinskainst ▶️ journals.sagepub.com/doi/full/10.1177/20552173251314118 -
MSJ
@MSJ_Research
Diagnosing #multiplesclerosis requires ruling out better explanations, and the most common alternative diagnoses are MOGAD, functional disorders and vascular disease.
From the Barcelona CIS cohort @andreuvilaseca7 @GeoArrambide @cemcat_em @vallhebron ▶️ journals.sagepub.com/doi/abs/10.1177/13524585251314749 -
MSJ
@MSJ_Research
The #multiplesclerosis Cognitive Scale is a novel tool to assess patient-reported cognitive difficulty, which proved psychometrically robust and reliable.
Development and validation from @JimSumowski @IcahnMountSinai @montclairstateu ▶️ journals.sagepub.com/doi/full/10.1177/13524585241309805 -
MSJ
@MSJ_Research
Using SWI, 82% paramagnetic rim lesions #prl were detected at 1.5T MRI, compared with 3T, with almost perfect interrater reliability, and all patients with #multiplesclerosis were accurately classified as having ⩾1 or no PRL.
Study from @NRU_SanRaffaele▶️journals.sagepub.com/doi/abs/10.1177/13524585251314358 -
MSJ reposted
Matthias Babin
@RadioBabz
Exactly ! Our recent work on perivascular enhancement pattern 🧠 :
www.sciencedirect.com/science/article/pii/S015098612500001X -
MSJ reposted
Matthias Babin
@RadioBabz
Our article on perivascular enhancement pattern ;)
www.sciencedirect.com/science/article/pii/S015098612500001X -
MSJ reposted
ibrahim acır
@assocprofacir
Thank you for your valuable comment 😊 We absolutely agree that a very careful approach is required for the diagnosis. In this patient, who did not accept any interventional procedures, the diagnosis was indeed challenging😊
-
MSJ
@MSJ_Research
On diffusion tractography, the fornix is smaller in pediatric #multiplesclerosis, implicating this is affected from early phases and could precede injury to connected gray matter seen in adult patients.
High resolution DTI study from @UAlberta ▶️ journals.sagepub.com/doi/full/10.1177/20552173251315161 -
MSJ
@MSJ_Research
Diagnostic challenges in SLIPPERS (Supratentorial Lymphocytic Inflammation with Parenchymal Perivascular Enhancement Responsive to Steroids) and related treatment implications.
Case report from @dribrahimacir @AYSEALT51949427 ▶️ journals.sagepub.com/doi/full/10.1177/20552173241312534 -
MSJ reposted
IJMSC
@IJMSCtweets
"The common thread that characterizes all of these advances is #multidisciplinary #collaboration among scientists in...consortia, working groups, or ad hoc partnerships. This may be the 'secret sauce' of modern science & the best strategy to stop, restore&end" #multiplesclerosis.
MSJ
@MSJ_Research
Innovative and collaborative multi-disciplinary research will be the key to stop, restore, and end #multiplesclerosis
Link to study from @UCSF ▶️ journals.sagepub.com/doi/full/10.1177/13524585251314756 -
MSJ
@MSJ_Research
Before the initiation of cladribine treatment, brain atrophy rates were significantly steep in relapsing #multiplesclerosis and progressively stabilised over 2 years after initiation.
Longitudinal study from @sheba_medical @TelAvivUni ▶️ journals.sagepub.com/doi/full/10.1177/13524585251313749 -
MSJ
@MSJ_Research
Innovative and collaborative multi-disciplinary research will be the key to stop, restore, and end #multiplesclerosis
Link to study from @UCSF ▶️ journals.sagepub.com/doi/full/10.1177/13524585251314756 -
MSJ
@MSJ_Research
Eculizumab was safe and effective treatment in the acute attack of pediatric AQP4+ #neuromyelitis #nmosd (along with steroids and plasma exchange), but the patient relapsed when transitioning to rituximab.
Case report from @kimoneillMD @nyugrossman ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241283650 -
MSJ
@MSJ_Research
📢February issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @GeisingerRsrch with their case report of colitis associated with ofatumumab treatment in #multiplesclerosis ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241303479 -
MSJ reposted
Paolo Preziosa
@paolopreziosa
In MS patients with mild disability, higher aerobic capacity can potentially mitigate the negative impact of spinal cord damage on clinical disability.
Let have a look to our study just published in @MSJ_Research
journals.sagepub.com/doi/10.1177/13524585251318647
@Neuroimaging_Research_Unit_SanRaffaele
@NRU_SanRaffaele
Aerobic capacity moderates the association between cervical cord atrophy and clinical disability in mildly disabled multiple sclerosis patients
Published in @MSJ_Research
@AlbergoniMatteo @paolopreziosa @agmmeani @PaolaValsasina @rocca_mara
#ms #mri
journals.sagepub.com/doi/10.1177/13524585251318647 -
MSJ reposted
@Neuroimaging_Research_Unit_SanRaffaele
@NRU_SanRaffaele
Aerobic capacity moderates the association between cervical cord atrophy and clinical disability in mildly disabled multiple sclerosis patients
Published in @MSJ_Research
@AlbergoniMatteo @paolopreziosa @agmmeani @PaolaValsasina @rocca_mara
#ms #mri
journals.sagepub.com/doi/10.1177/13524585251318647 -
MSJ reposted
ECTRIMS
@ECTRIMS
🧠 New in the MS Journal @MSJ_Research: The first study analyzing healthcare use 3 years before radiologically isolated syndrome (RIS) diagnosis did not find there was evidence of a systemic prodrome in these individuals with RIS. journals.sagepub.com/doi/full/10.1177/13524585241291471
#ms -
MSJ
@MSJ_Research
Did you attend the annual meeting of the International #multiplesclerosis Cognition Society?
#imscog2024 @imscogs
Have a look at the abstracts
🔽
journals.sagepub.com/toc/msja/31/1_suppl -
MSJ reposted
Andreu Vilaseca
@andreuvilaseca7
MS lacks a specific diagnostic biomarker, so considering alternative diagnoses is crucial,especially in high-risk patients!🤯
In CIS patients from @cemcat_em, we highlight these alternative diagnosis and the high specificity of MS criteria even here!✅
#multiplesclerosis &Beyond -
MSJ
@MSJ_Research
Testing for myelin oligodendrocyte glycoprotein #mogad antibodies: Who, what, where, when, why, and how!
Review from @adrianbudhram1 @LHSCCanada @WesternU @EoinFlanagan14 @MayoClinicNeuro ▶️ journals.sagepub.com/doi/full/10.1177/13524585251313744 -
MSJ reposted
Kerstin Hellwig
@KerstinHellwig
There are > 300 pregnancies in women with PNH exposed to ECU- a lifesaving drug for those- it should be continued during pregnancy in women with NMOSD! BF is also possible- hopefully updated reviews will follow in 2025- consider meningococcal 💉during 🤰
MSJ
@MSJ_Research
The use of eculizumab during pregnancy in a 34yo woman with AQP4+ #neuromyelitis #nmosd resulted safe for both mother and child.
Case report from @PIaffaldano @unibait ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241283648
🧵/1 -
MSJ
@MSJ_Research
The use of eculizumab during pregnancy in a 34yo woman with AQP4+ #neuromyelitis #nmosd resulted safe for both mother and child.
Case report from @PIaffaldano @unibait ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241283648
🧵/1
MSJ
@MSJ_Research
...and commentary from @DrWBRO @drruthdobson @UCLBrainScience @QSMSCENTRE @preventiveneur1 @NHSBartsHealth: There is increasing confidence in the use of eculizumab in pregnancy, also based on other diseases and similar medications.
🔽
journals.sagepub.com/doi/full/10.1177/13524585241310376
2/🧵 -
MSJ
@MSJ_Research
Neurofilaments in CSF are better outcomes than serum in progressive #multiplesclerosis, including hand function, information processing speed and brain volume loss.
Data from @MsSmartTrial @Florianadea @QSMSCENTRE @UCLBrainScience @blizard_inst ▶️ journals.sagepub.com/doi/full/10.1177/13524585241311212 -
MSJ reposted
Burcu Zeydan
@burcuzeydanmd
📣📣📣Our study on upper cervical spinak cord atrophy in MS - highlighting the importance of age, disease duration, male sex and menopause
MSJ
@MSJ_Research
Upper cervical spinal cord atrophy was more pronounced in people with #multiplesclerosis being older, males or menopause females, suggesting associations between hormones and neurodegeneration.
Study from @burcuzeydanmd @MayoClinicNeuro @MayoClinic ▶️journals.sagepub.com/doi/abs/10.1177/13524585241311441 -
MSJ
@MSJ_Research
Over 40 months, risk of activity was higher in people with #multiplesclerosis discontinuing treatments, though relapses and new brain MRI lesions were uncommon.
The DISCOMS extension trial from @CUMedicalSchool @nyugrossman ▶️ journals.sagepub.com/doi/full/10.1177/13524585241303489 -
MSJ reposted
Dr. Nara Michaelson MD, MS
@narologist
Interesting work on the use of upper spinal cord atrophy as a biomarker for progression in MS!
➡️Looking forward to the NAIMS workshop focusing on spinal cord. So much to learn about this critical part of the CNS
MSJ
@MSJ_Research
Upper cervical spinal cord atrophy was more pronounced in people with #multiplesclerosis being older, males or menopause females, suggesting associations between hormones and neurodegeneration.
Study from @burcuzeydanmd @MayoClinicNeuro @MayoClinic ▶️journals.sagepub.com/doi/abs/10.1177/13524585241311441 -
MSJ
@MSJ_Research
Upper cervical spinal cord atrophy was more pronounced in people with #multiplesclerosis being older, males or menopause females, suggesting associations between hormones and neurodegeneration.
Study from @burcuzeydanmd @MayoClinicNeuro @MayoClinic ▶️journals.sagepub.com/doi/abs/10.1177/13524585241311441 -
MSJ
@MSJ_Research
All pain outcome measures were reliable and accurate in people with #multiplesclerosis, and can be used for screening and monitoring of pain.
Study from @peterfeys_ @uhasselt ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241310139 -
MSJ reposted
Kerstin Hellwig
@KerstinHellwig
🤔 it true- in some cases we might be able to avoid any clinical symptoms … MS sine MS somehow
MSJ
@MSJ_Research
The radiologically isolated syndrome: Diagnosis, prognosis and perspectives within new #multiplesclerosis criteria.
The @ECTRIMS Confavreux lecture from @XtineLebrunF ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241311217 -
MSJ
@MSJ_Research
The radiologically isolated syndrome: Diagnosis, prognosis and perspectives within new #multiplesclerosis criteria.
The @ECTRIMS Confavreux lecture from @XtineLebrunF ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241311217 -
MSJ
@MSJ_Research
The long-axis diameter of a Gd+ lesion is the best predictor of subsequent paramagnetic rim formation, identify patients at high risk of transitioning to chronic active inflammation.
Study from @umassmemorial @UMassChan @NIH_NINDS ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241310764 -
MSJ
@MSJ_Research
Among 190 people with MOG antibody-associated disease #mogad, relapses were more frequent in the group with CSF-restricted oligoclonal bands, particularly within the first year of follow-up.
Study from @CHUdeLyon @marignierro ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241311435 -
MSJ
@MSJ_Research
Before diagnosis of radiologically isolated syndrome, there was increase in neurology visits related to headaches and anti-migraine drugs, thus not supporting the idea of a systemic prodrome.
Study from @XtineLebrunF @CRCSEPNice @EHESP @Inserm ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241291471
1/🧵
MSJ
@MSJ_Research
...and editorial from @clouapre @APHP @ParisBrainInst @skleros_hun @UNALOficial: The linkage of administrative and clinica data can shed light on the timeline from the onset of demyelinating lesions to clinical stages of #multiplesclerosis.
🔽
journals.sagepub.com/doi/full/10.1177/13524585241312758
2/🧵 -
MSJ
@MSJ_Research
Memory decline was observed in 44.4% people with #multiplesclerosis over 3 years and was associated with greater brain volume loss, mediated by structural and functional connectivity.
Testing a mechanistic model from @Columbia @ColumbiaMed ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241303491 -
MSJ reposted
Jaime Imitola MD., FAAN
@DrJim4MS
Feb 1, is the start of our @uconnhealth awareness campaign for #early MS. Despite the advances,we still have unmet needs in #ms. Please share our #ms #awareness work published in @MSJ_Research and RT @AANmember @BWHNeurology @mssociety @GlialLab @AUPN_leaders @cobanmd @DoctorQMd
-
MSJ
@MSJ_Research
📢 Most recent updates on multiple sclerosis, neuromyelitis optica, MOG-associated disease and related autoimmune diseases of the central nervous system? 🧠
Register here to receive our research
🔽
journals.sagepub.com/connected/MSJ -
MSJ reposted
Romain Marignier
@marignierro
Fascinating case! Pulmonary involvement in AQP4+NMOSD is probably under-recognized
-
MSJ reposted
EthelCiampiSCL
@EthelScl
Thank you for highlighting our research 🧠 Supporting RWE from Latin America
MSJ
@MSJ_Research
Among 305 people with #multiplesclerosis treated with ocrelizumab, in 29.5 months, 0.3% had a relapse, 12.4% had disability worsening, and 4.6% had serious infections.
Real-world study from Chile @NeuroinmunUC @ucatolica @SoterodelRio ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241309835 -
MSJ
@MSJ_Research
A 80-year-old man with AQ4+ #neuromyelitisoptica presented with cough and hiccups, and was found to have organizing pneumonia with AQ4 loss, IgG-binding, and complement deposits, akin to central nervous system lesions.
Case report from @Fukuoka_Univ_PR ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241310397 -
MSJ
@MSJ_Research
Among 305 people with #multiplesclerosis treated with ocrelizumab, in 29.5 months, 0.3% had a relapse, 12.4% had disability worsening, and 4.6% had serious infections.
Real-world study from Chile @NeuroinmunUC @ucatolica @SoterodelRio ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241309835 -
MSJ reposted
Kerstin Hellwig
@KerstinHellwig
Thank you @MSJ_Research for highlighting our research- inky 12 women with MS but for 🤱studies this is not small .
MSJ
@MSJ_Research
In 12 mothers with #multiplesclerosis, ofatumumab-exposed breastfeeding did not adversely affect infants’ health or development, with low risk of substantial antibody absorption.
Study from @KerstinHellwig @ruhrunibochum @HHU_de ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241307165 -
MSJ
@MSJ_Research
Work ability was lower in people with #multiplesclerosis than the general population, and was associated with type of occupation (see figure below), disability and fatigue.
Web-based survey in Sweden from @karolinskainst @StratNeuro ▶️ journals.sagepub.com/doi/full/10.1177/20552173241304324 -
MSJ reposted
Jaume Sastre-Garriga
@J_SastreGarriga
A great honor, but above all an enormou responsibility, which I am fortunate to share with all my fellow editors: @DanOntaneda @ahmedtoosy @anneke_vdw @MarcelloMoccia_ @rocca_mara @DrWBRO Ho Jin Kim - Jennifer Graves - Anna Hëdstrom - Declan Chard.
MSJ
@MSJ_Research
📢 January issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to new editor-in-chief @J_SastreGarriga and editorial board members keeping the #multiplesclerosis Journal forever young ▶️ journals.sagepub.com/doi/10.1177/13524585241311154 -
MSJ
@MSJ_Research
In 12 mothers with #multiplesclerosis, ofatumumab-exposed breastfeeding did not adversely affect infants’ health or development, with low risk of substantial antibody absorption.
Study from @KerstinHellwig @ruhrunibochum @HHU_de ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241307165 -
MSJ reposted
MS Int'l Federation
@MSIntFederation
A new publication in @MSJ_Research shares recommendations for a group of treatments that the MS community believes should be available in low-resource settings. 💊💉 The MS community can use these recommendations to advocate for change. 📣 Learn more. 👉 msintfederation.org/3WwzZvc
-
MSJ
@MSJ_Research
📢 January issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to new editor-in-chief @J_SastreGarriga and editorial board members keeping the #multiplesclerosis Journal forever young ▶️ journals.sagepub.com/doi/10.1177/13524585241311154 -
MSJ reposted
Adrian Budhram
@adrianbudhram1
Always appreciate the opportunity to collaborate with @EoinFlanagan14 , this time to review the "who, what, where, when, why, and how" of MOG antibody testing in @MSJ_Research . Hopefully helps facilitate accurate diagnosis of #mogad in clinical practice.
journals.sagepub.com/doi/10.1177/13524585251313744 -
MSJ reposted
The Sumaira Foundation
@TheSumairaFDN
A study by Farren Briggs & Jacqueline Shaia published in @MSJ_Research evaluated how common #nmosd is in the United States.
For more, visit www.sumairafoundation.org/research-summaries -
MSJ reposted
Burcu Zeydan
@burcuzeydanmd
Our paper is out📣 impact of age, sex & hormones on neurodegeneration in MS➡️smaller upper cervical cord area in men than women & in postmenopausal women than premenopausal women 👩🏻💻journals.sagepub.com/doi/abs/10.1177/13524585241311441 @MSJ_Research @nurneyal @neuronathoo @EoinFlanagan14
-
MSJ
@MSJ_Research
Post-acute sequela of #covid19 infection (including fever, cough, loss of smell/taste, and shortness of breath) were reported in 1.5% individuals with #multiplesclerosis (2x than not infected).
Survey from @NARCOMS1993 @SouthwesternU @umanitoba ▶️ journals.sagepub.com/doi/full/10.1177/13524585241310104 -
MSJ
@MSJ_Research
Quantitative MRI and gene expression atlas identified the key elements of AQP4 + #neuromyelitisoptica #nmosd pathophysiology.
Proof-of-concept study from @Lauz_Caccia @rocca_mara @NRU_SanRaffaele ▶️ journals.sagepub.com/doi/full/10.1177/13524585241307154 -
MSJ reposted
MS Int'l Federation
@MSIntFederation
Policymakers, patient advocacy groups, healthcare workers, and people with MS can use these recommendations to advocate for change. 📣 Learn about the recommendations and how to use them. 👉 msintfederation.org/3WwzZvc
MSJ
@MSJ_Research
Recommendations for essential medicines for #multiplesclerosis in low-resource settings.
A @MSIntFederation initiative including @DeannaSaylor1 @JohnsHopkins @twpiggott @QueensKingston @Ptbohealth ▶️ journals.sagepub.com/doi/full/10.1177/13524585241308134 -
MSJ
@MSJ_Research
Recommendations for essential medicines for #multiplesclerosis in low-resource settings.
A @MSIntFederation initiative including @DeannaSaylor1 @JohnsHopkins @twpiggott @QueensKingston @Ptbohealth ▶️ journals.sagepub.com/doi/full/10.1177/13524585241308134 -
MSJ
@MSJ_Research
...and letter from @KorayTascilar: The south-north prevalence gradient could be due to the lack of standardization, with differences in age distribution across provinces.
🔽
journals.sagepub.com/doi/full/10.1177/13524585241304969
MSJ
@MSJ_Research
Epidemiology of #multiplesclerosis in Turkey: Prevalence was 96.4 per 100,000, incidence 6.2 per 100,000, female-to-male ratio 2.1/1, and age at diagnosis 34.0 years.
Last name is @suayipbirinci 🇹🇷 Deputy Minister of Health ▶️ journals.sagepub.com/doi/10.1177/13524585241245318 -
MSJ
@MSJ_Research
Aerobic and resistance training elicited improvements in physical capacity in people with #multiplesclerosis, only moderately improved physical function.
Results from the MSBOOST trial @AarhusUni_int ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241305496 -
MSJ
@MSJ_Research
New issue of Multiple Sclerosis Journal – Experimental, Translational and Clinical is now available online journals.sagepub.com/toc/msoa/10/4 ▶️ and is full open access 🔓
-
MSJ reposted
Weill Cornell Medicine Radiology
@WCMRadiology
🧠 Read "Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model" by Ceren Tozlu (@crntozlu) et al. in @MSJ_Research 👉 journals.sagepub.com/doi/10.1177/13524585241303491?url_ve…
-
MSJ
@MSJ_Research
Cognitive reserve (measured using the Vocabulary Knowledge Test) was associated with trajectories of cognitive changes in #multiplesclerosis.
Study from @unicampania ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241302167 -
MSJ reposted
-
MSJ reposted
ECTRIMS
@ECTRIMS
🎉 We're delighted to welcome 51 participants from 29 countries to our Winter School, which opens today in Riga, Latvia! The programme is designed for young clinicians & fellows who want to learn about the revisions to the #ms diagnostic criteria. 👉 ectrims.eu/ongoing-educational-programmes/winter-schools/
-
MSJ reposted
Xavier Montalban
@XMontalban
Happy to contribute to this exceptional meeting.
ECTRIMS
@ECTRIMS
🎉 We're delighted to welcome 51 participants from 29 countries to our Winter School, which opens today in Riga, Latvia! The programme is designed for young clinicians & fellows who want to learn about the revisions to the #ms diagnostic criteria. 👉 ectrims.eu/ongoing-educational-programmes/winter-schools/
-
MSJ
@MSJ_Research
Trigeminal neuralgia occurred in 0.9%–1.9% people with #multiplesclerosis within the disease course of MS, and it was the first potential demyelinating symptom in 9.9% of cases (table below).
Multicentre study from @helsinkiuni @UofT @UVMLarnerMed ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241309257 -
MSJ
@MSJ_Research
In people with #multiplesclerosis with mild disability, nearly 2/3 had cognitive abnormalities, predominantly involving processing speed, working memory, executive function, and verbal fluency.
A cross-sectional study from South India ▶️ journals.sagepub.com/doi/full/10.1177/20552173241304302 -
MSJ reposted
Jaume Sastre-Garriga
@J_SastreGarriga
Proud and honoured to participate as speaker in the 3rd ECTRIMS Winter School in Riga, Latvia. Thanks very much to @ECTRIMS for moving forward this educational activitity and to @olgacicc and @ThINk_Basel for their kind invitation @cemcat_em @VHIR_
-
MSJ
@MSJ_Research
In Hispanic/Latinx Americans the age at onset of #multiplesclerosis is earlier and the initial progressive disease course is more common, compared with non-Hispanic White Americans.
Study from @DanOntaneda @umiamimedicine @ClevelandClinic ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241304976 -
MSJ
@MSJ_Research
Patients with a first clinical demyelinating event treated with cladribine had fewer relapses and less ambulatory impairments than never-exposed, at 9.5 years.
Findings for the ORACLE-MS cohort @Giovannoni62497 @blizard_inst @EMDSerono @merckgroup ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241302170 -
MSJ
@MSJ_Research
Ganglion cell-inner plexiform layer (GCIPL) on OCT was associated with cognitive performance (SDMT) in #multiplesclerosis, but showed limited utility when accounting for MRI measures.
Study from @olgacicc @QSMSCENTRE @UCLBrainScience ▶️ journals.sagepub.com/doi/full/10.1177/13524585241304356 -
MSJ
@MSJ_Research
Authors developed and validated SMARTCARE-EDSS training method to enable health care professionals to assess disability for decentralized trials in #multiplesclerosis.
A Swiss multicenter, randomized, cross-over study from @UniSpitalBasel @RC2NB ▶️ journals.sagepub.com/doi/full/10.1177/13524585241305966 -
MSJ
@MSJ_Research
Live-attenuated vaccines in people with #multiplesclerosis living in regions with endemic infections.
Topical review from @marianomarrodan @FleniOficial @iquifib40 @Conicet @UBAonline ▶️ journals.sagepub.com/doi/full/10.1177/13524585241305956 -
MSJ
@MSJ_Research
Barriers to follow-up visits in #multiplesclerosis are not having received disease modifying or symptomatic treatment, diagnosis before 2009, progressive course, and living in an outer region.
A nationwide register-based study from @UCPH_Research ▶️ journals.sagepub.com/doi/full/10.1177/20552173241307619 -
MSJ
@MSJ_Research
Sick leave due to neurological symptoms (but not to other medical issues) is associated with risk of subsequent diagnosis of #multiplesclerosis: prodromal phase or diagnostic delay?
Short report from @karolinskainst ▶️ journals.sagepub.com/doi/full/10.1177/20552173241305982 -
MSJ
@MSJ_Research
Welcome 2025 🥳 and welcome to our new #linkedin account ▶️ www.linkedin.com/company/msj-research/
-
MSJ reposted
NeuroinmunologiaUC
@NeuroinmunUC
Very proud to congratulate Dr. Adolfo del Canto and the Neuroimmunology UC team for their work published today in Multiple Sclerosis Journal on ocrelizumab in Chilean population—one of the largest Latin cohorts.
journals.sagepub.com/doi/10.1177/13524585241309835
#neurotwitter #multiplesclerosis -
MSJ
@MSJ_Research
Features extracted during simple speech tasks classify patient-reported fatigue in #multiplesclerosis: a novel simple, low-burden speech tasks for clinical practice?
Study from @BoveRiley @UCSF ▶️ journals.sagepub.com/doi/full/10.1177/13524585241303855 -
MSJ
@MSJ_Research
...and editorial from @UNI_FIRENZE: In addition to the established benefits of early treatment, addressing social determinants of health could yield substantial improvements in the outcomes of people with #multiplesclerosis.
🔽
journals.sagepub.com/doi/full/10.1177/13524585241302684
MSJ
@MSJ_Research
The percentages of people with #multiplesclerosis <40 years at onset and who initiated treatment before the age of 40 years were significantly higher in the groups with a higher education level.
Study from @RennesUniv_EN @EHESP @CNRS @Inserm ▶️ journals.sagepub.com/doi/full/10.1177/13524585241289276 -
MSJ
@MSJ_Research
The percentages of people with #multiplesclerosis <40 years at onset and who initiated treatment before the age of 40 years were significantly higher in the groups with a higher education level.
Study from @RennesUniv_EN @EHESP @CNRS @Inserm ▶️ journals.sagepub.com/doi/full/10.1177/13524585241289276 -
MSJ
@MSJ_Research
📢August issue is now available ▶️ journals.sagepub.com/toc/MSJ/current
...and the cover goes to @TheFlorey @unimelbMSPGH @UTAS_ @ResearchMenzies @UniMelb with increasing prevalence of #multiplesclerosis in Australia from 2010 to 2021 ▶️ journals.sagepub.com/doi/abs/10.1177/13524585241265890 -
MSJ
@MSJ_Research
The @MSTrust treatment decision tool is excellent in helping women with #multiplesclerosis. Recommendations were conveyed for the new live version and future updates.
Think Aloud methodology from @LubnaEssam @UCL_PCPH @_KSU @UCLBrainScience ▶️ journals.sagepub.com/doi/full/10.1177/20552173241262181 -
MSJ
@MSJ_Research
Epidemiology of #multiplesclerosis in Turkey: Prevalence was 96.4 per 100,000, incidence 6.2 per 100,000, female-to-male ratio 2.1/1, and age at diagnosis 34.0 years.
Last name is @suayipbirinci 🇹🇷 Deputy Minister of Health ▶️ journals.sagepub.com/doi/10.1177/13524585241245318 -
MSJ
@MSJ_Research
Our journals are part of the international community of
@ECTRIMS @ACTRIMS @PACTRIMS_admin @lactrims_org and @eurims
You can read our articles on:
Multiple Sclerosis Journal journals.sagepub.com/home/msj
MSJ Experimental Translational and Clinical journals.sagepub.com/home/mso

































































































































































































































































































































































































































































































































































